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General introduction 
Pain management is a major public health issue, a criterion for the quality and evolution of the 
health system, producing a significant social and economic burden. Above all, it responds to 
humanistic, ethical purposes and human dignity aims, because of the physical and psychological 
implications. It induces a disability among patients and excludes them gradually or suddenly from 
society. Physical pain and emotional suffering experienced at all stages of life, weakens even more 
people made vulnerable by illness. Rebel chronic pain is source of disability, handicap, disability and 
major alterations in quality of life. Medical advances allowed the healing of many serious diseases, 
but also favored the transformation of acute into chronic diseases. This result is an increase in life 
expectancy which can be accompanied by chronic pain. Estimates suggest that 20% of adults suffer 
from pain globally and 10% are newly diagnosed with chronic pain each year (1). It was also reported 
that 30 to 50% of patients with chronic pain also struggle with mood disorders, such as depression and 
anxiety (2, 3). Relieving pain is now an essential priority based on medical ethics (4). Currently, the 
most powerful and frequently used drugs for killing pain are morphine and synthetic opioids which 
interact with opioid receptors, located in the CNS (central nervous system) and peripheral organs. 
However, their chronic use could be associated with serious drawbacks, such as respiratory 
depression, tolerance and dependence, addiction, constipation, sedation, etc.... Therefore, there is an 
important need for efficient drugs active on moderate pain that can fill the gap between the narcotic 
and non-narcotic drugs. In spite of recent progress in the development of new compounds, there is yet 
no marketed drug fulfilling these properties (5).  
Endogenous neuropeptides such as Enkephalins, produce natural analgesia by activating opioid 
receptors located on central and peripheral neuronal cell membranes. They represent a promising way 
to alleviate the pain using natural analgesics devoid of morphine side effects. However, their fast 
enzymatic metabolism after injection and their inefficient permeability through the blood-brain-
barriers (BBB) or blood-nerve-barriers (BNB) restrict their clinical use.  
The aim of this project is to develop novel nanomedicine approach allowing the specific 
delivery of Enkephalin neuropeptide into inflamed tissues for pain control, using 
“squalenoylation” concept. It consists in the chemical linkage of enkephalin with squalene, a 
biocompatible and biodegradable lipid, in order to form amphiphilic prodrug which has the ability 
to self-assemble in water in nanoparticles of hundred nanometers of diameter. This nanoparticular 
formulation allow the enkephalins protection from rapid metabolism and thereby also enable them to 
reach safely opioid receptors.  
The introduction part will first give general informations concerning peripheral mechanisms of 
pain and analgesia. Then, the recent strategies aiming at optimizing the pharmacological profile 
of natural opioid peptides will be presented. A particular attention will be accorded to the strategies 
allowing the efficient delivery of opioid peptides to their site of action. Finally, the new concept of 
“squalenoylation” will be presented as well as an overview of recent advances in the development of 
squalene-based nanomedicines and their application to promising drug candidates with unfavorable 
pharmacokinetics and biodistribution profiles. 
The main part will first include the synthesis of bioconjugates of Leu-enkephalin (LENK) using 
squalenoylation approach. LENK neuropeptide will be coupled to squalene using three different 
chemical linkers, i.e., dioxycarbonyl, diglycolate, amide bond, and then formulated into 
nanoparticles (NPs). Their characterization and their ability to release in vitro the enkephalin will 
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also be adressed. A significant part of the research work will also be dedicated to the evaluation of 
analgesic effect of these LENK-SQ NPs on carrageenan-induced pain model using a thermal 
nociception test (Hargreaves). Pain sensitivity will be rated in response to a hot stimulus on the 
inflamed hind paw of rats. In addition, the biodistribution of NPs in mice using in vivo fluorescence 
imaging in order to assess their ability to target the inflamed tissue will be depicted. 
Through this study, we describe here a new nano-formulation based on the bioconjugation of 
LENK to squalene, capable of precise and efficient delivery of LENK for pain control associated with 
inflammatory events. 
Reference 
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Introduction 
I. GENERAL INFORMATION ON PAIN 
"Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage", as defined by the International Association for the 
Study of Pain (IASP). This highly disagreeable sensation results from an extraordinarily complex and 
interactive series of mechanisms integrated at all levels of the neuroaxis, from the periphery, via the 
dorsal horn to higher cerebral structures (1, 2).  
Pain typically involves a noxious stimulus (e.g., cutting, crushing, or burning stimuli) that 
activates nociceptors (specialized peripheral sensory neurons distributed throughout the body) that 
convey signals to the central nervous system (3), where they are processed and generate multiple 
responses, including the “unpleasant sensation of pain”.  
1. Nociceptors 
“A high-threshold sensory receptor of the peripheral somatosensory nervous system that is capable 
of transducing and encoding noxious stimuli”, according to IASP. The term “nociceptor” comes from 
Latin “nocere” which means to harm or to damage. Charles Sherrington introduced it for the first time 
in 1906 to redefine the neural apparatus responsible for detecting a noxious stimulus.  
Nociceptors are sensory nerve endings responsible for detecting noxious stimuli which can be 
mechanical (painful pressure, squeezing or cutting the tissue), thermal (extreme heat or extreme cold) 
or chemical (stimulation by inflammatory mediators). These nerve cells are constituted by a body 
(located in the dorsal root ganglion (DRG)) and 2 axons: peripheral and central. The peripheral axon 
innervates tissues such as skin and whose terminals react to sensory stimuli. The central axon enters 
the spinal cord in order to transfer information to the central nervous system (CNS) by synaptic 
communication. These nociceptors are frequently in close contact with small distal blood vessels, 
lymphatic vessels, and mast cells (4).  
These sensory neurons convert external noxious stimuli into internal electrical impulses. Indeed, 
the noxious stimulus generates a graded potential in axons that if strong enough, causes the 
sensory neuron to produce an action potential that is relayed into the central nervous system (CNS), 
where it is integrated with other sensory informations to become a conscious perception of that 
stimulus.  
There are two major classes of nociceptors that respond to different modalities of noxious stimuli: 
C-fibers and Aδ-fibers. 
C-fibers are the most common group of nociceptors with unmyelinated axons, which have a small 
diameter and conduct slowly. They respond to noxious thermal, mechanical, or chemical stimulation 
(5). Via detectors located in their membrane at their ends, these nociceptors convert the stimulus 
energy into electrical impulses, which in turn are propagated throughout the nervous system. C-fibers 
represent the majority of sensory neurons in the peripheral nervous system. Aδ-fibers are nociceptors 
with thinly myelinated axons. These nociceptors are slightly larger in diameter, conduct more rapidly 
than do unmyelinated C-fibers and likely convey “fast” (or sharp) momentary pain, as opposed to 
slow, diffuse pain, which is transmitted by the C-fibers. Aδ fibers typically respond to a discrete type 
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of stimulus, such as mechanical stimuli or damaging hot or cold temperatures. They are also 
sensitized to tissues injury. They are less likely to be polymodal receptors than are C fibers which 
respond to mechanical, thermal, chemical stimuli (6, 7). 
In addition to the Aδ- and C-fibres that carry noxious sensory information, there are primary 
afferent Aβ-fibres that carry non-noxious stimuli. Aβ-fibres are highly myelinated and of large 
diameter, therefore allowing rapid signal conduction. They have a low activation threshold and are 
normally not involved in pain transmission but usually respond to light touch and convey tactile 
information (Table. 1).    
Table 1. Characteristics of different types of sensory fibres 
 C-fibres Aδ-fibers Aβ-fibres 
Diameter Smallest <2 μm Small 2-5 μm Large 
Myelination unmyelinated Thinly myelinated Highly myelinated 
Conduction velocity <2 ms
-1
 5-15 ms
-1
 >40 ms
-1
 
Receptor activation 
thresholds 
High High and low Low  
Sensation on stimulation Slow, diffuse, dull pain Rapid, sharp, localized 
pain 
Proprioception, ligh 
touch, non-noxious 
Of note, in addition to sending the information to the cerebral cortex, nociceptor systems have a 
vital role in triggering reflexes that protect the body from the source of pain, such as the withdrawal 
reflexes.  
2. Nociception and Pain 
Nociception and pain are distinct concepts. Sherrington coined the term “nociception” to describe 
the detection of a noxious event by nociceptors, which includes the peripheral and central nervous 
system (CNS) processing of information about the internal or external environment (8). However, it is 
important to note that the responses of neurons to noxious stimuli do not necessarily lead to pain. 
Indeed, noxious stimulation triggers multiple physiological and behavioral responses, such as 
increases in blood pressure and heart rate, withdrawal reflexes, etc., and pain sensation is not 
necessarily implied. Indeed, the threshold for eliciting pain must be high enough to allow the 
achievement of most activities largely pain-free, but sensitive enough to immediately alert if an injury 
is impending. 
Typically, noxious stimuli, including tissue injury, activate nociceptors that are present in 
peripheral structures and that transmit information to the spinal cord dorsal horn or its trigeminal 
homologue, the nucleus caudalis. From there, the information continues to the brainstem and 
ultimately the cerebral cortex, where the perception of pain is generated (Fig. 1) (9).  
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Fig. 1. Anatomical distribution of nociception and pain. 
3. Pain classification 
Pain can be defined simply as the subjective experience of harm in a part of one's body. In reality, 
however, pain is a multidimensional phenomenon with sensory, physiological, cognitive, affective, 
behavioural and spiritual components. Indeed, there are multiple forms of pain, which involve a 
variety of distinct biological processes. Several ways are used to categorize pain, according to the 
causes, or the duration and pattern of occurrence, or the regions of body involved, etc. 
According to their mechanisms, Clifford J. Woolf et al. suggested the classification of pain as 
nociceptive pain, inflammatory pain and pathological pain (Fig. 2) (1, 10). 
 Nociceptive pain 
Nociceptive pain is an early-warning physiological protective system, essential to detect and 
minimize contact with damaging or noxious stimuli. It involves activation of pain receptors by a 
noxious stimulus such as exposure to heat or cold, extreme physical pressure, etc. It is a highthreshold 
pain only activated in the presence of intense stimuli.  
 Inflammatory pain 
It resulted from activation and sensitization of the nociceptive pain pathway by a variety of 
mediators released at a site of tissue inflammation, involving the release of cytokines and the 
infiltration of immune cells. Inflammatory pain occurs subsequent to injury, but can be triggered 
independently by bacterial infections. 
Both nociceptive pain and inflammatory pain are physiological adaptive and protective systems. 
While the former is essential to minimize contact with noxious stimuli, the later tends to reduce 
further risk of damage and promotes recovery. 
 Pathological pain 
Unlike nociceptive pain, pathological pain is caused by nerve hypersensitivity due to (i) peripheral 
or central nerve damage (Neuropathic pain) or (ii) its abnormal function such as phantom limb pain, 
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diabetic neuropathy (Dysfunctional pain). 
 
Fig. 2. Pain classification. © 2010 American Society for Clinical Investigation.(1)  
It should be noted that pathological pain is not protective, but maladaptive. Physiological pain 
may progress to a pathological condition itself if persistent, in which case pain does not represent 
anymore a symptom of disease but rather abnormal sensory processing. Unfortunately, many 
pathological pain conditions remain poorly understood and resist currently available treatments (11). 
Nociceptive pain is not a clinical problem, except in the specific context of surgery and other clinical 
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procedures that necessarily involve noxious stimuli, where it must be suppressed by local and general 
anesthetics or high-dose opioids. Indeed, under inflammatory pain or pathological pain condition, the 
sensitivity to noxious stimuli may increase, causing hyperalgesia, or pain is triggered from stimuli 
that do not normally provoke pain (innocuous stimuli), inducing allodynia (Fig. 3)(12). Hyperalgesia 
and allodynia are the result of changes in either the peripheral or central nervous systems, referred to 
as peripheral or central sensitization, respectively.  
 
Fig. 3. Sensitization to pain. This graphical representation of the shift in pain thresholds during a pain state 
shows both enhanced response to noxious, normally painful, stimuli (hyperalgesia) and pain triggered by non-
noxious stimuli (allodynia) like the gentle brush of the skin. These two painful states do not always coexist, and 
it is increasingly apparent that they are driven by distinct mechanisms in different sets of sensory neurons. © 
Stéphane Lolignier, Niels Eijkelkamp, and John N. Wood, 2014. (12) 
Depending on their durations, pain can be categorized as acute pain and chronic pain. Acute 
pain typically comes on suddenly and lasts a short time while chronic or persistent pain is of longer 
duration (3 months or more). Acute pain is frequently provoked by a specific disease or injury, 
serving a useful biologic purpose. This type of pain usually settles as the tissues heal. In some cases 
acute pain does not settle and persists, becoming thus chronic. Chronic pain, in contrast, may be 
considered as a disease state. This kind of pain that persists after the normal time of healing, if 
associated with a disease or injury (13).  
4. Pain pathway 
The pain system is normally described in a simplified way, as described in Fig. 4. Generally, pain 
is generated by activation of peripheral nociceptors (stimulation) in response to a noxious stimulus. 
Then, these nociceptors transform this stimulus into electrical signals (transduction) which are 
conducted to the brain through the spinal cord (transmission). At this level, signals are processed and 
generate multiple responses, including the “unpleasant sensory and emotional experience” 
(perception). Then, within the cerebral structure, some neurons by descending nociceptive pathway 
(neurotransmitters) modulate the activity of spinal cord nociceptive neurons (modulation) (5). 
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Fig. 4. Ascending pathways of pain perception. ©Copyright 2010 Board of Regents of the University of 
Wisconsin System 
 Primary sensation 
All sensory systems must convert incoming environmental stimulus information into 
electrochemical signals. Pain occurs when nociceptors are stimulated by thermal, mechanical, or 
chemical stimulation. The physiochemical properties of noxious stimuli are converted to electrical 
activity by the detectors located on the terminals of sensory neurons, for example, the transient 
receptor potential-generating channels (TRP channels) and purinergic channels (Fig. 5). The electrical 
activity formed is then amplified by sodium, potassium, and calcium channels to elicit action 
potentials that travel to the central nervous system (5, 14).  
 
Fig. 5. Highly simplified diagram of the “pain axis”. Activation of molecular signal detectors such as TRP 
channels in the membranes of peripheral sensory nerves by harmful or irritating stimuli generates an electrical 
pulse that is converted into an action potential in neurons. The action potential, in turn, induces still other 
membrane proteins to trigger complex signal transduction cascades in the spinal ganglion and subsequently in 
the spine. The information is then transmitted to various areas of the brain that are ultimately responsible for the 
perception of pain. © Max Planck Institute of Experimental Medicine/Schmidt. 
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 Pain signal transmission 
When peripheral sensory fibers (primary afferent fibers) respond to noxious stimuli, they transmit 
this information as electrical signals (action potentials) via axons by depolarizing the presynaptic 
membrane and inducing the opening of voltage-sensitive calcium channels when it reaches the 
presynaptic knob. Diffusion of Ca
2+
 ion in the presynaptic knob causes the movement of synaptic 
vesicles that carry the neurotransmitters to the surface of the knob. Synaptic vesicles then fuse with 
the presynaptic membrane and get rupture to discharge its content (ie. neurotransmitters) into synaptic 
cleft. Neurotransmitters, such as glutamate SP, CGRP, nitric oxide (NO), prostaglandins (PG), and 
brain-derived neurotropic factor (BDNF), bind with specific protein receptors on the postsynaptic 
membrane of the second-order neuron and change its membrane potential. The depolarization of the 
postsynaptic membrane then opens the sodium and calcium channel, causing respective influx of Na
+
 
and Ca
2+
 ions. In this way, the nerve signal gets transmitted to next neuron along the synapse. The 
transmission of nociceptive information at the spinal level is modulated by interneurons (mainly 
inhibitory) through the release of opioid pepides and GABA and also by supraspinal descending 
neurons (“Descending pathways”) through the release of 5-hydroxytryptamine (5-HT) and 
noradrenaline (NA). Descending pathways may inhibit or enhance nociceptive transmission from the 
spinal cord. (Fig. 6) 
 
Fig. 6. Simplified representation of the spinal transmission. © The American Society for Pharmacology and 
Experimental Therapeutics, 2012. (5) 
 Inflammatory pain and hyperalgesia 
Inflammation produces a condition known as hyperalgesia, which is characterized by enhanced 
pain sensation and reduced pain threshold. It is the result of exposure to inflammatory mediators 
released at the site of injury (15). Indeed, tissue damage lead to the local formation and release of 
numerous chemicals around the primary afferent nerve endings due to disruption of cells and 
activation of various specialized cells including mast cells, macrophages, T-cells, neutrophils and 
other immune cells. Mast cells play a key role in non-neural inflammation (16). Mediators released 
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include bradykinin (BK), interleukins (e.g. IL-1β), serotonin (=5-hydroxytrytamine, 5-HT), histamine 
(Hi), prostaglandins (e. g. PGE2), protons (H
+
), purines (e. g. adenosine triphosphate, ATP), nerve 
growth factor (NGF), and tumor necrosis factor (TNF). Together these (and other) mediators 
constitute the inflammatory soup. They contribute to the increased sensitivity of peripheral 
nociceptors by coupling to membrane-bound ion channels (including transient receptor potential (TRP) 
channels (e.g. TRPV1), acid-sensitive ion channels (ASICs) and purinergic (P2X) receptors) and 
kinase linked receptors (e.g. NGF-, TNF-α and IL-1β receptors) and G protein-coupled receptors (e. g. 
bradykinin2- and prostaglandin-receptors), through the action of receptor-initiated second messenger 
cascades. These mechanisms can lead to depolarization and excitation of the neuron as well as long 
term alteration of gene regulation (e.g. NGF and bradykinin increasing the expression of TRPV1 
and prostaglandins increasing the expression of voltage gated sodium channels (VGSC). Increased 
synthesis of TRPs and VGSC represents another mechanism for the development and maintenance of 
inflammatory hyperalgesia (17, 18). In addition peripheral nociceptor terminals may themselves 
release substance P (SP) and calcitonin gene related peptide (CGRP), which cause vasodilatation and 
plasma extravasation at the injury site (19).  
 
Fig. 7. Mechanisms involved in of peripheral sensitization during inflammation (19). 
II. OPIOID SYSTEM 
Over the past two centuries, opium and its derivatives have become the most widely used 
analgesics for severe pain. Morphine, as the major active ingredient of opium, was isolated in 1805 by 
the German pharmacist Wilhelm Sertürner and subsequently named after the Greek god of dreams, 
Morpheus. In 1973, three independent teams showed that opiates bind to membrane receptors in the 
brain (20-22). In 1976, Martin’s group proposed distinctive classes of opioid binding sites: mu 
(morphine), sigma (SKF 10047, N-allylnormetazocine) and kappa (ketocyclazocine)(23). Lord and 
colleagues, in 1977, discovered a binding site in the isolated mouse vas deferens with high affinity for 
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enkephalins and named it the delta (deferens) receptor (24). The three opioid receptors, μ, δ and κ 
have been cloned and the recombinant receptors shown to have binding and functional characteristics 
consistent with their endogenous counterparts (21, 25-27). In that respect, the authentification of 
specific receptors for opiate alkaloid and related synthetic drugs led to a search for specific 
endogenous ligands and the discovery of the enkephalins (28),  β-endorphin (29), and dynorphins (30). 
A search for related receptors by homology cloning led to the identification of a receptor which 
displays 60% substantial sequence identity in comparison with the “classical” opioid receptors. As 
none of the known endogenous opioid peptides could interact with this receptor, it was named opioid 
receptor-like (ORL-1). This receptor was considered as “orphan” until the formal identification of its 
endogenous ligand (nociceptin/orphanin FQ (N/OFQ)) (31).  
Thus the opioid receptors and their endogenously produced ligands compose the innate pain-
relieving system, the opioid system. 
1. Opioid receptors and their ligands 
 Opioid receptors 
Opioid receptors belong to the group of inhibitory G-protein coupled receptor (GPCR), a vast 
family of membrane-traversing proteins, also known as 7-transmembrane receptors (7-TM receptors) 
(21, 32, 33). The GPCRs are essential to the ability of eukaryotic life to detect and mount an 
intracellular response to a diverse range of extracellular stimuli. They are by far the most abundant 
class of cell-surface receptors, which are the targets of about 35% of the approved/marketed drugs 
(34).  
Opioid receptors are mainly found in various brain regions, the dorsal horn of the spinal cord, on 
peripheral nerve terminals, in peripheral tissues including the gastrointestinal tract and on immune 
cells (35, 36). In the periphery, opioid receptors are widely distributed in neuronal and non-neuronal 
cells, including neuroendocrine, immune and ectodermal cells (32, 37). In the gastrointestinal tract 
tract they are present in smooth muscle cells and at the terminals of sympathetic and sensory 
peripheral neurons (38).  
 Endogenous opioids  
Terenius (39) and Hughes (40) reported for the first time, in 1975, the existence of endogenous 
factor in the brain acting as an agonist on opiate receptor in neural tissues. Then Hughes characterized 
two morphine-like material as pentapeptides and termed them methionine enkephalin (Met-
enkephalin) and leucine enkephalin (Leu-enkephalin) (28, 41). In addition to enkephalins, two other 
classes of endogenous opioid peptides have been identified afterwards, such as endorphins (42) and 
dynorphins (30, 43, 44). Each opioid peptide is derived from a large precursor protein. There are 
three such large precursors in mammals: pro-enkephalin (ProEnk), pro-dynorphin (ProDyn) and 
pro-opiomelanocortin (POMC). Met-enkephalin is generated after the proteolyic cleavage of 
proenkephalin, while Leu-enkephalin is produced predominantly from prodynorphin and with less 
copy from proenkephalin. -Endorphin generated by pro-opiomelanocortin is the longest opioid 
peptide (31 amino acids) and shows highly potent and long-lasting analgesic properties. Endogenous 
peptides derived from these precursors share a common N-terminal sequence (Tyr-Gly-Gly-Phe-
Leu/Met) and they have varied affinity for μ, δ and κ receptors. Enkephalin can activate both μ- and 
δ-opioid receptors, with significantly higher (10-fold) affinity for the later, but with negligible affinity 
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for κ receptors (45). -Endorphin preferentially binds to the μ-opioid receptor while dynorphins 
prefers κ-opioid receptors. Nociceptin or orphanin FQ (N/OFQ) originating from pro-nociceptin, 
binds to ORL-1 receptors. Finally, endomorphins (EMs), including EM-1 and EM-2 amide 
tetrapeptides, display a high binding affinity and selectivity to the μ-opioid receptors. (Table 2) 
Endogenous opioid peptides are produced and often released together with other neurotransmitter 
molecules in the brain, pituitary gland, and adrenal gland as well as by single neurons in the 
central and peripheral nervous systems (46). Additionally, opioid peptides are also synthesized and 
secreted by immune cells in response to stressful stimuli or stimulation by corticotropin-releasing 
factor (CRF), formyl peptides and chemokines (CXCL2/3).  
Table 2. Mammalian endogenous peptide (adapted from (45) with permission). 
Precursor Endogenous peptide Amino acid sequence Affinity for 
opioid 
receptors 
Pro-enkephalin [Met]enkephalin 
[Leu]enkephalin 
 
 
Metorphamide 
Tyr-Gly-Gly-Phe-Met 
Tyr-Gly-Gly-Phe-Leu 
Tyr-Gly-Gly-Phe-Met-Arg-Phe 
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu 
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2 
,  
( >> ) 
Pro-opiomelanocortin -endorphin Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-
Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu 
,  
( = ) 
Pro-dynorphin Dynorphin A 
 
Dynorphin A (1-8) 
Dynorphin B 
α-Neoendorphin 
β-Neoendorphin 
[Leu]enkephalin 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln 
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro 
Tyr-Gly-Gly-Phe-Leu 
, ,  
( >>  = ) 
Pro-nociceptin Nociceptin Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln ORL 
Unknown Endomorphin-1 
Endomorphin-2 
Tyr-Pro-Trp-Phe-NH2 
Tyr-Pro-Phe-Phe-NH2 
 
 Distribution of enkephalins 
Concerning Enkephalins, they are widely distributed throughout the brain and the spinal cord, the 
highest concentrations being in the hypothalamus, anterior pituitary, reticular formation, caudate, 
hippocampus, amygdala, periaqueductal gray, substantia nigra, and neocortex. Although similar ratios 
of the methionine- and leucine-enkephalins are seen in whole brain extracts, the ratio varies 
considerably in different brain regions and from one sepecies to another. It was stipulated that 
methionine- and leucine-enkephalin may exist in two separate neurotransmitter systems with possibly 
diverse functions (47). As with other brain peptides, appreciable quantities of enkephalins are also 
found in the intestine and in small amounts in other peripheral tissues such as peripheral ganglia and 
postganglionic neurons. It was also reported that enkephalin activity in sympathetic ganglia and in the 
vagus nerve suggests that the enkephalins may have a widespread role in the control of peripheral 
autonomic activity (47).  
2. Mechanism of opioid analgesic activity 
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The binding of endogenous ligands to their opioid receptors results in conformational changes of 
these receptors allowing thus intracellular coupling of heterotrimeric G proteins (consisting of Gα, Gβ 
and Gγ subunits) to the C terminus of the receptor. The activated receptor promotes exchange of GTP 
for GDP on Gα protein by dissociation of the GDP-bound in favour of GTP-bound. This results in the 
activation of the trimeric G-protein complex, which dissociates into Gα (binded to GTP) and Gβγ 
subunits (Fig. 8). Then, Gα·GTP inhibits adenylyl cyclases (ACs) and consequently cyclic adenosine 
monophosphate cAMP production, which in turn inhibits the cAMP-dependent calcium influx, 
resulting in attenuated excitability of neurons and/or reduced neurotransmitter release. Regarding to 
Gβγ, it directly interacts with different ion channels of the membrane, facilitating the opening of 
potassium channels (efflux of potassium), while inhibiting the opening of calcium channels. The 
inhibition of calcium entry, as well as, the efflux of potassium causes the hyperpolarization which 
inhibits transmitter's release, therefore blocking the transmission of the pain (Fig. 9) (32, 48). At 
the postsynaptic membrane, opioid receptors mediate hyperpolarization by opening K
+
 channels, 
thereby preventing excitation and/or propagation of action potentials (49, 50). 
 
Fig. 8. General principle of the GPCR signaling system. 
Morphine and other opiates are widely used in clinical practice for alleviation of the most severe 
pain syndromes or for anesthetic purposes. Morphine is primarily an agonist ligand for the μ receptor 
(51). Endogenous peptides, for their part, share similar mechanism with morphine in blocking pain 
transmission (Fig. 9). However, morphine application is usually associated with many severe side 
effects including nausea, constipation, drowsiness, sedation, and even more severe as respiratory 
depression, development of tolerance and addiction, which relate to the overstimulation of central 
opioid receptors (52). 
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Fig. 9. Mechanism of morphine on blocking pain process. 
3. Peripheral analgesia and inflammation 
Since a long time, anti-nociceptive effects of opiates were often associated with the activation of 
central nervous system opioid receptors. The discovery of the anti-nociceptive effects mediated by the 
opioid receptors on peripheral nerve endings at the primary afferent neurons, opened new 
perspectives for the treatment of pain (36, 53-55). Indeed, the activation of peripheral opioid receptors 
was found to produce a potent analgesia, devoided of centrally mediated unwanted effects (56, 57), 
such as respiratory depression and dependence, etc.  
The injury of the body (infection, wound, burn or damage by chemical irritants) triggers the body’s 
defense system inducing the inflammatory response. This process is orchestrated by the release of a 
wide range of chemical factors into the extracellular space by recruited immune cells, damaged tissue 
and even by the sensory fibres (58). These inflammatory mediators are believed to play a key role in 
the development of the inflammatory pain (59) which results in the up-regulation of peripheral 
opioid receptors (60). Opioid receptors are first synthesized in the dorsal root ganglion (DRG) and 
then transported along the intra-axonal microtubules into the periphery of the primary afferent neuron 
(61). The inflammation process can also disrupt the perineural barrier surrounding the neurons, 
facilitating the access of opioid ligands to the receptors (62, 63). The peripheral opioid receptors can 
then interact with exogenous or endogenous opioid ligands. Endogenous opioid ligands are found in 
sensory neurons, as well as, in immune cells (49). Their secretion is stimulated by the inflammatory 
soup. Once released from immune cells the opioid peptides activate the up-regulated opioid receptors 
on sensory nerve terminals thus generating analgesia (Fig. 10) (49, 56, 64, 65). 
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Fig. 10. Migration of opioid-containing immune cells and opioid release within inflamed tissue. Adhesion 
molecules facilitate endothelial transmigration of immune cells. In response to stress or releasing agents (e.g., 
CRF, IL-1, CXCL8), the immune cells secrete opioid peptides. Opioid peptides or exogenous opioids bind to 
opioid receptors on primary afferent neurons, leading to analgesia. Copyright © 2013 Iwaszkiewicz, Schneider 
and Hua (56).  
Noteworthy, central and peripheral mechanisms of endogenous opioid analgesia are interconnected, 
particularly in the early stages of inflammation (66), whereas at later stages the peripheral opioid 
antinociception played an an increased role. (67). 
Targeting peripheral endogenous opioid receptors to avoid central side-effects. Several 
attempts were conducted to specifically deliver morphine to peripheral opioid receptors, thus avoiding 
the side effects associated with the over-excitation of the central opioid receptors. With this aim, a 
serie of hydrophilic analogues of morphine were synthesized, among which 14-O-methylmorphine-6-
O-sulfate (14-O-MeM6SU) exhibits peripheral antinociception in rat and mouse inflammatory pain 
models, without displaying central adverse effects (68, 69). S. González-Rodríguez et. al. reported 
another peripherally restricted opioid formulation, by covalently linking morphine to hyperbranched 
polyglycerol (PG-M). Due to the high-molecular weight and the hydrophilicity of this conjugate, 
morphine release was restricted to the injured tissue and blood-brain-barrier permeation was 
hampered which allowed to avoid central side effects of morphine(70). 
Moreover, studies have shown that macrophages and polymorphonuclear leukocytes at the 
inflammation site could secrete a variety of products on exposure to different stimuli. These include 
enzymes from lysosomes that capable of hydrolyzing a wide variety of both natural and synthetic 
substrates, including simple and complex polysaccharides, oligopeptides, polypeptides, phosphate 
esters, lipids, and so forth (71, 72).  
III. OPIOID PEPTIDES FOR DRUG DEVELOPMENT 
Peptide drugs are recognized for being highly specific with low off-target toxicity and, most 
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importantly, they present a remarkable efficiency. Given their attractive pharmacological profile and 
intrinsic properties, peptides represent an excellent starting point for the design of novel therapeutics 
and their specificity has been seen to translate into excellent safety, tolerability, and efficacy profiles 
in humans (73).  
In some cases, distinct differences have been demonstrated for opioid peptide ligands in 
comparison with their nonpeptide counterparts. Indeed, in vivo studies revealed that the high 
specificity of peptide ligands for opioid receptors could minimize off-target side effects compared to 
small molecule ligands (74, 75). However, these endogenous opioid peptides are often not directly 
suitable for use as convenient therapeutics because of their intrinsic weaknesses, including poor 
chemical and physical stability, and a short circulating plasma half-life. In this respect, it was reported 
that extremely high quantities (120 to 200 μg) of enkephalins are required to induce analgesia even 
when microinjected into rat cerebral ventricles (76) and brain (77), due to brain enzymatic activity. It 
was also reported that enkephalins half-life in plasma ranged from few (78) seconds to 2-3 minutes 
(79). These important limitations have to be seriously taken in account for their use as medicines. 
Thus, a range of attempts has been proposed to improve the proteolytic stability of these 
neuropeptides for improving their analgesic activity. These attempts include the chemical 
modification of peptides (enkephalin analogs), the synthesis of prodrugs, the use of enzyme inhibitors 
and the development of novel drug delivery systems. 
1. Enkephalin analogues 
 Incorporation of non-proteinogenic amino acids 
Since the first sequencing of endogenous opioid pentapeptides, extensive researches were 
conducted concerning the chemical modification on enkephalins structure in order to enhance their 
resistance to metabolization (80). For this purpose, thousands of enkephalin analogues have been 
synthesized since then (81). These approaches include the incorporation of nonproteinogenic amino 
acids such as D-amino acids (82), the cyclization (83), the glycosylation (84), and the alteration of the 
amide bond (85).  
 
Fig. 11. Structure of Leu (or Met) enkephalins. 
The fundamental building blocks of peptides and proteins are natural L-amino acids. L-amino acids 
and their D-amino acids enantiomers, shares identical chemical and physical properties, except their 
ability to rotate plane-polarized light (in opposite directions). Unlike L-amino acids, D-amino acids 
rarely act as the substrates of endogenous proteases. The replacement of L-amino acid by its D-
enantiomer represents therefore a very useful tool to prevent proteolytic degradation. With regard to 
this stereochemical advantage, a series of enkephalin analogs containing D-amino acid(s) have been 
synthesized and studied. It is important to note that for enkephalins, the preservation of the structure 
and configuration on Tyr
1
, Gly
3
, and Phe
4
 is essential to preserve peptide’s biological activity (77, 86, 
87). Thus, much more latitude is allowed at the remaining two positions (Gly
2
 and Met/Leu
5
). In this 
context, Pert et al. designed the substitution of glycine in the second position by D-alanine in Met-
enkephalin and in addition, a C-terminal amidation. The resulting analogue ([D-Ala
2
]-Met-enkephalin 
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amide, DALA) considerably increased the in vivo agonist potency of Met-Enkephalin (88). This was 
the first significant step forward in synthesizing an in vivo potent enkephalin derivative. However, its 
analgesic activity has been emphasized only after intracerebroventricular (i.cv.) administration. No 
activity was observed after intravenous (i.v.) administration. The hexapeptide Leu-enkephalin 
analogue dalargin ([D-Ala
2
, Leu
5
]-enkephalyl-Arg), also showed good blood stability (81). Like 
DALA, dalargin only induced analgesic effects after i.cv. injection. No pharmacological activity was, 
indeed, observed after its systemic administration (89). It has to be noted that the replacement of D-
alanine by D-methionine (90, 91) or D-norleucine at position 2 increased peptide stability.  These 
analogues were actually more resistant to metabolization than those with D-alanine. However, 
substitution by basic (D-lysine) or aromatic (D-phenylalanine) amino acids reduced peptides’ activity. 
A real breakthrough was achieved when proline residue was introduced in position 5 (92). These 
proline analogues were the first systemically (intravenously and subcutaneously) active enkephalin 
derivatives. Interestingly, the substitution of methionine in position 5 with its D-isomer or with D-
proline did not increase the efficacy, if comparing them to the most active proline enkephalin-
analogues i.e. to [D-Ala
2
, Phe
5
]- enkephalin amide (coded as GYKI-14 238). This analogue was found 
to be 80-times more efficient than morphine when i.cv. injected and about twice more potent if 
administrated intravenously both in mice and rats (88, 91, 93). Analogs such as [D-Ala
2
, MePhe-Met 
(O)-ol
5
]-enkephalin (FK-33824) (94) and [D-Thr
2
, Thz-NH2
5
]-enkephalin (95) have also been found 
to be excellent analgesics. For instance, FK-33824 was tested clinically in human volunteers. 
However, because of its serious side effects, clinical trials had to be stopped. Receptor selectivity 
could also be manipulated in this way. DAMGO ([D-Ala
2
, N-MePhe
4
, Gly-ol]-enkephalin, μ-opioid 
spscific ligand) and DADLE ([D-Ala
2
, D-Leu
5
]-Enkephalin, δ-opioid spscific ligand) are two 
successful example of this strategy.  
 Cyclization 
The small, linear pentapeptide enkephalins are flexible molecules and their biologically active 
conformation may only be realized through their complexation with the corresponding receptor. In 
this way, cyclization of enkephalins represents an important route to chemically modulate peptide 
structure and activity, in order to promote enzymatic stability and to maintain the peptide drug 
structure in a rigid conformation that can promote receptor binding. Actually, the reduction in 
conformational freedom by cyclization may result in higher receptor-binding affinities (96). In 
general, the stability of the cyclic analogues were remarkably higher than the corresponding native 
peptides, due to the lack of both carboxyl and amino termini (97). Unfortunately, in vivo, the 
development of these peptides into viable clinical candidates has been limited by their lack of 
enzymatic stability and undesirable physicochemical properties.  
Therefore, the cyclic prodrug strategy (Fig. 12) was employed to create cyclic peptide prodrugs 
that would overcome these problems, while maintaining the biological activity. This strategy has three 
main objectives: (i) to enhance membrane permeation, (ii) to increase metabolic stability towards exo- 
and endopeptidases, and (iii) to promote rapid prodrug bioconversion.  
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Fig. 12. A schematic illustration of prodrug concept. The linkage of a promoiety to the peptide can increase 
its lipophilicity, resulting enhanced permeability through biological barriers.  
In this context, cyclic peptide prodrugs were designed to further increase the metabolic stability of 
DADLE towards peptidases. This approach was accomplished through the cyclisation of the N- and 
C-termini of the peptide. The cyclic design resulted in DADLE prodrugs with greater stability against 
exo- and endopeptidases (98, 99). In fact, the group of Ronald T. Borchardt has synthesized a series 
of esterase-sensitive cyclic prodrugs of enkephalin and DADLE with different promoiety linkers, i.e., 
acyloxyalkoxy (AOA) (100, 101), coumarinic acid (CA), phenylpropionic acid (PPA), or oxymethyl-
modified coumarinic acid (OMCA) linkers (Fig. 13) (98, 102). These cyclic prodrugs exhibited high 
lipophilicity and low hydrogen bonding potential, which are the favorable physicochemical 
characteristics for optimal transcellular permeation (103). During this route of permeation, the 
prodrugs travel through the cells membrane, and then, released in vitro and in vivo the parent active 
peptide via esterase-sensitive pathway. However, these prodrugs were also proved to be substrate for 
efflux transporters P-glycoprotein (Pgp) (expressed on luminal membranes of the endothelium blood 
vessel) which thus restricted their blood-brain-barrier (BBB) permeation (104, 105).  
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Fig. 13. Cyclic prodrug strategies of opioid peptides. (A) Acyloxyalkoxy-based prodrug; (B) phenylpropionic 
acid-based prodrug; (C) coumarinic acid-based prodrug. Copyright © 1999 Elsevier Science B.V. Used with 
permission. 
 Others 
Replacement of the amide bond(s) by thiomethylene ether linkage or thioamide can also lead to 
enkephalin analogues with increased stability in serum (85, 106). However, the amide bond 
replacement led to a loss of selectivity and efficiency towards δ-opioid receptors in comparison with 
their parent compounds (107). On the other hand, Glycosylation strategy, which consists in coupling 
a glycosyl units to opioid peptides, was also adopted in order to prevent peptide metabolisation and to 
improve the BBB translocation (108). However, the linkage of β-D-glucose to Met-enkephalin 
analogue peptide resulted in a decrease of opioid receptors binding and a total inactivity in vivo. (109).  
2. Enzyme inhibitors 
As mentioned above, enkephalins are substrates of peptidases which hydrolyse them in inactive 
fragments. The aminopeptidases N (APN) [EC 3.4.11.2], for instance, cleave the N-terminal Tyr
1
-
Gly
2
 bond, while neutral endopeptidases (NEP) [EC 3.4.24.11] or angiotensin converting enzymes 
(ACE) cleave the Gly
3
-Phe
4
 bond. In addition, a dipeptidyl peptidase III (DPP III) [EC 3.4.14.4] 
cleaves the Gly
2
-Gly
3
 bond, whereas the carboxypeptidase A [EC 3.4.17.1] cleaves the Phe
4
-Leu
5
 (or -
Met
5
) bond (Fig. 14) (110, 111).  
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Fig. 14. Inactivation of endogenous enkephalins by various enzymes. 
Therefore, a novel approach to prolong the anti-nociceptive activity of enkephalins was proposed 
by using enkephalinases inhibitors. In general, once released within the extracellular space following 
prolonged depolarization of the neuronal membrane, enkephalins activate the opioid receptors before 
being quickly removed from the synaptic cleft and degraded by enkephalinases. Thus, the inhibition 
of these enkephalin-degrading enzymes may result in an extended duration of action of enkephalins, 
thus prolonging their anti-nociception effect. Biological studies showed that thiorphan, a NEP 
inhibitor (112) or bestatin, an APN inhibitor (113) could only partially prevent enkephalin catabolism, 
whereas their combination resulted in a better reduction of peptide degradation leading to a higher 
analgesic response (113). It is important to note that the degradation of enkephalins is induced by the 
concomitant action of APN, NEP and DPP III enkephalinases, and especially by APN and NEP. 
Hence, inhibition with only one inhibitor didn’t show improvements in anti-nociceptive responses 
(114, 115). The development of dual or multiple inhibitors of enkephalinases (110) was then tested 
thereafter. The enkephalinases inhibitors have been classified as illustrated in Fig. 15 according to 
their respective substrates.  
 
Fig. 15. Classification of enkephalin degrading enzyme inhibitors. (110) 
In order to improve analgesic potency, highly potent inhibitors of multiple enkephalinases, able to 
coordinate the catalytic zinc ion of metallopeptidases, were also designed. Indeed, enkephalin-
degrading enzymes such as aminopeptidases, enkephalinase, dipeptidylaminopeptidases, belong to the 
family of metallopeptidases. These peptidases cleave their substrate (the enkephalin) in a single step 
involving solvent molecule (water) and a catalytic metal ion such as Zinc. In order to inhibit these 
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metallopeptidases, zinc-chelating agents were built by introduction of hydroxamate group, able to 
coordinate metallopeptidases active zinc site (116, 117), therefore blocking their metabolic activity. 
Compounds such as kelatorphan (118) or RB-38A are two examples of such inhibitors, which 
exhibited an analgesic potency significantly higher than that of bestatin/thiorphan combination in vivo. 
Based on this concept, a large number of bidentate-containing inhibitors with nanomolar affinities for 
both APN and NEP have been synthesized. However, in vivo, these compounds could not cross the 
blood-brain-barrier after systemic administration, because of their high hydrophilic properties. But, a 
promising orally administered ONO-9902 enkephalinase inhibitor was shown to produce significant 
effects in cases of visceral pain. Subsequently, a series of lipophilic “dual prodrug inhibitors”, able to 
block two different enzymes and crossing the BBB were developed, such as RB101 (119, 120). These 
dual compounds were made up by the association through a disulfide bond of β-amino thiol, a potent 
inhibitor of APN, with a mercaptoacylamino ester, a potent NEP inhibitor. RB101 was shown to cross 
the BBB after i.v. administration and could generate the release of APN and NEP inhibitors after 
disulfide bond cleavage by cerebral reductases. Then, once chelating the metallopeptidases in the 
brain, both APN and NEP inhibitors contributed to the increase of enkephalins level, thus inducing a 
prolonged anti-nociceptive effect. However, the duration of the action was short. On the other hand, 
the oral administration of RB-101 led to the absence of any pharmacological activity, probably due to 
precipitation within the gut. RB 120, a structural analogue of RB 101, has been synthesized 
subsequently, and showed strong analgesic effects in mice and rats after oral administration (121). 
Another promising dual enkephalinase inhibitor PL265 which acts by inhibiting APN and NEP, was 
developed by Bernard P. Roques et al. It is a prodrug with cleavable carbamate as N-terminal 
protection and can be slowly transformed in plasma into its active metabolite (PL254), which inhibit 
both APN and NEP (122). Administrated orally, this inhibitor allowed an increase of the local 
concentration of enkephalins, thus triggering a local and sustainable pain relief. PL265 completed a 
phase Ia single ascending dose and demonstrated good safety. The compound is currently being 
evaluated in a phase Ib multiple dose escalation for neuropathic pain at Pharmaleads (123, 124). A 
new series of dual aminophosphinic inhibitors of the two enkephalin-catabolizing enzymes has also 
been designed (125, 126). Among them, RB3007 presented all the antinociceptive properties of 
RB101 but with a significant increase in the duration of action after systemic administration (i.p., i.v., 
or p.o.). 
In this way, Enkephalin-degrading enzyme inhibitors are high beneficial since they allow the 
increase of enkephalins concentrations, thus producing a potent analgesic activity without the opioid-
like side effects. It was also reported that high-dose dual enkephalinase inhibitors therapy didn’t result 
in respiratory depression, emesis, constipation, sedation, tolerance or dependence (127). However, the 
problems with this approach center on the lack of biochemical selectivity towards the peptidase 
involved in enkephalins metabolism. It should be stressed that enkephalins are not the only substrates 
of NEP and APN, and the possible involvement of these enzymes in other peptidergic pathways that 
have not been characterized cannot be excluded (128, 129).  
3. Gene therapy 
Gene therapy represents another potential approach for chronic pain treatment. It introduces genetic 
materials (DNA or RNA) for the over-expression of endogenous analgesic or anti-inflammatory 
compounds, or to inhibit genetic transcription of nociceptive proteins. As mentioned before, opioid 
peptides play an essential role in the control of pain. They are derived from the protein precursor, 
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such as proenkephalin (ProEnk) or pro-opiomelanocortin (POMC), which in turn is encoded by the 
corresponding Preproenkephalin (PPE) or Preproopiomelanocortin (PPOMC) genes. Gene therapy 
was applied to these neuropeptides precursor genes by cloning their complementary DNA (cDNA) 
fragments to import the coding sequence in host cells to express those specific neuropeptides. In that 
respect, PPE cDNA- or PPOMC cDNA-coated gold microcarriers (1.5 to 2.0 μm) were injected into 
the bladder wall of adult female rats using gene gun technique to suppress the nociceptive response on 
bladder hyperactivity induced by intravesical acetic acid or capsaicin. These data suggested that the 
PPE gene increased expression of enkephalins in bladder which resulted in the suppression 
nociceptive responses (130, 131). Despite these encouraging results, the progress of gene gun in 
clinics is challenged due to its limited efficiency to transfect larger and deeper areas, and because of 
its high cost (132).  
Viral-mediated gene transfer is more commonly used for pain alleviation (133). Viral vectors 
include adenovirus (AdV), adeno-associated virus (AAV), retrovirus, and herpes simplex virus (HSV) 
vectors. HSV vectors represent an obvious candidate for the delivery of opioids to primary afferents 
(Fig. 16). Indeed, HSV infections naturally begin in peripheral tissues, travels along sensory nerve 
fibers and hides out indefinitely in ganglia aligned near the brain and spinal cord (134). Moreover, as 
approximately half of the HSV genome is not essential for its replication in cell cultures (135), 
numerous viral genes can be replaced with multiple or large therapeutic transgenes.  In addition, 
unlike with other viral vectors, the potential risks of viral integration into host genome are avoided, 
which reduces the possibility of mutagenic events (136-138). The first HSV vector-based gene 
therapy that has been reported with analgesic properties was a replication-competent vector. It was 
derived from attenuated viruses which were genetically modified, in order to express PPE. This viral 
vector inducted an increase of enkephalin peptides which were released from transduced neurons(139). 
J. M. Antunes Bras et. al. demonstrated that the inoculation of the viral vector into the footpad 
resulted in a strong expression of preproenkephalin mRNA in the dorsal root ganglion. Increased 
levels of radioimmunoassayable Met-enkephalin-like material was also detected in the dorsal root 
ganglion and in the dorsal horn of the spinal cord (140). Moreover, this gene therapy approach 
encoding PPE has been tested and shown to be effective for treating inflammatory, neuropathic, and 
visceral pain in various rat models (141-146). This strategy has been pushed into phase I clinical trial, 
showing that this treatment was well tolerated (139, 147). However, the phase II study did not meet its 
primary objective of reducing pain in subjects with severe intractable cancer pain.  
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Fig. 16. HSV-mediated enkephalin (Enk) expression in chronic pain conditions. (1) Intradermally injected 
HSV particles are taken up into sensory nerve endings. (2) The viral nucleocapsid is retrogradely transported to 
the neuronal perikaryon in the dorsal root ganglion (DRG). (3) The DNA delivered by the HSV vector remains 
in the nucleus of the host cell and is transcribed by the host transcription machinery. (4) The synthesized Enk is 
transported to the presynaptic terminals of primary nociceptive afferents, where it is released (5). This Enk can 
activate opioid receptors that are found presynaptically on the terminals of primary nociceptive afferents. HSV 
vectors can also spread transsynaptically from neuron to neuron and can induce expression of Enk in other 
neurons of the CNS. Copyright © 2016 Elsevier Inc. (148) 
4. Nanomedicine 
Recently, application of nanotechnology in drug delivery has attracted great attention. It allowed 
the development of nanoparticle-based drug formulations (nanomedicines) able to deliver drugs to 
specific tissues and provide controlled release. This targeted and sustained drug delivery may 
decrease the drug related toxicity and increase patient’s compliance with less frequent drug 
administrations. Nanomedicines are, on the other hand, very useful to increase drug stability, aqueous 
solubility, absorption and bioavailability.  
In the past few decades, considerable attention has been focused on the development of novel drug 
delivery systems for peptide drugs in order to protect them from enzymatic degradation and to carry 
the transported peptides to the site of action.  
As mentioned before, a majority of the opioid receptors exists in the central nervous system. 
However, the accessibility of the administered neuropeptides to their receptors in the brain is 
insurmountably restricted by the blood-brain-barrier (BBB), which is a highly selective semi-
permeable hurdle that separates the blood circulation from the brain. The same type of barrier exists 
also in the spinal cord and is called the blood-spinal cord barrier (BSCB)(149). The BBB controls 
the CNS homeostasis, allows the proper neuronal function, as well as, the protection of the neural 
tissue from toxins and pathogens. The presence of tight junctions between adjacent endothelial cells 
forms the most tight cell-to-cell connection. There are several natural transport routes by which 
molecules can cross the BBB or the BSCB (Fig. 17). Small water-soluble molecules simply diffuse 
through the tight junctions when small lipid soluble substances, like alcohol and steroid hormones, 
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penetrate transcellularly. However, with regard to the other essential molecules for CNS, they take 
specific transport routes such as transport proteins (carriers), specific receptor-mediated or vesicular 
mechanisms (adsorptive transcytosis) to cross the BBB (150). Highly hydrophilic molecules, such as 
the neuropeptides with molecular weights often exceeding 500 Da, are not able to cross the BBB 
using these natural transport routes. Thus, the conception of drug delivery systems protecting the 
neuropeptides from degradation and allowing them to reach the opioid receptors located in the 
nervous system is a challenging goal. Indeed, despite numerous attempts, only few nanoparticulate 
drug delivery systems could be applied to enkephalins or enkephalin derivatives as reported below. 
 
Fig. 17. Transport routes across the BBB. 
Poly (butylcyanoacrylate) (PBCA) nanoparticles (NPs) were the first polymer-based nanoparticle 
system used to deliver drugs to the CNS (151-155). In these first studies, dalargin (Tyr-D-Ala-Gly-
Phe-Leu-Arg), a synthetic analog of enkephalin, was incorporated onto the surface of NPs before 
coating with polysorbate 80. In vivo studies demonstrated that dalargin-loaded PBCA particles 
exhibited an anti-nociceptive effect (152, 156). More extended studies showed that polysorbate 80 
(also known as Tween 80) appeared to enhance the CNS penetration of systemically-delivered 
polymer nanoparticles (153, 157, 158). Concerning the mechanism of action, Kreuter et al. 
hypothesized that apolipoproteins B and E were involved in the mediation of polysorbate 80-coated 
PBCA NPs transport across the BBB. Polysorbate 80-coated NPs could, indeed, adsorb these 
apolipoproteins from the blood circulation after iv injection and subsequently ressemble lipoprotein 
particles to undergo endocytosis by brain capillary endothelial cells (receptor-mediated endocytosis) 
(155, 159, 160). This mechanism is, however, still controversial (161). Of note, the potential toxicity 
associated with polysorbate 80-coated PBCA nanoparticles is one of the important concerns 
remaining with this approach (162) since polysorbate 80 was shown to induce BBB disturbance 
following i.v. injection (163, 164).  
Among all polymers, poly(lactic-co-glycolic acid) (PLGA) was the most widely-applied in biology 
and biomedicine fields. Indeed, these biocompatible and biodegradable polymers decompose inside 
the body in non-toxic natural byproducts such as water and carbon dioxide. These biomaterials were 
approved by the FDA for clinical use in humans (165), and have been extensively envisaged for the 
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vectorization of drugs, proteins and various other macromolecules such as DNA, RNA and peptides. 
In that respect, among neuropeptides, only Dalargin was incorporated into PLGA or PEGylated 
PLGA NPs (166). However, no in vivo studies have been reported so far.  
Chitosan is another interesting polymer that has been extensively used in medical application. It is 
either partially or fully deacetylated chitin, giving the chitosan nanoparticles a positive charge. This 
mucoadhesive biocompatible polymer was approved by the U.S. FDA for dietary use and wound 
dressing applications (167). However, positively charged chitosan is only soluble in acidic conditions. 
On the contrary, Trimethyl chitosan (TMC) is a water soluble positively charged quaternized chitosan 
derivative, devoid of toxicity and presenting the same mucoadhesive properties than chitosan. LENK-
loaded TMC nanoparticles has been designed for brain delivery of LENK via the nasal route (168). 
This readily accessible route of administration is of great interest for delivering hydrophilic drugs to 
the brain, along the olfactory and trigeminal nerve pathways.  Indeed, it is known that nasal mucosa 
has a highly vascularized epithelium, a porous and easily accessible endothelial membrane and a large 
surface area for rapid drug absorption. As a cationic ligand, TMC was supposed to facilitate the active 
transport of nanoparticles via absorption-mediated transcytosis through the BBB. Enhanced brain 
uptake of LENK, as well as, significant improved antinociceptive effect were observed with this 
nanoformulation.  
The group of I. F. Uchegbu has proposed a strategy for Leu-enkephalin (LENK) brain delivery via 
oral route. For this purpose, they developed palmitic LENK prodrug nanofibers coated with chitosan 
amphiphile polymer (GCPQ). The oral route administration of this nanoparticle-prodrug formulation 
increased the brain drug levels by 67% and significantly increased LENK’s antinociceptive activity 
(169). In that respect, this technology increased the upper gastrointestinal drug residence time due to 
the adherence of GCPQ NPs to the gastrointestinal mucosa. Once absorbed into the blood the prodrug 
is bioconverted to LENK by plasma and liver esterases (170-172). Of note, a nanoformulation of 
native LENK coated by chitosan polymer (LENK-GCPQ) exhibited similar brain levels of LENK, 
while the pharmacodynamic activity was shorter in duration. These results are quite surprising since 
the bioavailability of nanoparticles after oral administration remains in general very low. And since 
2012, there was no follow-up concerning this approach.  
The use of liposomes as drug carriers for transdermal delivery of Leu-Enkephalin (LENK) using 
iontophoretic transport was also investigated by Ajay K. Banga et. al. The experiments were 
conducted under pH conditions corresponding to LENK isoelectric point and were performed using 
human cadaver skin (173, 174). This preliminary ex vivo study indicated that the liposomal 
formulation prolonged the protection of the LENK from degradation which occured into the skin by 
proteolytic enzymes. However, once released from the liposomes during transdermal transport, the 
neuropeptide underwent rapid degradation within the skin. 
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Squalenoylation: 
 
Squalenoylation technology, an innovative and original concept, allows the formation of a wide range 
of drug molecules as nanoparticles in order to increase their bioavailability and pharmacological 
efficacy. 
 
Squalenoylation involves the linkage of squalene to therapeutic agents, in order to create squalene 
based bioconjugates (or prodrugs) which have the ability to form nanoparticles. Compared with other 
nanocarries, squalenoylation represents a novel technology with numerous advantages: 1) significant 
high drug loading; 2) free of the "burst" release; 3) enhanced drug concentration within targeted 
tissues. 
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ABSTRACT OF THE ARTICLE 
This article reviews the innovative and original concept the “squalenoylation”, a technology 
allowing the formulation of a wide range of drug molecules (both hydrophilic and lipophilic) as 
nanoparticles. The "squalenoylation" approach is based on the covalent linkage between the squalene, 
a natural and biocompatible lipid belonging to the terpenoid family, and a drug, in order to increase its 
pharmacological efficacy. Fundamentally, the dynamically folded conformation of squalene triggers 
the resulting squalene-drug bioconjugates to self-assemble as nanoparticles of 100–300 nm. In general, 
these nanoparticles showed long blood circulation times after intravenous administration and 
improved pharmacological activity with reduced side effects and toxicity. This flexible and generic 
technique opens exciting perspectives in the drug delivery field.  
 
Keywords: Squalenoylation, Prodrug, Nanoassemblies, Drug loading, Oncology, Intracellular 
infections, Neurological disorders 
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1. INTRODUCTION 
 The use of nanotechnology in drug delivery has gained great attention in recent years. 
Nanocarriers can be used to increase drug stability and solubility, deliver drug to specific site in the 
body and thus minimize the side effects. The concept of nanocarrier was inspired by the idea of the 
“magic bullet”, proposed by Paul Ehrlich at the beginning of 20th century (1). However, it was only 
until the 1970s that the first nanoparticles were developed by professor Peter Speiser and his 
colleagues (2). Nanocarriers have been extensively studied since then. So far, different kinds of 
nanocarriers have been explored, such as nanoparticles, liposomes, polymersomes, micelles, 
dendrimers, ultrasmall iron oxide nanoparticles (USPIO) etc. However, despite the impressive 
progress made in the design of various nanoparticles, only a few nanoparticle-based medicines have 
reached the market. In other words, currently available nanoparticle technologies have not been able 
to improve the activity of a great number of drugs. This is probably due to the following reasons: (i) 
Poor drug loading (the ratio of the transported drug to the total material), which usually does not 
exceed 5%. As a result, a great quantity of carrier materials needs to be administrated in order to reach 
a pharmacologically active concentration of the drugs, which in turn may generate toxicity and 
undesirable side-effects and (ii) "Burst" release of the drug immediately after intravenous 
administration, generally corresponding to the release of the drug fraction which is simply adsorbed 
(or anchored) at the surface of the nanocarrier. As a consequence, a significant fraction of the drug 
will be released before reaching the pharmacological target in the body, resulting in lower activity and 
more side effects.  
Among these colloidal systems, lipid-drug conjugates (LDC) nanoparticles have exhibited 
considerable advantages in some cases because of their high drug payload. They have been shown to 
prolong drug release, decrease toxicity, improve pharmacokinetic properties, and increase the 
therapeutic index of the corresponding drugs (3). There have been some reports of LDC that already 
reached clinical trials (4, 5). In this context, Couvreur et al. have developed a novel lipid-drug 
conjugate nanoparticle platform based on squalene (6). 
Squalene is a natural endogenous lipid belonging to the terpenoid family. It is an intermediate 
metabolite in the synthesis of cholesterol, structurally similar to beta-carotene. It is widespread in 
nature and with reasonable amounts found in shark liver oil, olive oil, wheat germ oil and rice bran oil. 
It received its name because of its occurrence in shark liver oil (Squalus spp.) (7). In human body, 
squalene is produced in the liver and the skin, transported by very low density lipoproteins (VLDL) 
and low density lipoprotein (LDL) in the blood, and then secreted in large quantities by the sebaceous 
glands (8, 9). It is well tolerated after exogenous administration, whether parenterally or orally, and its 
high oral absorption (>60%) may be used to increase the oral bioavailability of some drugs. 
Additionally, squalene has been extensively used as excipient in several pharmaceutical formulations 
for oral and parenteral administration, but it has never been used as covalent partner for drug delivery 
and targeting purposes before the introduction of the "squalenoylation" by Couvreur's group (6). 
Squalenoylation involves the linkage of squalene to therapeutic agents, in order to create squalene 
based bioconjugates (or prodrugs) which have the ability to form nanoparticles. Since prodrugs are 
bioreversible derivatives that undergo an enzymatic and/or a chemical transformation in vivo to 
release the active drug, bio-cleavable linkages, such as direct ester or amide bond, have been used 
between squalene and the drug. It should be noted that sometimes, for chemical incompatibility 
reasons or steric hindrance, the synthesis of bioconjugates required the intercalation of a spacer 
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between the ester or amide bond and the squalene. Thus, the synthesis of various squalene-drug 
conjugates involves first the functionalization of one of the terminal double bond of the squalene into 
acid, amino or hydroxyl group, as seen in Fig. 1, to allow further conjugation with therapeutic 
molecules. 
 
Fig. 1. Chemical structures of squalene and squalene derivatives. 
Owing to the rigid structural property of squalene, the resulting squalene-drug conjugates may self-
assemble in aqueous media without the use of any surfactant into compacted nanoparticles with high 
drug loading. The nanoparticle conformation allows protecting drug molecules from 
degradation/metabolization, which results in greater plasmatic half-life, when a controlled and 
prolonged release of the drug may also be obtained. Unlike polymer nanoparticles or liposome 
nanoformulations which encapsulate by physical means the active principles into their matrices, the 
squalene-drug conjugates nanoparticles employ a chemical encapsulation approach, thus avoiding the 
"burst" release (6). Moreover, these nanosystems facilitated drug's passage through biomembranes 
due to the lipophilic properties of squalene, resulting in an enhanced drug concentration within 
targeted tissues and cells and generating dramatic increase in drug pharmacological activity. This 
article aims to give an overview of recent advances in the development of squalene-based 
nanoparticles, a generic platform for the discovery of new nanomedicines.  
2. SQUALENE-BASED BIOCONJUGATES WITH HYDROPHILIC DRUGS 
2.1. Squalene-nucleoside analogue prodrugs 
Nucleosides are endogenous compounds involved in the synthesis of DNA and RNA. Nucleoside 
analogues are chemically modified molecules that were developed to mimic their physiological 
counterparts in terms of cellular uptake, cellular metabolism and incorporation into newly synthesized 
DNA and RNA, for instance in order to inhibit DNA chain elongation. Some nucleoside analogues 
can also interact with and inhibit the enzymes involved in the synthesis of DNA and RNA, including 
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DNA or RNA polymerases, kinases, pyrimidine and purine nucleoside phosphorylase and DNA 
methyltransferases (10), etc. All these effects may lead to inhibition of cell division or viral 
replication. Thus nucleoside analogues have great potential in the treatment of cancer (such as 
cytarabine, gemcitabine, mercaptopurine), viral infection (such as didanosine, zalcitabine), 
rheumatologic diseases (such as azathioprine, allpurinol) and even bacterial infections (such as 
trimethoprim). 
However, these compounds face various limitations that restrict their use. They have a short plasma 
half-life, undergo rapid intracellular and extracellular metabolism, and have a poor permeability 
across biological membranes due to their hydrophilicity. On the other hand, most of them display 
severe side effects because of lack of specificity and they induce resistance to treatments of cancer 
and infectious diseases. Squalenoylation of these hydrophilic molecules were proposed and developed 
to increase their therapeutic index and decrease above-mentioned side effects (11). 
 
Fig. 2. Chemical structures of squalene-nucleoside (T-SQ: thymidine-squalene; Ad-SQ: adenosine-
squalene), squalene-nucleoside analogue (Gem-SQ: gemcitabine-squalene; ddC-SQ: 2′,3′-
dideoxycytidine-squalene; ddI-SQ: 2′,3′-dideoxyinosine-squalene) and squalene-nucleoside analogue 
monophosphate (Gem-SQ-MP: gemcitabine-squalene monophosphate; ddC-SQ-MP: 2′,3′-
dideoxycytidine-squalene monophosphate) conjugates.  
2.1.1. Squalene-Gemcitabine prodrugs 
Concerning cancer treatment, “squalenoylation” was first applied to the delivery of nucleoside 
analogues such as gemcitabine (dFdC) in order to inhibit DNA replication in cancer cells (6). 
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Gemcitabine has been demonstrated to be active against a wide range of solid tumors, including colon, 
lung, pancreatic, breast, bladder, and ovarian cancers (12, 13). However, this molecule is rapidly 
metabolized in the body by deoxycytidine deaminase into the chemotherapeutically inactive uracil 
derivative (14, 15), resulting in a short plasma half-life (1.5 h). Another concern is the drug resistance 
due to nucleoside transporter down regulation or to deoxycytidine kinase (dCK) deficiency. 
 
Fig. 3. Cryo-TEM images of Gem-SQ NAs. The supramolecular organization is clearly visible. NAs of 
hexagonal shape (A and B) are surrounded by an external shell and display an internal structure. The Fourier 
trans-forms of (A) and (B) assessed by ImageJ software reveal a hexagonal symmetry (D) between columns 
with a 4.67-nm periodicity (C). Figures adapted with permission from [16]. © 2008 John Wiley & Sons. 
Squalenoylation of gemcitabine was achieved by covalent coupling of the squalene derivative, 
squalenic acid, with gemcitabine. In order to protect gemcitabine from deamination, squalenic acid 
was linked onto the amino group of the nucleoside heterocycle through an amide bond (Fig. 2). The 
resulting gemcitabine-squalene (Gem-SQ) bioconjugates could self-organize as homogeneous 
nanoassemblies (NAs) with average diameter of 130 nm in aqueous solutions and with a unimodal 
size distribution (6). The use of surfactant is not necessary to provide colloidal stability of Gem-SQ 
NAs. The internal structure of Gem-SQ nanoparticles, using cryogenic transmission electron 
microscopy (cryo-TEM) and small angle X-ray scattering (SAXS), revealed an inverse hexagonal 
structure, with a lattice parameter of 87.7 Å, which was the first report of hexagonal-type organization 
with squalene derivative (Fig. 3). The aqueous cores of close-packed cylinders were ringed by 
hydrophilic gemcitabine molecules linked to squalene chains (16, 17). The gemcitabine loading was 
41%, which is much higher than when gemcitabine was encapsulated in more conventional 
nanoparticles (i.e., liposomes or polymer nanoparticles). When entrapped into NAs, gemcitabine was 
protected from deamination after incubation in plasma (80% of the Gem-SQ remained intact after 24 
h). In vitro, it was found that Gem-SQ was hydrolyzed and free gemcitabine released after incubation 
with cathepsin B and D, two lysosomal enzymes responsible for degrading amide-bearing drugs. 
Gem-SQ NAs were found to be 6- to 8-fold more cytotoxic than gemcitabine free on MCK-7 and 
KB3-1 cells, respectively (6). Because, as discussed before, the induction of resistance represents an 
important limitation in gemcitabine treatment, murine resistant leukemia L1210 10K cells (deficiency 
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in deoxycytidine kinase responsible for gemcitabine phosphorylation) and human leukemia resistant 
cell line CEM/ARAC8C (nucleoside transporter-deficient cell line) were chosen to test the efficacy of 
Gem-SQ NAs. The greater cytotoxicity of Gem-SQ NAs on these two cell lines indicated ability of 
these nanoparticles to overcome cellular resistance (18), which was explained, in the L1210 10K cell 
line, by the slow release of gemcitabine from the NAs, avoiding to overflow the low intracellular 
enzymatic activity of deoxycytidine kinase. Moreover, the protection of gemcitabine from 
deamination under NAs formulation also contributed to this potent effect. On the other hand, the 
higher cytotoxicity of Gem-SQ NAs on CEM/ARAC8C cells, in comparison with gemcitabine free, 
was probably due to their difference of cellular uptake pathway. The uptake of the latter is nucleoside 
transporter dependent, while for Gem-SQ NAs, passive diffusion constitutes the main cell penetration 
corridor. In more details and as shown in Fig. 4, it was observed that Gem-SQ monomers were first 
released from the NAs once associated with extracellular proteins, and then diffused toward the cell 
plasma membrane where they accumulated in large quantities. Gem-SQ molecules then distributed 
between cell plasma membrane and the intracellular membranes. Finally, Gem-SQ bioconjugates 
underwent enzymatic cleavage by cathepsins B and D on the amide bond, and free gemcitabine was 
released, allowing the expression of biological activity after triphosphorylation by dCK (19, 20). Thus, 
in the case of Gem-SQ NAs, the deficiency of nucleoside transporter in CEM/ARAC8C cells didn’t 
affect the penetration of gemcitabine inside cells and didn't abolish anticancer activity. All these 
results showed that SQdFdC NAs were able to bypass various types of resistance mechanisms in 
leukemia cells, resulting in greater cytotoxicity compared to the gemcitabine free. 
 
Fig. 4. Intracellular metabolization pathway of Gem-SQ. Gem-SQ monomers are firstly released from the 
NAs mediated by extracellular proteins, followed by diffusing toward the cell membrane. The Gem-SQ 
molecules are then distributed between cell membrane and the intracellular membranes. Afterward, free 
gemcitabine is released after the cleavage of the amide bond between squalene and gemcitabine, which is either 
phosphated into the biological active dFdC-TP, or pumped out of the cell through equilibrative membrane 
transporters. Adapted with permission from [20], © 2010 Elsevier. 
Gem-SQ NAs also exhibited superior in vivo anticancer activity on a mouse aggressive metastatic 
leukemia model grafted by intravenous injection of L1210 wt cells (18). Interestingly, groups treated 
with Gem-SQ NAs showed higher survival rates than those treated with free gemcitabine. Almost half 
of the mice (~43%) survived after treatment with Gem-SQ NAs (15 mg/kg eq. gemcitabine) (Fig. 5). 
The anticancer activity of Gem-SQ NAs was then compared with gemcitabine at maximum tolerated 
doses (MTD, 4×20mg for Gem-SQ NAs versus 4×100mg in the case of free gemcitabine) in L1210 
wt bearing mice (21). Gem-SQ NAs were much more efficient than gemcitabine at MTD, leading to 
Figure 4. Cell penetrationand intracellular fate of Gem-SQ. Gem-SQ monomersare firstly released from the NAs mediated by 
extracellular proteins, followed by diffusing toward the cell membrane.The Gem-SQ molecules are then distributed between cell 
membrane and the intracellular membranes. Afterward,free gemcitabine is released after the cleavage of the amide bond between squalene 
and gemcitabin, which is either phosphated into the biological active dFdC-TP, or pumped out of the cell through through equilibrative 
membrane transporters. Adapted with permission from [19], © 2010 Elsevier. 
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75% long-term survivors. 
 
Fig. 5. Survival of the mice after treatment of Gem or Gem-SQ. Untreated (—), SQ NAs (– –), SQ + Gem 5 
mg/kg ( ), Gem 5 mg/kg (▬ ▬), Gem-SQ NAs equivalent to 5 mg/kg Gem (▬), Gem 15 mg/kg (····), 
Gem-SQ NAs equivalent to 15 mg/kg Gem (─ · ─), n = 7–8. *Kaplan–Meier test was significant for the L1210 
wt leukemia bearing mice at both 5 mg/kg and 15 mg/kg (P < 0.05) doses. Figures adapted with permission 
from [18]. © 2007 Elsevier. 
Because gemcitabine is the main chemotherapeutic agent for the treatment of pancreatic cancer 
which represents the fourth commonest cause of cancer-related death in western countries (22), Gem-
SQ NAs were also tested on experimental model of pancreatic cancer (23). Thus the anticancer 
activity of Gem-SQ NAs was evaluated on pancreatic cancer cell lines in vitro. In comparison with 
free gemcitabine, Gem-SQ NAs exerted higher antiproliferative and cytotoxic effects against Capan1 
and BxPc3 sensitive cell lines and Panc1 resistant cell lines. In addition, Gem-SQ NAs were found to 
demonstrate higher inhibition of tumor growth in both Panc1 and Capan1 subcutaneous tumor models. 
To be closer to clinical situation, a Panc1 orthotopic mouse model was also considered to test the 
anticancer activity of Gem-SQ NAs comparatively to gemcitabine. It was observed that Gem-SQ NAs 
inhibited the growth of primary tumors by 68%, which was 36% higher than after treatment with free 
gemcitabine. Additionally, comparatively to gemcitabine free, Gem-SQ NAs led to longer survival of 
mice bearing primary pancreatic tumor. These results correlated with a higher induction of cellular 
apoptosis as determined by TUNEL analysis and caspase-3 staining, and a higher reduction of the 
proliferation maker Ki67 in the tumor tissue after Gem-SQ NAs treatment. 
 Pharmacokinetics study of Gem-SQ NAs after intravenous injection showed controlled and 
prolonged release of gemcitabine. It considerably increased plasma half-life and mean residence time 
compared with free gemcitabine. Additionally, the linkage of gemcitabine to squalenic acid on its 
amino group noticeably delayed the metabolism of gemcitabine into its inactive difluorodeoxyuridine 
metabolite (dFdU), compared with free gemcitabine. Moreover, the elimination of radiolabeled Gem-
SQ NAs was considerably lower compared with the free drug, as indicated by the lower radioactivity 
counts found in urine and kidneys. Gem-SQ NAs also underwent considerably higher distribution to 
the organs of the reticuloendothelial system (RES), such as liver and spleen, which are the major 
metastatic organs of leukemia (24). The pharmacokinetic and biodistribution insights may also 
explain the higher efficacy of Gem-SQ NAs against experimental leukemia. 
All these studies have demonstrated that squalenoylation of gemcitabine, favorably modified in 
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vivo the pharmacokinetics, metabolism, and biodistribution of this compound. The squalenoyl NAs of 
gemcitabine acted as a reservoir of gemcitabine due to its modified distribution compared with free 
gemcitabine while minimizing the rapid exposure of the drug to deamination. 
Interestingly, Gem-SQ NAs may be combined with other drug molecules to design so-called 
“multidrug” nanoparticles with pluripotent pharmacological activity. This has been recently 
performed by co-nanoprecipitation of isocombretastatin A-4 (isoCA4) with Gem-SQ. It was observed 
that by combining antiangiogenic (i.e., isocombretastatine) and cytostatic (i.e., gemcitabine) 
compounds in the same nanocomposite, both colon carcinoma cells and endothelial cells could be 
simultaneously affected. Such “multidrug” NAs resulted in better in vivo anticancer activity than after 
treatment with both compounds administered separately in preclinical model of human colon cancer 
(25). Nevertheless, multidrug nanoparticles based on the co-nanoprecipitation of squalenoylated 
gemcitabine and sunitinib, a tyrosine-kinase inhibitor, didn’t exhibit improved efficacy comparatively 
to the physical mixture of individual monodrug NAs on MIA PaCa-2 pancreatic cancer cells. 
However, it didn’t exclude therapeutic improvement in dynamic conditions in vivo (26).  
Chemical modification of Gem-SQ NAs surface was conducted in order to ensure their effective 
distribution in the brain after convection-enhanced delivery (CED). For this purpose, pegylated Gem-
SQ NAs (Gem-SQ-PEG NAs) were obtained after co-nanoprecipitation of PEG-SQ and Gem-SQ 
bioconjugates. The Gem-SQ pegylation enhanced the NAs distribution both in healthy and tumor-
bearing brains after CED which increased the survival of rats bearing RG2 glioma (27). 
2.1.2. Squalene-ddI and -ddC prodrugs 
The concept of squalenoylation was also applied to antiviral nucleoside analogues, such as ddC (2′-
3′-dideoxycytidine) and ddI (2′,3′-dideoxyinosine). The chemical conjugation of squalenic acid and 
ddC was also achieved onto the amino group of the nucleobase through an amide bond, while ester 
bond was chosen to link the squalenic acid onto the 5′-nucleoside hydroxyl group of the 
dideoxyfuranose moiety of ddI. As control, thymidine was also coupled with squalenic acid on its 5'-
hydroxy position through an ester bond (Fig. 2). All ddC-SQ, ddI-SQ and thymidine-squalene (T-SQ) 
could self-organize in water as nanoassemblies with a size in the range of 100 to 250 nm and 
homogeneous size distribution (polydispersity index of 0.2 maximum) (6). It was observed by SAXS 
that both thymidine and ddI derivatives self-organized as lamellar phases, when Cryo-TEM images 
showed spherical nanoparticles. On the contrary, ddC-SQ NAs displayed an inverse bicontinuous 
cubic organization, made by a bilayer lying on a periodic minimal surface (17). As Gem-SQ, ddI-SQ 
NAs and ddC-SQ NAs also possessed high drug loading, ie., 38% and 36%, respectively. 
The antiviral activities of ddC-SQ and ddI-SQ NAs were tested on HIV-1-infected lymphocytes 
compared with corresponding free ddI and ddC. Both ddI-SQ NAs and ddC-SQ NAs were found to be 
2- to 3- times as potent as the corresponding parent molecules in their ability to inhibit viral 
replication and they were shown to be quite 2 fold more selective. In order to increase the efficiency 
of the NAs, ddC-SQ bioconjugates were co-nanoprecipitated with pegylated cholesterol (chol-PEG). 
The resulting NAs were obtained with smaller size of around 70 nm. These NAs showed higher anti-
HIV activity, however with an increased cytotoxicity. In the case of HIV-1 strains resistant to ddI 
and/or ddC (HIV-1-144 and HIV-1-146), the squalenoylated derivatives also exhibited higher 
antiviral activity than the free drugs (6, 28). The enhanced anti-HIV activity of ddI-SQ NAs could be 
explained by the higher intracellular concentrations of dideoxyadenosine triphosphate (ddA-TP), the 
active metabolite of ddI, after HIV-infected cells were treated with ddI-SQ NAs (28). 
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2.1.3. Monophosphate Squalene-Gemcitabine and Squalene-ddC prodrugs 
As mentioned above, following entering into cells, the nucleoside analogues should be converted 
firstly into monophosphate derivatives and finally into active triphosphate form by cellular kinases. It 
is important to note that the monophosphorylation represents the rate-limiting step for the 
phamacological activity to occur. Direct delivery of nucleoside monophosphate offers an alternative 
to skip this rate-limiting step (29). However, the high polarity of monophosphate nucleosides restricts 
their penetration into cells. 
Therefore, trialkylammonium salts of Gem-SQ monophosphate (Gem-SQ-MP) and ddC-SQ 
monophosphate (ddC-SQ-MP) bioconjugates were then designed and synthesized by phosphorylating 
respectively the 5′-hydroxy free group of Gem-SQ and ddC-SQ (Fig. 2) to increase the cellular uptake 
of nucleoside monophosphate. 
The Gem-SQ-MP molecules self-assembled in water into very homogeneous nanoparticles of 153 
nm, displaying unilamellar liposome like structures. The phosphorylated NAs displayed considerably 
lower IC50 values (6.7 nM) on L1210 wt leukemia cell line and improved anticancer activity, 
comparatively to SQdFdC nanoassemblies (30). This strategy also showed the potency to reverse the 
drug-resistant phenotype of pancreatic adenocarcinoma caused by the deficiencies in drug 
transport/drug activation (31). 
Concerning ddC-SQ-MP bioconjugates, they also self-assembled in water to give nanoparticles 
(109 nm). These NAs were then tested in vitro on HIV-1-infected peripheral blood mononuclear cells 
for their antiviral activity. They were found to be just as active as ddC but with an increased 
selectivity index due to a reduced cell toxicity (30). This approach could be of great interest to by-
pass resistance phenomena due to deficiency in intracellular deoxycytidine kinase and to eliminate 
viral sanctuaries in HIV-infected patients. 
2.2. Squalene-nucleoside prodrugs 
Nucleosides and nucleotides are involved in different physiological processes in the body. In 
particular, purine nucleotides and nucleosides play an important role in the regulation of the 
development and plasticity of nervous system (32). Adenosine is an endogenous nucleoside which 
should act as a potent endogenous neuroprotectant during ischemic stroke by slowing down neuronal 
metabolism and enhancing cerebral blood flow, and by acting as an intra- and intercellular messenger 
(33, 34). Adenosine has also many potential other therapeutic applications among which multiple 
sclerosis, and spinal cord injury treatment. However, rapid metabolization (half-life of adenosine in 
blood is 10 sec) and poor permeability through the blood-brain-barrier (BBB) of adenosine 
dramatically restrict the clinical applications of this molecule. 
Therefore, the conjugation of adenosine to elongated squalenic acid (by one isoprene unit) has been 
considered in order to improve its pharmaceutical profile. The coupling of the squalene derivative 
onto the amino group of adenosine nucleobase through an amide bond was intended to protect the 
fragile adenosine from metabolization. The corresponding nanoassemblies were obtained with highly 
monodisperse size distribution (PdI less than 0.15) and with a mean diameter of around 120 nm. The 
drug loading reached 37 %. Structural studies of Ad-SQ NAs using SAXS and cryo-TEM revealed a 
sponge-like-phase in which the inner aqueous channels could provide a favorable accessibility for 
enzymes to ensure the prodrug activation and the adenosine release (35). 
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Fig. 6. Systemic administration of Ad-SQ nanoassemblies (NAs) provides significant neuroprotection both 
in a mouse model of cerebral ischaemia (a) and a model of spinal cord injury in rats (b-e). (a). Ischaemic 
volumes in control and treated mice subjected to transient (2 h MCAo and 22 h reperfusion) and permanent (24 
h MCAo) focal cerebral ischaemia were identified by reduced Nissl staining under a light microscope 
(magnification×10, insets) (data are presented as mean (mm3) ± s.d., N = 6 animals per group; † and * indicate 
P < 0.05 compared to respective controls). Intravenous administration of 7.5 mg kg−1 or 15 mg kg−1 SQAd 
nanoassemblies just before ischaemia or 2 h post-ischaemia significantly decreased the infarct volume compared 
with control groups that received vehicle (dextrose 5%), adenosine-unconjugated SQ nanoassemblies (9.45 mg 
kg−1) or free adenosine (5.5 mg kg−1). A significant therapeutic effect was also observed when SQAd 
nanoassemblies were administered 2 h post-ischaemia in the permanent MCAo model. (b-d) After 72 h, the 
SQAd nanoassemblies-injected animals showed the absence of visible traumatic area on the cord (d) compared 
with the trauma group (b) and the adenosine treated group (c). e After 24 h, 48 h and 72 h and up to 28 days 
post-trauma, the animals were functionally graded using the Basso, Beattie and Bresnahan grading scale (data 
presented as mean ± s.e.m., #, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Figures 
adapted with permission from [36]. © 2014 Nature. 
It was reported that pre- or post-ischemic intravenous bolus administration of Ad-SQ NAs dose-
dependently decrease the infarct volume in mice subjected to 2 h of middle cerebral artery occlusion 
(MCAo) and 22 h of reperfusion (Fig. 6.a). It was also shown that after intravenous injection, Ad-SQ 
NAs exhibited longer blood retention versus adenosine free (36, 37), allowing a prolonged interaction 
with the neurovascular unit which resulted in the improvement of the brain microcirculation, allowing 
a more efficient reperfusion and a better neuroprotective effect. Using hCMEC/D3 cell line, a well-
recognized BBB model, the transport mechanism of Ad-SQ NAs across the blood-brain-barrier (BBB) 
was revealed. It showed that the NAs were firstly endocytosed as intact nanostructures via an energy-
dependent pathway involving the LDL receptors. Then, the prodrugs were hydrolyzed inside the cells 
before adenosine free was exocytosed towards the baso-lateral compartment of the cell insert model 
(38). 
Moreover, in spinal cord injury in Sprague–Dawley rats that undergo a T9 contusion injury, it was 
shown that the injection of Ad-SQ NAs (5 min post-injury), could provide neuroprotection through 
peripheral and central effects (39, 40). Indeed, as illustrated in Fig. 6.b-d, the Ad-SQ NAs could 
avoid the occurrence of visible traumatic area on spinal cord after T9 contusion injury. All animals 
receiving Ad-SQ NAs showed a good motor recovery of the paralyzed hindlimbs what adenosine free 
could not (Fig. 6.e). This study further confirmed the extended neuroprotective potency of this 
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nanomedicine. 
All these results open new exciting perspectives for the treatment of severe neurological diseases 
where tissue ischaemia and/or trauma are involved. 
2.3. Squalene-β-lactam antibiotics prodrugs 
Intracellular infection poses a great challenge in antibiotic therapy. Indeed, several facultative and 
obligate intracellular bacteria can enter and multiply within phagocytic cells, where they are shielded 
from host defenses and antimicrobial therapy (41). In fact, many antibiotics show poor activity on 
intracellular bacteria, either because of their rapid metabolization into inactive agents, or their 
restricted penetration into cells, or because they induce low intracellular retention and subtherapeutic 
concentration in infected intracellular compartments. Thus, the use of nanomedicine provides an 
alternative solution to selectively carry the antibiotics into infected cells (42). 
 
Fig. 7. Chemical structures of PNG-SQ with non-sensitive linker and sensitive linker. 
Coupling squalene to the carboxylate function of penicillin G (PNG) has been achieved by using 
both sensitive and non-sensitive linkers located between the squalene hydrophobic chain and the 
penicillin G (Fig. 7). Both linkers were attached to the PNG through an ester bond. In the first PNG-
SQ bioconjugate, the ester bond was less hydrolyzable than in the second. The two bioconjugates 
were able to form NAs yielding impressive antibiotic loading (44 wt %). Their average diameter was 
around 150 nm with a very low polydispersity index (∼0.1) and Cryo-TEM analysis indicated a 
spherical and regular shape of the nanoparticles. X-ray diffraction studies by SAXS and wide-angle 
X-ray scattering (WAXS) highlighted that PNG-SQ NAs did not display any supramolecular 
organization (absence of any crystal structure). 
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Fig. 8. Confocal fluorescence microscopy images of viable bacteria in J774 cells. J774 cells were A) non-
treated; B) pretreated with SQ-Pen G NPs with sensitive linker; C) pretreated with Pen G, then infected with S. 
aureus and fixed with paraformaldehyde, permeabilized with 0.2% Triton X-100, and double-labeled with 
propidium iodide and Syto9 (LIVE/DEAD BacLight kit). Viable S. aureus cells are stained in green, while red 
signals represent dead bacteria. Figures adapted with permission from [43]. © 2012 ACS. 
The minimum inhibitory concentration (MIC) for proliferation of bacteria of free PNG and PNG-
SQ NAs was evaluated in several bacterial strains. As expected, PNG-SQsens (with sensitive bond) 
had lower MIC than PNG-SQ with non-sensitive bond because of its lower stability. The cell capture 
of both PNG-SQ and PNG-SQsens NAs by macrophages was studied, using J774 cell line (a murine 
macrophage model) when NAs were tagged with fluorescent BODIPY-cholesterol. The strong 
intracellular fluorescent signal and absence of fluorescence signal at the cell surface indicated that 
most of the PNG-SQsens NAs were internalized inside the cells rather than localized onto the cell 
surface. The intracellular bactericidal effect of NAs was then evaluated on S. aureus ATCC 55585 
strain sensitive to PNG.  PNG-SQsens NAs were found to be more efficient in killing intracellular 
bacteria than free PNG which diffused insufficiently into the cells (Fig. 8). This clearly suggested that 
NAs improved PNG cell penetration. Moreover, the higher antibacterial effect observed with PNG-
SQ NAs using the sensitive linker (versus NAs with the non-sensitive linker) was explained by a more 
efficient release of PNG into the cells (43).  
2.4. Squalene-doxorubicin prodrugs 
Doxorubicin is one of the leading anticancer drugs in the treatment of a wide range of cancers, 
including many types of carcinoma (solid tumors), hematological malignancies (leukaemia, 
lymphoma) and soft tissue sarcomas. The mechanisms by which doxorubicin acts in the cancer cell 
include: (i) intercalation into DNA and inhibition of macromolecular biosynthesis and (ii) generation 
of free radicals that cause damage to DNA, cellular membranes and proteins. But, the clinical efficacy 
of doxorubicin is also hindered by acute and subacute adverse effects, mainly cardiotoxicity and 
myelosuppression (44, 45).  
Various nanocarriers have been developed in order to reduce the adverse effect of doxorubicin, 
including liposomes, dendrimers, micelles, solid-lipid, and polymer nanoparticles. Among these 
nanocarriers, only doxorubicin liposomes reached the market (Myocet, Doxil, PEGylated Caelyx) and 
are the first FDA-approved nano-drugs. Despite liposome formulation contributed to decrease 
doxorubicin cardiotoxicity, it generated some other side effects like  “hand-foot” syndrome which 
affects the quality of life of the patients. Noteworthy, all these commercially available liposomes have 
only moderate doxorubicin loading. In order to increase drug payload, squalenic acid was coupled on 
doxorubicin via ester bond in order to obtain C-14 ester derivatives (squalenoyl doxorubicin, Dox-SQ) 
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(Fig. 9A). This linkage allowed the formation of NAs of 130 nm mean diameter, without the use of 
PEG or any other surfactant and showed an impressive drug payload (i.e., 57%). Surprisingly, Dox-
SQ NAs displayed an original “loop-train” structure (Fig. 9B, 9C) never observed before, which may 
explain their long-circulating ability in the blood stream after intravenous injection, since elongated 
nanoparticle structures are less prone of capture by the macrophages of the mononuclear phagocyte 
system (MPS) (46). 
 
 
Fig. 9. (A) Chemical structure of Dox-SQ. (B) Cryo-TEM appearance of the Dox-SQ NAs. (Scale bar, 100 
nm) (C) TEM appearance of the Dox-SQ NAs. (Scale bar, 500 nm) Figures adapted with permission from 
[47]. © 2014 PNAS. 
The antitumor efficacy of these NAs has been investigated on two resistant human pancreatic 
(MiaPaCa-2) and murine lung (M109) carcinomas. The in vitro experiments showed a very fast 
uptake of Dox-SQ NAs into MiaPaCa-2 cells (5-min postincubation) and a greater internalization of 
the drug via active endocytosis, resulting in higher cell apoptosis than after incubation with free 
doxorubicin. Furthermore, in vivo experiments have shown that, comparatively to doxorubicin free, 
the Dox-SQ NAs greatly improved the anticancer efficacy on both experimental models. In particular, 
the growth of M109 lung tumors was inhibited by 90% after treatment with Dox-SQ NAs versus only 
3% with free Doxorubicin when inhibition was 95% in MiaPaCa-2 pancreatic tumor xenografts 
versus 29% with doxorubicin free in the same model (Fig. 10 A-D). Toxicological studies indicated 
that the MTD of Dox-SQ NAs was five times higher than that of free doxorubicin and also that these 
NAs did not cause any apparent cardiac toxicities such as those induced by the drug free (Fig. 10 E-
H). In a nutshell, the increase of the antitumor activity and the decrease of the cardiac toxicity of Dox-
SQ NAs was explained by their prolonged systemic circulation time, their enhanced accumulation 
within tumor tissue and the reduction of drug concentration in the heart (47). Thus, squalenoylation of 
the Doxorubicin remarkably improved the doxorubicin’s therapeutic index without using 
biocompatible transporter material.  
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Fig. 10. Tumor growth inhibition by DOX-SQ NAs and the body-weight changes of mice bearing 
MiaPaCa-2 (A and B) or M109 (C and D) tumors (n = 10, **P < 0.01). Cardiotoxicity of (E) Saline-treated 
rat showing myocardium without any lesions (no ventricle focal inflammatory cell). (F) DOX-SQ NAs-
treated rat (dose: 1 mg·kg·wk equivalent doxorubicin, during 11 wk) showing myocardium without any 
lesions. (G) Doxorubicin-treated rat (dose: 1 mg·kg·wk, during 11 wk) showing infiltration with ventricle 
hypercellularity. (H) DOX-SQ NAs-treated rat (dose: 2 mg·kg·wk equivalent doxorubicin, during 11 wk) 
showing myocardium without any lesion, only a slight incidence of minimal myocardiopathology was 
observed. Figures adapted with permission from [47]. © 2014 PNAS. 
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3. SQUALENE-BASED BIOCONJUGATES WITH POORLY HYDROPHILIC 
DRUGS 
3.1. Squalene-paclitaxel prodrugs 
The squalenoylation concept was also applied on taxoid compounds, such as paclitaxel (PTX), a 
drug with poor solubility. PTX is one of the most important chemotherapeutic agents, which is 
clinically used to treat ovarian, lung, pancreatic, breast and other cancers, as well as Kaposi’s sarcoma. 
The mechanism of action of PTX involves promoting assembly of tubules into stable microtubules 
and interfering the normal depolymerization of microtubules during cell division. On the basis of this 
action, the cell cycle is arrested in the late G2/M phase, which is the main toxic mechanism of PTX 
(48). Although PTX shows great efficacy as anticancer agent, its very low aqueous solubility needs 
the development of specific formulations for intravenous administration. Practically, the formulation 
for clinical use consists in a PTX emulsion in a 50:50 mixture of absolute ethanol and Cremophor EL 
and is diluted with buffer prior to intravenous administration to the patient. However, the use of 
Cremophor is associated with a series of adverse effects, such as hypersensitivity reactions, abnormal 
lipoprotein patterns, hyperlipidaemia, neuropathy, peripheral neurotoxicity, etc. (49). 
 
Fig. 11. Chemical structures of the reported squalenol paclitaxel prodrugs: (14) PTX; (15) PTX-SQ with 
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ester limker; (16) PTX-SQ with succinate ester linker; (17) PTX-SQ with diglycolate ester linker; (18), (19) 
PTX-SQ with succinate ester-PEG linker; (20) DHA-PTX prodrug; (21), (22) DHA-SQ hybrid paclitaxel 
prodrug; (23) PTX-SQ with disulfide-containing linker. Adapted from [51, 52, 53]. 
To circumvent these limitations, PTX has been conjugated to squalene in order to design a less 
toxic nanoformulation for intravenous administration. Thus, squalenic acid were coupled on the 2′- 
OH of PTX using either a direct ester bond or intercalating various spacers such as succinate ester, 
diglycolate ester, or succinate ester-PEG (50) in order to modulate the hydrophobicity of the prodrugs 
(Fig. 11). All those bioconjugates were able to form NAs in aqueous solution with drug payload 
ranging from 45% to 69%, which was considerably higher than when PTX was encapsulated in 
liposomes or polymer nanoparticles. These NAs were found to be remarkably stable in water but the 
diglycolate linkage was observed to be more susceptible to hydrolysis in serum than the succinate 
linkage. Because microtubules are the main target of PTX, which promotes the assembly of tubules 
and suppresses microtubule dynamics, a test based on microtubule bundle formation was carried out 
on HT-29 and KB-31 cancer cell lines. The pharmacological activity of the PTX-SQ bioconjugates 
with simple ester bond appeared with 50 times higher doses than PTX free which suggested that only 
a small fraction of PTX was released from PTX-SQ NAs and could generate the formation of 
microtubule bundle (Fig. 12). 
Similarly, PTX-SQ NAs with different linkers showed a decreased cytotoxicity in comparison with 
free PTX toward M109 cancer cell line in the following order of activity: diglycolate linker, succinyl 
linker, and PEG linker. Actually, a close correlation was observed between the PTX-SQ prodrug 
cytotoxicities and their linkage stabilities. Indeed, diglycolate linker was the most susceptible to 
hydrolysis among the other linkers and displayed highest cytotoxicity (50). Clearly, the anticancer 
activity of PTX-SQ NAs was found much lower than PTX free on various experimental models in 
vivo (unpublished results). It is hypothesized that the very strong lipophilicity of PTX-SQ 
bioconjugates hinders enzymatic access, necessary for triggering the drug release. Apparently, the use 
of specific hydrophilic linkers was not sufficient for improving the anticancer activity of PTX-SQ. 
A quite similar approach has been reported previously with docosahexaenoic acid–PTX (DHA-
PTX) prodrugs, made by covalently conjugating the essential fatty acid DHA to the 2'-OH position of 
the PTX molecule (Fig. 11). DHA-PTX, when incorporated into lipid vehicles such as liposomes, oil 
emulsions or micelles, was shown to be very efficient prodrugs that even reached the phase III clinical 
trial for the treatment of metastatic malignant melanoma (5). Thus, a new series of squalene PTX 
prodrugs were designed in which a 1,4-cis, cis pentadiene unit was incorporated between the PTX and 
the squalene chain. The bioconjugates differed mainly by the number of bonds between the ester 
linkage (on the 2'-hydroxy position of the PTX) and the diene with two or three methylene groups 
respectively. Such new bioconjugates were expected to take advantage of the potent release of the free 
drug observed with DHA-PTX, while preserving the capacity to form NAs inherent to squalene 
bioconjugates (51). This study first showed that the introduction of such linkers did not disrupt the 
self-organizing capabilities of the squalene derivatives, and NAs of 90-150 nm could be obtained. In 
vitro, these PTX-SQ NAs displayed notable cytotoxicity on several tumor cell lines, including lung 
cell line A549, colon cell line HT-29, or nasopharyngeal epidermoid cell line KB 3.1. Especially, the 
cis, cis-squalenyl-deca-5, 8-dienoate prodrugs showed improved activity over PTX-SQ prodrugs (with 
a simple ester bond), highlighting the favorable effect of the dienic linker. Then, the antitumor 
efficacy of these NAs has been studied in vivo on human lung (A549) carcinoma xenograft model in 
mice: the NAs demonstrated comparable antitumor efficacy than the parent drug, but with lower 
subacute toxicity as seen by measuring body weight loss. 
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Fig. 12. Microtubule bundle formation induced by paclitaxel and PTX-SQ with simple ester bond (15 in 
Fig. 11) in cultured HT-29 cells (left) and KB-31 (right). Cells were incubated with FITC antitubulin 
antibody after exposure to paclitaxel 100 nM (panel B) and compound 1 at 5 μM (panel C) for 14 h. Panel A, 
control (solvent). Figures adapted with permission from [50]. © 2010 ACS. 
Stella Borrelli and coworkers synthesized another kind of PTX-SQ prodrug, with disulfide-
containing linkage (52). The obtained compound was effectively able to form NAs and to release the 
parent drugs in vitro. Immuno-fluorescence assay revealed that those bioconjugates entered A549 
cells and stained microtubule bundles. But, in vitro cytotoxicity study showed that the disulfide-
containing PTX-SQ derivatives displayed similar biological activity than the free drugs. 
3.2. Squalene-curcumin prodrugs 
Curcumin is a natural compound extracted from turmeric, with pleiotropic activities including 
antioxidant, anti-inflammatory, antitumor, and neuroprotective. Moreover, it shows therapeutic 
potential against parasites, such as Leishmania responsible of Leishmaniasis. However, the 
phamocological applications of curcumin are severely restricted by its very low aqueous solubility, 
short half-life, poor absorption and extremely low bioavailability. 
To enhance the therapeutic efficacy of curcumin, the squalenoylation strategy was applied. 
Monosqualenoyl-curcumin and bis-squalenoylcurcumin were synthesized by coupling the squalenic 
acid to the free phenol group(s) of the curcumin. The resulting bioconjugates could spontaneously 
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form NAs in 5% dextrose solution, with sizes around 100 nm (53). 
Both monosqualenoylcurcumin and bis-squalenoylcurcumin NAs showed improved activities 
against promastigotes and axenic amastigotes but not against intramacrophagic forms. 
4. SQUALENE-BASED BIOCONJUGATES WITH MACROMOLECULES 
4.1. Squalene-siRNA prodrugs 
Small interfering RNA (siRNA), have gained increasing attention due to their unique ability to 
specifically interfere with mRNA gene expression by base-pairing with complementary nucleotide 
sequences within mRNA, degrading it after transcription and inhibiting the expression of target 
proteins (54). Thus, siRNA holds great promise as potential therapeutic agent by inhibiting disease-
causing genes. Compared with conventional small molecules, siRNA show high specificity and 
activity. However, as a polyanionic macromolecule, siRNAs poorly diffuse across biological 
membranes and insufficiently penetrate intracellularly, owing to low affinity for negatively charged 
cell membranes. Moreover, in vivo, naked siRNAs are very unstable in the biological fluids due to 
their degradation by nucleases, renal clearance and elimination by reticuloendothelial system (RES) 
(55). 
Thus, there is an urgent need to develop competent systems for the delivery of siRNA. So far, a 
wide range of approaches including viral vectors as well as nonviral delivery systems have been 
proposed to enhance nucleic acids bioavailability and pharmacodynamic activity (56). However, the 
safety of viral vectors is doubtful because of possible random recombination, oncogenic potential and 
immunogenicity. Thus, cation-based nanoplexes have been designed as a non-viral alternatives to 
improve oligonucleotides stability and cellular uptake (57).  
Nevertheless, some important limitations remain, such as strong interactions with proteins after 
intravenous injection and intrinsic toxicity due to polycationic charges (58, 59). Thus, the conjugation 
of oligonucleotides with neutral lipids like cholesterol, squalene or fatty acids represents another 
alternative (60) to ensure the safe delivery of oligonucleotides through membranes and to improve 
their efficacy (61). 
There are several positions for ligand conjugation to oligonucleotides, at the 5′- or 3′-ends or on the 
entire backbone structure (62). Generally, the conjugation occurs at the 5′- or 3′-ends. Since siRNA 
has two complementary strands (sense and antisense), there are four terminal ends as potential 
conjugation sites. Because the antisense siRNA strand needs to be incorporated into an effector 
complex or RISC complex before recognition of the homologous mRNA, this strand should not be 
chemically modified for steric reasons. On the contrary, the inactive sense strand can be used for 
chemical conjugation (61).  
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Fig. 13. Chemical structures of the siRNA sense strand and RET/PTC1 siRNA-SQ sense strand conjugate. 
Adapted from [63]. 
Thus, for squalene conjugation, 3′-end of the siRNA sense strand was chosen (Fig. 13) (61). 
Taking advantage of 3-mercaptopropyl phosphate group which was introduced at the 3′-end of the 
sense strand of each siRNA sequence during manufacturing on solid support, the more efficient 
conjugation was achieved by using maleimide group as thiol acceptor. For this purpose, squalene 
maleimide was first considered. In order to facilitate the accessibility of the maleimide functional 
group towards the modified SiRNA sense strand, a small ether linker was introduced between the 
maleimide group and the SQ group. 
As thyroid papillary carcinoma (PTC) is often associated with RET gene rearrangements that 
generate RET/PTC fusion oncogene, a siRNA complementary to RET/PTC mRNA was used. 
Specifically, RET/PTC1 siRNA was used in this study because RET/PTC1 oncogene is one of the 
most frequent variant with RET/PTC3. Then, once the bioconjugate RET/PTC1 siRNA-SQ sense 
strand was synthesized, it was then hybridized with the antisense strand to form the duplex. The 
bioconjugates could then self-assemble in water into spherical NAs with a size of around 170 nm as 
measured by laser light scattering.  
Compared with naked RET/PTC1 siRNA, RET/PTC1 siRNA-SQ NAs clearly improved the 
nucleic acid stability in serum. After intravenous injection, using RET/PTC1 xenograft mouse models, 
siRNA-SQ NAs were showed to inhibit tumor growth as well as oncogene and oncoprotein 
expression (63, 64). Similar studies with RET/PTC 3 siRNA-SQ NAs have confirmed these results 
(65). 
Squalene based technology was also applied to prostate cancer (PCa), the most common neoplasia 
in men. SiRNA against TMPRSS2-ERG fusion oncogene which is found in 50% of patients, was 
recently squalenoylated using the same approach as mentioned above. The resulting siRNA 
TMPRSS2-ERG-SQ NAs showed improved therapeutic effectiveness against Pca, compatatively to 
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siRNA free (66, 67). 
Thus, squalenoylation offers a new non-cationic platform for the administration and transport of 
therapeutic siRNA. 
4.2. Squalene-fondaparinux complex 
Fondaparinux (Fpx) is the first-line anticoagulant in the treatment of short- and medium-term 
thromboembolic disease. Although molecular weight of fondaparinux (1728 Da) is much lower than 
low molecular weight heparin, this molecule has a very low bioavailability by oral route due to 
hydrophilic and polyanionic character. In addition, fondaparinux is instable in the acidic medium of 
the stomach and it undergoes fast enzymatic degradation. For those reasons, it is only administrated 
via subcutaneous route. Few strategies have been proposed to allow oral administration of Fpx, like 
Fpx-based emulsions, but the preparation methods are complicated, need heating, involve numerous 
excipients, and in fine, the drug loading is very low (less than 5%). As squalene is well known for its 
high oral bioavailability (more than 60%), its use could be very profitable to face all these 
disadvantages and may open a new way for the oral delivery of poorly bioavailable drugs. 
It was experienced that the conjugation of squalene to Fpx was highly complicated and resulted in 
the loss of Fpx anticoagulant properties. Therefore, an ion-pair association between squalene and Fpx 
has been considered through the synthesis of monovalent (trimethyl ammonium chloride salt, SQ+) 
and bivalent (1,20-bis-trimethylammonium dimethanesulfonate salt, SQ++) cationic squalene 
derivatives before complexation polyanionic Fpx. SQ-Fpx NAs gave monodisperse and stable NAs 
with a mean diameter in the range of 120-150 nm. To note, SQ+-Fpx NAs showed a higher stability 
and encapsulation efficiency than SQ++-Fpx NAs. The encapsulation efficiencies were around 80% 
and the Fpx loadings reached 39 wt.%. Cryo-TEM and SAXS revealed spherical multilamellar 
"onion-type" nanoparticles which structure probably consisting in layers of SQ+ interacting with 
hydrated layers of Fpx. Presumably, both SQ+-SQ+ hydrophobic interactions and Fpx-SQ+ 
electrostatic interactions played a role in maintaining the cohesion of the nanoassemblies. In vivo 
experiments on rats showed that a small fraction of Fpx was absorbed after oral feeding of Fpx-SQ 
NAs. Nanoparticles were found to be completely disaggregated in the blood circulation, free Fpx 
being released from NAs in this compartment. Fpx NAs increased the plasmatic concentrations of Fpx 
in a dose-dependent manner but their oral bioavailability remained, however, very low (around 0.3%). 
Nevertheless, it has to be noted that maximal plasma concentration of Fpx observed after oral 
administration was close to the required plasma concentration in venous thromboembolism treatment. 
Furthermore, the Fpx oral bioavailability could be seriously increased (up to with 9%) when NAs 
were inserted in gastroresistant capsules (68).  
5. SQUALENE-BASED BIOCONJUGATES WITH CONTRAST AGENTS 
Magnetic resonance imaging (MRI) is one of the most powerful and widely used techniques for 
non-invasive diagnosis of diseases. It is based on the difference of relaxation times of protons 
(longitudinal T1 and transverse T2) and water concentration in normal and abnormal tissues.  The 
intensity of the signal is modified by the presence of contrast agents (CAs) such as gadolinium 
chelates (mainly affecting T1 relaxation) using specific MRI sequences. This technique permits 
exploration of opaque organisms in 3D. 
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Among CAs, gadolinium (Gd
3+
)-based CAs are the most commonly used in clinics because of their 
ability to improve the contrast in MRI scans between normal and abnormal tissues. However, the lack 
of specificity of most CAs generate insufficient relaxivities for certain applications so that high doses 
of CAs are generally required in order to generate a local alteration of the water intensity signal which 
may induce toxicity in patients. Thus, squalenoylation of Gd
3+
 complex was explored to increase the 
relaxivity by guiding Gd
3+
 specifically within the tumor.  
 
Fig. 14. Structure of DO3A 26 and SQ-Gd
3+
complexes 27–29. Adapted from [69]. 
A family of Gd
3+
 chelates-squalene derivatives was obtained by covalent coupling of the secondary 
amino group of the cyclen belonging to DOTA [1,4,7,10-tetrakis (carboxymethyl)-1,4,7,10-
tetraazacyclododecane] to amino squalene derivatives using various linkers (Fig. 14). All of these 
Gd3+ chelates-squalene derivatives had the ability to self-assemble into micelles (8 to 30 nm for 27-
29b compounds) or liposome-like (spherical to elliptical shape) structures (80-120 nm for 29c 
compound) with good Gd
3+
 payload (10-17 wt.%). The relaxivities of supramolecular CA were 
greatly enhanced (r1 = 15–22.1 mM-1 s-1 at 20 MHz and 15.6–20.4 mM-1 s-1 at 60 MHz and 310 K), 
which were about 5 times higher than clinically used Gd-DOTA (r1 = 3.5 and 3.1 mM-1 s-1, at 20 and 
60 MHz and 310 K). Thus, squalenoylation of Gd3+ chelates provides a platform to conceive CAs 
with a greater degree of relaxivity efficacy (69). 
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Co-nanoprecipitation of Gem-SQ (4) and SQ-Gd
3+
 (27) were also performed to design 
nanoparticles with both imaging functionality and anticancer effect. The internal structure of Gem-
SQ/SQ-Gd
3+
 NAs, revealed by electron microscopy after freeze-fracture (FFEM) and SAXS, an 
inverted bicontinuous cubic structure, with a lattice parameter of 100 Å. This novel nanoparticles 
showed high relaxivity (r1 = 20.1 mM-1s-1at 20 MHz) and significant cytotoxicity on MIA PaCa-2 
pancreatic cancer cells, with potential applications in theranostics (i.e., medicines combining 
therapeutic and diagnostic capabilities). 
Squalene-based NAs consisting of ultrasmall superparamagnetic iron oxide particles (USPIO) 
encapsulated into a series of squalenoylated anticancer compounds (i.e., Gem-SQ, PTX-SQ, 
cisplatine-SQ, DOX-SQ) are another example of nanocomposite for theranostic applications (70, 71). 
These nanomagnetite/squalenoyl antitumor prodrugs showed very good magnetic responsiveness and 
anticancer activity. 
CONCLUSION 
Since its first application in 2006, squalenoylation nanotechnology has showed great potential for 
the delivery of various therapeutic agents in a safer and more efficient manner. These nanomedicines 
represent a new concept with numerous advantages in comparison with the conventional nanocarriers, 
incl. absence of “burst release”, high drug loading and biocompatibility. Their in vivo applications 
generally show high ability to act like a reservoir by protecting drugs from rapid 
degradation/metabolization, allowing to increase the drug plasma half-life, and to progressively 
release the drug inside the cell. In addition, they facilitate drugs to cross biological membranes, thus 
increasing drug concentration within the target cells or tissue. Proofs of this concept have been done 
with drugs presenting different physicochemical characteristics, like small hydrophilic or lipophilic 
molecules, and charged macromolecules. In general, the squalenoylation favorably modifies the 
pharmacokinetic profile and biodistribution of the carried drug, allowing its intravenous 
administration as nanoparticles and increasing its therapeutic index. This innovation has a versatile 
and generic character and has been awarded as the “European Inventor Award 2013”. 
LIST OF ABBREVIATIONS 
Ad-SQ adenosine-squalene 
BBB blood-brain-barrier 
CAs contrast agents 
CED convection-enhanced delivery 
CNS central nervous system 
cryo-TEM cryogenic transmission electron microscopy 
dCK deoxycytidine kinase 
ddA-TP dideoxyadenosine triphosphate 
ddC 2′,3′-dideoxycytidine 
ddC-SQ 2′,3′-dideoxycytidine-squalene 
ddC-SQ-MP 2′,3′-dideoxycytidine-squalene monophosphate 
ddI 2′,3′-dideoxyinosine 
ddI-SQ 2′,3′-dideoxyinosine-squalene 
DHA docosahexaenoic acid 
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DOTA 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
DOX-SQ doxorubicin-squalene 
FFEM electron microscopy after freeze-fracture 
Fpx fondaparinux 
Gem-SQ gemcitabine-squalene 
Gem-SQ-MP gemcitabine-squalene monophosphate 
isoCA-4 isocombretastatin A-4 
LDC lipid-drug conjugates 
LDL low density lipoproteins 
MCAo middle cerebral artery occlusion 
MIC minimum inhibitory concentration 
MRI magnetic resonance imaging 
MPS mononuclear phagocyte system 
MTC maximum tolerated concentration 
MTD maximum tolerance doses 
NAs nanoassemblies 
PCa prostate cancer 
PEG polyethylene glycol 
PNG penicillin G 
PNG-SQ penicillin G-squalene 
PNG-SQsens penicillin G-squalene with sensitive bond 
PTX paclitaxel 
RES reticuloendothelial system 
SAXS small angle X-ray scattering 
T-SQ thymidine-squalene 
USPIO ultrasmall superparamagnetic iron oxide particles 
VLDL very low density lipoproteins 
WAXS wide-angle X-ray scattering  
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Squalenoylated Leu-enkephalin Nanomedicine: 
 
As mentioned in the previous section, squalenoylation has showed great potential for the delivery of 
various therapeutic agents in a safer and more efficient manner. This new nanotechnology exhibits 
numbrous advantages in comparison with the conventional nanocarriers, including absence of “burst 
release”, high drug loading and biocompatibility. Therefore, we propose to couple Leu-enkephalin 
with squalene to give the Leu-enkephalin-squalene bioconjugates. We hypothesized that these 
bioconjugates can form nanoparticles, which could protect the peptides from rapid degradation 
during circulation. 
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ABSTRACT OF THE ARTICLE 
The clinical use of endogenous neuropeptides has historically been limited due to pharmacokinetic 
issues, including plasma stability and blood-brain-barrier permeability. In this study, we show for the 
first time, that the rapidly metabolized Leu-enkephalin (LENK) neuropeptide may become 
pharmacologically efficient owing to a simple conjugation with the lipid squalene (SQ). LENK 
neuropeptide was included into nanoparticles (NPs) by conjugation to squalene using three different 
chemical linkers, i.e., dioxycarbonyl, diglycolate, and amide bond. This new squalene-based 
nanoformulation prevented rapid plasma degradation of LENK and conferred to the released 
neuropeptide a significant anti-hyperalgesic effect in a carrageenan-induced paw edema model in rats 
(Hargreaves test) which lasted longer than after treatment with morphine. Pretreatment with opioid 
receptor antagonists such as naloxone (brain-permeant) and naloxone methiodide (brain-impermeant) 
reversed the nanoparticles induced anti-hyperalgesia, indicating that the LENK-SQ NPs acted through 
peripherally located opioid receptors. Moreover, the biodistribution of DiD-fluorescently labeled 
LENK-SQ NPs showed a strong accumulation of the fluorescence within the inflamed paw, while no 
signal could be detected in the brain, confirming the peripheral effect of LENK-SQ NPs. This study 
represents a novel nanomedicine approach, allowing the specific delivery of LENK neuropeptide into 
inflamed tissues for pain control. 
Keywords: Nanomedicine, Leu-Enkephalin, Squalene, Prodrug, Bioconjugate, Hyperalgesia, 
Inflammatory Pain, Opioid receptors, Peripheral effect, Rat 
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INTRODUCTION 
Pain represents an important global health challenge for many reasons, including high prevalence, 
serious associated sequelae and the relative lack of efficient treatment， especially for neuropathic 
pain alleviation. Pain relevant disorders such as arthritis, cancer and pathological changes in nervous 
system are highly prevalent and bring great inconvenience and distress to the patients (1). Chronic 
pain has a significant impact not only on the patients themselves, but also on the broader community 
and economy. By activating μ-opioid receptors, the most powerful and widely used painkillers in 
current clinical practice are morphine and the related synthetic opioids. But morphinic treatments are 
associated with severe side effects, such as respiratory depression and addiction linked to the 
development of opioid tolerance and dependence (2). According to CDC/NCHS, National Vital 
Statistics System (3), every day, more than 115 people in the United States die after overdosing on 
opioids. The misuse of and addiction to opioids, especially morphine, represents a serious national 
crisis in the US (and probably also in other countries) that affects public health, as well as, social and 
economic welfare. This highlights the need to urgently find new painkillers. In this context, 
endogenous neuropeptides, such as enkephalin, remain an attractive option. Enkephalins activate both 
μ- and δ-opioid receptors, but with a ten-fold higher affinity towards δ-opioid receptors (4). 
Compared with μ-opioid receptor agonists, δ-opioid receptor ligands are believed to have a much 
lower abuse potential (5), as well as, reduced respiratory (6), gastrointestinal (7) and cognitive (8) 
impairments. However, enkephalins have historically been limited because of pharmacokinetic issues, 
and rapid plasma metabolization. 
To date, the two main approaches to enhance the analgesic activity of opioid peptides relied on (i) 
the increase of the stability of endogenous peptides using enkephalinase inhibitors, or (ii) the 
chemical synthesis of exogenous peptides with enhanced lipophilicity and degradation resistance. 
However, due to insufficient enzymatic specificity, the enkephalinase inhibitors are often endowed 
with poorly tolerated side effects (9). In addition, the derivatization of peptides often ends-up with 
biologically inactive compounds, and the same applies to neuropeptides covalently linked to transport 
vectors for crossing the blood-brain-barrier (BBB) (10). This explains why none of the research 
efforts performed since decades ago has resulted in marketed medicines. 
On the other hand, although nanoparticulate drug delivery systems represent an efficient approach 
for protecting drug molecules from rapid metabolization, only few were applied to enkephalins and 
enkephalin derivatives. In a primary study, Kreuter et al. (11) showed that intravenously injected 
dalargin-loaded polybutylcyanoacrylate nanoparticles coated with a non-ionic surfactant, induced 
time- and dose- dependent antinociceptive effects. In subsequent studies, positively charged 
nanocarriers were also used for the delivery of opiate-related drugs and peptides into the brain (12-15). 
Nevertheless, these approaches have met with limited success because, in general, the amount of 
nanoparticles able to cross the BBB remains very low (less than 1% of the injected dose) (16). In 
addition, the toxicity and elimination of nanoparticles from the brain parenchyma remain a major 
issue and this is especially true for the above mentioned cationic nanodrugs. 
Thus, the design of safe analgesic nanoformulations able to restrict their activity peripherally and to 
optimize drug concentration at the site of injury may overcome these issues. Another advantage of 
targeting peripheral opioid receptors is to prevent and reverse the effects of multiple excitatory agents 
expressed in damaged tissue (17). 
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We report here a very simple and easy way to use the currently unusable LENK as analgesic drug 
following intravenous injection. To this goal, a new nanoformulation was achieved which proved 
capable of precise and efficient delivery of LENK for pain control. Practically, LENK was conjugated 
to squalene, a natural and biocompatible lipid, through various chemical linkers, resulting in a library 
of LENK lipidic prodrugs, which allowed the controlled release of the peptide. As shown previously 
with anticancer compounds (18), the linkage of LENK with squalene triggered the spontaneous self-
assembly of the bioconjugates into LENK-squalene nanoparticles (LENK-SQ NPs) in water, which 
was attributed to the dynamically folded conformation of the natural lipid. The analgesic effect of 
these LENK-SQ NPs was evaluated on carrageenan-induced pain model using a thermal nociception 
test (Hargreaves) to assess hyperalgesia. Pain sensitivity was rated in response to a hot stimulus on the 
inflamed hind paw of rats. In addition, the in vivo biodistribution of NPs was investigated in mice 
using in vivo fluorescence imaging for assessing the ability of the LENK-SQ NPs to target the 
inflamed tissue. Finally, a toxicological study was also performed to ensure these NPs safety. 
RESULTS 
Synthesis of LENK-SQ conjugates 
In this study, various squalenoyl-Leu-enkephalin (LENK-SQ) conjugates were designed with 
different linkers using bioconjugation (Fig. 1). Conjugation of squalene to LENK was performed by 
exploiting 2 sites: C-terminal acid and N-terminal amine. In order to modulate the release kinetics of 
LENK from NPs, three linkers were used with different sensitivity to hydrolysis in the following 
order: dioxycarbonyl (LENK-SQ-Diox also called “sensitive bound”) > diglycolic (LENK-SQ-Dig) > 
amide (LENK-SQ-Am). 
Practically, the squalenic acid was coupled to C-terminal LENK using a dioxycarbonyl linker 
(LENK-SQ-Diox, conjugate 1) or squalenol was conjugated to N-terminal LENK through a diglycolic 
spacer (LENK-SQ-Dig, conjugate 2). Starting from squalenic acid, it was also possible to perform the 
linkage to N-terminal LENK using a simple amide bond (LENK-SQ-Am, conjugate 3). 
The LENK-SQ-Diox conjugate was synthesized by alkylation of the carboxylate function of the 
peptide with the chloromethyl ester of squalenic acid, which was prepared upon treatment of 
squalenic acid with chloromethyl chlorosulfate. In order to avoid N-terminal conjugation, Fmoc 
strategy was first adopted for the protection of the primary amino group of LENK, but due to early 
release of the peptide from Fmoc-LENK-SQ during the deprotection step, this approach was 
abandoned in favor of Alloc (allyloxycarbonyl) strategy. Thus, the LENK was protected with an Alloc 
group on its N-terminal amine prior to react with the chloromethyl ester of squalenic acid. Subsequent 
deprotection of Alloc-LENK-SQ under neutral conditions was then achieved by catalytic transfer 
hydrogenation method using triethylsilane and 10% Pd-C (19), affording pure LENK-SQ-Diox in 9.5% 
yield. 
The LENK-SQ-Dig prodrug with 2′-diglycolate spacer was synthesized by reaction of the 
squalenol with diglycolic anhydride before reaction with the condensing agent and LENK, resulting in 
69% yield. The oxa moiety of the linker was intended to enhance the susceptibility to hydrolysis by 
increasing the distance between LENK and squalene and so the accessibility to the linkage. 
Direct conjugation between LENK and squalenic acid via single amide bond was achieved by acid 
activation using ethyl chloroformate, affording LENK-SQ-Am in 73% yield. 
Squalenoylated Leu-enkephalin nanomedicine 
 78 
 
Fig. 1. Chemical structures of the bioconjugates. (1) Leu-Enkephalin-squalene with dioxycarbonyl linker 
(LENK-SQ-Diox), (2) Leu-Enkephalin-squalene with diglycolic linker (LENK-SQ-Dig), and (3) Leu-
Enkephalin-squalene with amide linker (LENK-SQ-Am). 
Preparation and characterization of LENK-SQ NPs 
All bioconjugates showed the capability to self-assemble as NPs in aqueous solution after 
nanoprecipitation from LENK-SQ ethanolic solutions. When measured by DLS, the size of the NPs 
varied from 60 to 120 nm, depending on the linkage between squalene and enkephalin (Fig. 2). The 
difference in NPs zeta potential was related to the nature of the exposed amino acids onto the NPs 
surface. Indeed, in case of the LENK-SQ-Diox bioconjugate, the squalene conjugation on the C-
terminus LENK peptide let its N-terminus site free (primary amino group), leading to a net positive 
charge. On the contrary, the zeta potential became negative when the conjugation with SQ was 
performed on the N-terminus LENK peptide (LENK-SQ-Dig and LENK-SQ-Am). Drug loadings 
(Fig. 2) ranged between 53% and 60% which was much higher than in conventional nanoparticles or 
liposomes which amounted to a maximum of 5% (20, 21). Fig. 2 shows representative cryogenic 
transmission electron microscopy (cryo-TEM) images of the LENK-SQ NPs at concentrations of 4 
mg/mL in Milli-Q water. They displayed spherical and monodisperse structures with sizes ranging 
from 50 nm to 100 nm. The slight discrepancy between DLS and Cryo-TEM size measurements could 
be attributed to the known hydrodynamic radius-related differences (22). The sizes and the surface 
charges of the LENK-SQ NPs were found to be quite stable at +4°C (Fig. S6). 
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Fig. 2. NPs characterization. Representative Cryo-TEM images showing the formation of NPs from different 
bioconjugates: (A) LENK-SQ-Diox NPs, (B) LENK-SQ-Dig NPs, and (C) LENK-SQ-Am NPs. Scale bars = 
100 nm. Physicochemical characteristics of NPs (ie. size, polydispersity index (PDI), zeta potential and % drug 
loading) are shown in the table.  
In vitro release of LENK from NPs in serum 
The incubation of LENK-SQ-Diox in serum resulted in a decrease of the bioconjugate, which 
correlated well with the release of the peptide (Fig. 3A). The concentration of the bioconjugate 
decreased gradually till 7h, while LENK-SQ-Diox NPs progressively released the free LENK peptide. 
The peptide was then slowly degraded by the peptidases of the serum but still lasted beyond 10 h 
post-incubation (Fig. 3A). The incubation of LENK-SQ-Dig in serum resulted in a decrease of the 
bioconjugate until completely disappearance at 2 h, but no presence of free peptide was detected. The 
RP-HPLC analyses, however, highlighted a slow release of the peptide still attached to its linker. This 
release reached a maximum at 45 min followed by progressive degradation of the peptide-linker 
fragment which could still be detected over 10h (Fig. 3B). On the contrary, LENK-SQ-Am remained 
stable in serum, without significant decrease during 48 h, and no peptide was released in the course of 
the experiment (Fig. 3C). It was observed that the degradation of LENK free was very fast (half-life 2 
min), whereas the LENK-SQ bioconjugate was unaffected during the course of the experiment (60 
min) (Fig. S7).  
 
Fig. 3. In vitro bioconversion of LENK-SQ bioconjugates into LENK in the presence of serum. (A) LENK-
SQ with dioxycarbonyl linker (B) LENK-SQ with diglycolic linker (C) LENK-SQ with amide bond. Solid lines 
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and dashed lines represent the bioconjugates and the released peptides, respectively. 
Analgesic efficacy of LENK-SQ NPs 
The anti-hyperalgesic effect of LENK-SQ NPs was determined in a carrageenan-induced paw 
edema model in rats. Baseline measurements of paw withdrawal latencies (PWL) were made prior to 
carrageenan injection using Hargreaves test (23) and presented a mean value ± SEM (n = 8) of 6.65 ± 
0.37 s. Then, thermal sensitivities were evaluated 3 h after carrageenan injection into the right hind 
paw, which corresponded to the peak inflammatory response. Anti-hyperalgesic effects were assessed 
using the same test at various times after acute administration of the different drug treatments at this 3 
h inflammation peak (Fig. 4).  
 
Fig. 4. Experimental design for algesimetry. The antinociceptive effect of NPs was tested in a 
pathophysiological context induced by an intraplantar carrageenan injection (2% in saline, 100 μL). 
Involvement of central or peripheral opioid receptors was performed using a brain-permeant opioid antagonist 
naloxone (Nal) and a brain-impermeant opioid receptor antagonist naloxone methiodide (Nal-M). NPs 
suspensions or control solutions were injected intravenously with a dose volume of 10 mL/kg during 30 s. 
Hargreaves test was performed 10 min after NPs administration and then every 30 min till 250 min. The dose of 
LENK-SQ NPs 20 mg/kg was equiv. to 11.48 mg/kg LENK and to 8.28 mg/kg SQ NPs, and corresponded to 
20.66 mmol/kg for both LENK-SQ and LENK. 
Effect of intraplantar λ-carrageenan injection on thermal sensitivity. Intraplantar injection of 
λ-carrageenan into the right hind paw induced a local inflammatory response characterized by marked 
edema, hyperthermia, and hyperalgesia restricted to the injected right hind paw. Thermal 
hypersensitivity was developed in all the rats with a mean decrease of 52.48% of PWL compared to 
the basal PWLs in naïve rats. (P < 0.001; see Fig. 5).  
Effect of morphine on thermal hyperalgesia. The acute treatment with 1 mg/kg morphine (Fig. 
5A) reduced the thermal hyperalgesia as shown by the resulting significant increase in PWLs. Indeed, 
10 min post-morphine injection, the PWL reached 12.87 ± 1.38 s, while it remained at 3.05 ± 0.20 s 
after treatment with a control dextrose solution (Fig. 5A). However, morphine anti-hyperalgesic 
pharmacological activity disappeared rapidly and no longer significant effect was observed as soon as 
100 min post-morphine administration (Fig. 5A).  
Effect of LENK-SQ NPs on thermal hyperalgesia. The anti-hyperalgesic effect of LENK-SQ 
NPs with the 3 different linkers was evaluated during 4 h after their administration (Fig. 5C-H). All 
injected rats with LENK-SQ NPs displayed significant reduction of thermal hyperalgesia, as 
expressed by a dramatic increase of respective AUC values in comparison with λ-carrageenan-treated 
rats injected with either the free LENK peptide or the blank SQ NPs (Fig. 5D, F, H). In particular, the 
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anti-hyperalgesic activity was significant at all time points from 10 min to 130 min in rats injected 
with LENK-SQ Diox NPs or LENK-SQ Am NPs (Fig. 5C, G). As shown in Fig. 5E, LENK-SQ-dig 
NPs also displayed a significant anti-hyperalgesic effect, with a maximum increase in PWL 
maintained from 10 min to 130 min post-injection, and a progressive decline down to baseline at 220 
min. Interestingly, maximal PWL values reached after administration of LENK-SQ NPs in λ-
carrageenan-treated rats corresponded to basal PWL values measured in control naïve rats, before λ-
carrageenan treatment (Fig. 5C, E, G), indicating a pure anti-hyperalgesic action of these 
nanoparticles. In contrast, morphine injection in λ-carrageenan-treated rats resulted in PWL values 
twice as high as those found in control naïve rats (Fig. 5A), as expected of not only an anti-
hyperalgesic effect but also the well established analgesic effect of the opiate agonist. In addition, 
blank SQ NPs (without the LENK) did not demonstrate any anti-hyperalgesic activity (Fig. 5), which 
indicated that the analgesic response to LENK-SQ NPs administration resulted from the release of 
LENK peptide.  
Effects of opioid receptor blockade using naloxone and naloxone methiodide. In order to 
ascertain the involvement of central or peripheral opioid receptors during the anti-hyperalgesic effect 
of LENK-SQ NPs, naloxone (Nal, brain-permeant opioid receptor antagonist) or naloxone methiodide 
(Nal-M, brain-impermeant opioid receptor antagonist) (24) were subcutaneously injected 15 min prior 
to the injection of morphine or NPs (Fig. 4). Pre-administration of the non-selective opioid receptor 
antagonist Nal (0.5 mg/kg s.c.) abolished the amplitude and the duration of the anti-hyperalgesic 
effect of morphine (PWL 3.20 ± 0.59 s vs 12.87 ± 1.38 s at 10 min) and decreased the corresponding 
AUC value by 81% in comparison with the morphine group (Fig. 5B). The peripheral opioid receptor 
antagonist, Nal-M, was markedly less effective since it reduced the morphine’s effect by only 13%. 
(Fig. 5A and 5B). Interestingly, pre-administration of either Nal or its quaternary derivative Nal-M, 
abrogated the anti-hyperalgesic effect of the three LENK-SQ NPs (Fig. 5C-H). Indeed, Nal pre-
treatment caused a reduction of 66%, 105% or 73% of the AUC values compared to these found in 
rats injected with LENK-SQ-Diox, LENK-SQ-Dig and LENK-SQ-Am NPs alone, respectively. The 
corresponding reductions in AUC values with Nal-M reached 81%, 99% and 96%, respectively, 
indicating that the selective blockade of peripheral opioid receptors only was enough to abrogate the 
anti-hyperalgesic effects of LENK-SQ NPs.  
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Fig. 5. Anti-hyperalgesic effects of acute treatment with Morphine (A, B), LENK-SQ-Diox NPs (C, D), 
LENK-SQ-Dig NPs (E, F) and LENK-SQ-Am NPs (G, H) in λ-carrageenan-induced inflammatory pain 
injected rats. Administration of morphine, LENK-SQ NPs, Nal, Nal-M, LENK, blank SQ NPs or dextrose 
solution (vehicle) was performed (arrow, 0 on abscissa) 3 h after λ-carrageenan injection into the right hind paw. 
Morphine (A), LENK-SQ-Diox NPs (C), LENK-SQ-Dig NPs (E) and LENK-SQ-Am NPs (G) induced an 
increase in paw withdrawal latency (in seconds, mean ± SEM of independent determinations in 5-9 animals per 
group) in the Hargreaves test. *, #, $ P<0.05, **, ##, $$ P<0.01, ***, ###, $$$ P<0.001 (*: compared to 
dextrose solution or LENK solution, #: compared to morphine; $: compared to LENK-SQ NPs. Two-way 
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Anova with repeated measures, Bonferroni post test.). Nal or Nal-M was administered 15 min prior to morphine 
or LENK-SQ NPs injection. Basal on abscissa: control (naïve) rats (prior to λ-carrageenan injection). B, D, F 
and H: Bars are the mean ± SEM of AUCs (second x minute) of the cumulative durations derived from the time 
course changes (A, C, E and G) in paw withdrawal latency after the various treatments. *, $ P<0.05, **, 
$$ P<0.01, ***, $$$ P<0.001, one way Anova, Tukey post test, *: compared to dextrose (vehicle) or LENK 
solution, $: compared with LENK-SQ NPs. 
Biodistribution of LENK-SQ NPs 
The in vivo biodistribution of LENK-SQ-Am NPs was assessed after intravenous injection of DiD- 
fluorescently labeled LENK-SQ-Am NPs in a murine λ-carrageenan-induced paw edema model 
(right hind paw). The fluorescence in tissues was monitored up to 24h, non-invasively, from the 
abdomen side using an IVIS Lumina (Fig. 6). Mice injected with saline into the paw were used as 
non-inflamed control. The real-time in vivo imaging showed, in comparison with the healthy paw, an 
increase by 2-3 times of the average radiant efficiency within the inflamed paw after iv injection of 
fluorescent LENK-SQ-Am NPs (Fig. 6A, D, F). In a control experiment, when the λ-carrageenan 
administered mice were intravenously injected with a single DiD solution, no significant 
accumulation of fluorescence was observed in the inflamed paw (Fig. 6C, F). In another control 
experiment, mice were injected locally with saline in the hind paw and intravenously treated with 
fluorescent LENK-SQ NPs. No significant accumulation of fluorescence at hind paw level was also 
observed under this condition (Fig. 6B, E) showing that the accumulation of fluorescence in the λ-
carrageenan-inflamed paw was not due to the local hind paw injection per se. In an additional 
experiment, it was shown that the incubation in serum of LENK-SQ NPs containing the fluorescent 
dye (DiD) and a fluorescent quencher (DiR) resulted in the progressive appearance of fluorescence, 
the dynamics of which indicating a relatively slow dissociation of LENK-SQ nanoparticles in serum: 
20% after 5 min and 50% after 30 min. This suggested that under our in vivo conditions, a significant 
proportion of intact NPs could reach the inflamed tissue (Fig. S8). 
Finally, in a separate experiment, 4 h after the intravenous injection of fluorescent NPs or DiD 
solution, animals were euthanized and transcardially perfused with 40 mL of saline to remove the 
fluorescence from the blood. After collection of tissues, a strong ex vivo fluorescence signal was again 
observed in the inflamed paw, but also in the liver, the spleen and the lungs, whereas no detectable 
accumulation of fluorescence occurred in the brain of the animals (Fig. S9).  
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Fig. 6. IVIS® Lumina scan of mice and of their organs after intravenous administration of fluorescent 
LENK-SQ-Am NPs or control fluorescent dye solution (ventral view). (A) Biodistribution of fluorescent 
LENK-SQ-Am NPs in mice with inflamed right hind paw. (B) Biodistribution of fluorescent LENK-SQ-Am 
NPs in mice with non-inflamed hind paw (saline only injected into the right hind paw). (C) Biodistribution of 
free dye in mice with inflamed right paw. (D) Zoom of group A at 2 h. (E) Zoom of group B at 2 h. (F) 
Quantitative analysis of the paws with the same region of interest (ROI). R= right hind paw and L= left hind 
paw. 
Toxicity study 
The overall toxicity of LENK-SQ NPs was investigated 24 h and 48 h after their intravenous 
administration (20 mg/kg) in rats and compared to control animals injected with 5% dextrose solution. 
The levels of aspartate transaminase (AST) (Fig. S10A) and alanine transaminase (ALT) (Fig. S10B) 
were not increased in the LENK-SQ NPs group, indicating no toxicity towards the liver which was 
confirmed by histological analysis of this tissue at 24h and 48 h (Fig S10C-F). The observations of 
Squalenoylated Leu-enkephalin nanomedicine 
 85 
the spleen (Fig. S10G-J), the kidneys (Fig. S10K-N), the lungs (Fig. S10O-R) and the heart (Fig. 
S10S-V) didn’t show any morphological damage after LENK-SQ NPs administration, too. Together, 
these results show that the LENK-SQ NPs may be considered as safe upon systemic intravenous 
administration at the therapeutic dose of 20 mg/kg.  
DISCUSSION 
Peptides and proteins have great potential as therapeutic macromolecules. However, their use in the 
clinical practice is generally hampered by poor serum stability and rapid metabolization (25). In this 
context, the «squalenoylation» technology should be of great interest as we showed here, for the first 
time, that it allows the delivery of therapeutic amounts of LENK neuropeptide for efficient pain 
control. The so-called squalenoylation approach, which refers to the linkage of a drug to the squalene, 
has already been proposed for small molecules, mainly for anticancer compounds, like gemcitabine, 
doxorubicine or cis-platin (26) or for the other molecules, like adenosine, ddI or ddC (27). 
Nevertheless, the conjugation of a peptide to squalene has been an innovative, rather tricky 
achievement for the following reasons: (i) peptides are unstable biomolecules, and their chemical 
engineering is not easy, (ii) peptides are hydrophilic molecules, whereas squalene is a lipid, insoluble 
in water. This makes the chemical reaction rather uncertain and (iii) the chemical modification of a 
peptide often results in a loss of its pharmacological activity. The chemical approach used in the 
present study has overcome all these complications, allowing the design of a small library of 
innovative enkephalin-squalene bioconjugates with a preserved pharmacological activity. For the 
synthesis of these bioconjugates, we took advantage of the remarkable dynamically folded 
conformation of squalene to chemically conjugate this natural lipid with the neuropeptide using 
different linkers. Although it is well known that the N-terminal of LENK is required for binding to 
opioid receptors (28), the conjugation on N-terminal was also achieved, based on the fact that the 
amide bond is susceptible to be cleaved by overexpressed peptidases within inflammation site (29). 
Thus, the resulting LENK-SQ prodrugs were synthesized with either direct amide bond, diglycolic or 
dioxycarbonyl linker in order to investigate the possible influence of the linkage stability on the 
peptide release. It was expected that LENK-SQ-Diox released faster than LENK-SQ-Dig, and LENK 
-SQ-Am was supposed to trigger the slower release as reported in the literature (30). Both LENK-SQ-
Am and LENK-SQ-Dig, were obtained in good yields (around 70%). The third one with 
dioxycarbonyl linker led to a lower yield due to an additional step for removal of the alloc group, 
followed by two successive purifications.  
The LENK-SQ bioconjugates were then formulated as nanoparticles in dextrose solution (2 mg/mL) 
with impressively high drug payload (i.e. 53 to 59%), using simple nanoprecipitation technique 
without the aid of any surfactant. It is noteworthy that such drug payload was dramatically higher than 
into liposomes (20) or PLGA (21) enkephalin-loaded nanoparticles (respectively 0.4% and 4.75 % 
drug loading), which might explain why the latter two nanoformulations had never been used for in 
vivo pharmacological studies. The size of the NPs varied from 61 nm to 112 nm, depending on the 
peptide and the conjugation site (Fig. 2). The NPs displayed spherical and monodisperse structures 
with net positive or negative surface charge (Fig. 2), which could be attributed to the free terminal 
function of the peptide depending on the bioconjugation mode. Indeed, free N-terminal amine 
function led to a net positive surface charge while free C-terminal acid function resulted in a net 
negative surface charge. 
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In order to ascertain that free LENK peptide could be released from the LENK-SQ nanoparticles, 
we tested the chemical stability of the different linkers (i.e., direct amide or dioxycarbonyl or 
diglycolate spacers) after incubation of the LENK-SQ NPs with mouse serum (Fig. 3). Corresponding 
experiments clearly showed that LENK peptide was released from LENK-SQ-Diox and LENK-SQ-
Dig but not from LENK-SQ-Am (Fig. 3). In the case of LENK-SQ-Diox and LENK-SQ-Dig, the 
release of the respective LENK and LENK-linker fragment was followed by a progressive 
degradation of the peptide, due to serum enkephalinases (Fig. 3A and 3B). Of note, in the case of the 
LENK-SQ-Diox bioconjugate, both the LENK and the squalene moieties were each linked through an 
ester bond to the dioxycarbonyl linker. In the case of the LENK-SQ-Dig bioconjugate, the diglycolate 
linker was attached on one side to squalene by an ester bond and on the other side to the LENK 
through an amide bond when in the LENK-SQ-Am bioconjugate a direct amide bond connected the 
LENK to the SQ moiety. The absence of release of LENK from LENK-SQ-Am was not surprising 
given that, generally, amide bond is chemically and enzymatically more stable than ester bond (31, 
32). Furthermore, it is well known that N-terminal modification of linear peptides increases the 
peptidase resistance, which is the case for LENK-SQ-Am and LENK-SQ-Dig (33). Finally, as mouse 
serum is particularly rich in esterases, it was expected that the release of LENK from LENK-SQ NPs 
mainly resulted from enzymatic hydrolysis of ester bond (31). Despite these in vitro data showing that 
depending on the type of linker, whether or not the LENK peptide was released, all the 3 conjugates 
were recruited for anti-hyperalgesia experiments. It was expected that the more aggressive in vivo 
enzymatic content, particularly rich in proteolytic enzymes at the inflammation site, will contribute to 
the release of LENK from all the bioconjugates (29). Indeed, the presence of high concentrations of 
proteolytic enzymes like chymotrypsin, cathepsin D and other proteases in inflammatory exudates has 
been reported which also indicates their important role in the inflammatory
 
process (29).  
Then, anti-hyperalgesic properties of LENK-SQ NPs were evaluated using an animal model 
of inflammatory hyperalgesia that mimics human clinical pain conditions (34). The anti-hyperalgesic 
activity was assessed after a single intravenous administration of the different LENK-SQ NPs in the 
λ-carrageenan-induced inflammatory paw model using Hargreaves test. All LENK-SQ NPs displayed 
a significant anti-hyperalgesic effect on inflamed hind paw. The anti-hyperalgesic effect was less 
intense than after morphine treatment, but nanoparticles evidenced a much longer lasting effect. 
Surprisingly, LENK-SQ-Am NPs, which was expected to release the peptide slower in comparison 
with the other two NPs, exhibited a stronger effect with a shorter duration, probably because the 
enzymatic serum capability is not predictive of the enzymatic ecosystem in the inflamed paw. LENK-
SQ-Dig NPs and LENK-SQ-Diox NPs had nearly the same anti-hyperalgesic profile with prolonged 
effect, resulting in a significantly higher AUC than morphine and LENK-SQ-Am NPs. In particular, 
the LENK-SQ-Dig NPs showed an anti-hyperalgesic effect which lasted twice as long as morphine. In 
addition, as expected for an analgesic compound, PWL values after morphine treatment in λ-
carrageenan-treated rats exceeded basal values in naïve healthy rats, whereas, in contrast, under the 
conditions used here, PWL values after LENK-SQ NPs just reached these basal values (Fig. 5). This 
would suggest that LENK nanoparticles are devoid of analgesic properties but are especially potent to 
counteract hyperalgesia in chronic pain suffering subjects. However, further studies are required to 
assess this hypothesis. 
Pretreatment with Nal (a prototypical opioid antagonist) prevented the increase in PWL evoked by 
LENK-SQ NPs as well as morphine, indicating that the anti-hyperalgesic effect of all these 
compounds was mediated by opioid receptors. On the other hand, pretreatment with Nal-M (which 
does not cross the BBB, (24)) only marginally decreased the anti-hyperalgesic effect of morphine, 
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suggesting that the drug acted mainly through central and, to a lesser extent, peripheral opioid 
receptors. In contrast, Nal-M pretreatment abolished the anti-hyperalgesic effect of LENK-SQ NPs, 
which clearly demonstrated that all three LENK-SQ NPs acted exclusively through peripherally 
located opioid receptors. 
In order to investigate the ability of LENK-SQ NPs to address the peptide towards the inflamed 
tissue, biodistribution studies were performed using in vivo fluorescence imaging in a mouse 
carrageenan-induced paw edema model. Our data clearly highlighted the ability of the nanoparticles 
to gain access to the peripheral inflamed tissue. Indeed, intravenous injection of fluorescent DiD-
labeled LENK-SQ NPs in inflammation-bearing mice resulted in a dramatic increase of fluorescence 
within the inflamed hind paw, up to a level 3-fold higher than in the contralateral non-inflamed paw 
or in the paw of mice treated with saline only (instead of λ-carrageenan). The very low accumulation 
of fluorescence in the non-inflamed paw and in the brain confirmed that the anti-hyperalgesic effect 
resulted from the targeting of LENK-SQ NPs toward peripheral opioid receptors in inflamed tissue, 
rather than central opioid receptors. It is likely that the LENK-SQ distributed within the inflamed area 
as nanoparticles rather than in a single LENK-SQ molecular form. Indeed, whole body imaging of Fig. 
6 shows strong fluorescence in the inflamed paw, which was not the case when the fluorescent dye 
was injected as a free compound. In addition, after incubation of LENK-SQ NPs in serum, a 
significant proportion of NPs remained intact (Fig. S8). 
Finally, safety of LENK-SQ NPs after i.v. injection was confirmed by normal levels of 
transaminases as well as normal histology of vital organs. 
Thus, the novelty of the approach resulted from the unexpected ability of the peptidic nanoparticles 
to target the small area of the body where inflammation and nociception are occurring. As this 
resulted in an effective pain alleviation, which lasted even longer than with morphine and avoided any 
diffusion into the CNS, such properties of LENK-SQ NPs might open novel perspectives for pain 
management. 
CONCLUSION 
Based on the bioconjugation of LENK to squalene, we describe here a new nano-formulation 
capable of precise and efficient delivery of LENK for pain control associated with inflammatory 
events. Our data demonstrated that the anti-hyperalgesic activity of LENK-SQ NPs took place at the 
level of peripheral opioid receptors. The experimental approach to make these nanoparticles is simple 
and easy (i.e., it doesn’t require any complicated nanoparticle surface functionalization), which should 
facilitate further pharmaceutical development and clinical translation. Although further studies are 
needed to more precisely determine how dosage, administration frequency and timing of treatment 
with LENK-SQ may affect the clinical outcome, this study opens a new exciting perspective for an 
efficient treatment of intense pain, which evades from the severe side effects associated with 
morphine or related synthetic opioids. Finally, due to the versatility of the approach, the application to 
this delivery system to other therapeutic peptide molecules may be reasonably envisioned. 
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MATERIALS AND METHODS 
Materials 
All the chemicals used were of analytical grade. Squalene (SQ), diglycolic anhydride, ethyl 
chloroformate, chloromethyl chlorosulfate, ammonium acetate, n-Bu4NHSO4, triethylsilane, 
triethylamine, were purchased from Sigma-Aldrich, France. Pd-C was obtained from Alfa Aesar, 
France and DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyan-ine, 4-chlorobenzenesulfonate 
salt) from PromoKine, Germany. Roti®-Histofix 4 % (formaldehyde) was provided by Roth, 
Germany. 
All the drugs used were of analytical grade. Morphine sulfate salt pentahydrate, λ-carrageenan, 
naloxone hydrochloride (Nal, μ, δ, κ opioid-receptor antagonist), naloxone methiodide (Nal-M, a 
nonspecific opioid receptor antagonist that does not cross the BBB) were purchased from Sigma-
Aldrich (Saint-Quentin Fallavier), France. Ketamine and xylazine were purchased from Centravet 
(Maisons-Alfort), France. 
Leucine enkephalin (LENK) and Alloc-Leucine enkephalin were purchased from Ontores 
Biotechnologies (Zhejiang), China.  
General information on chemicals 
Analytical thin-layer chromatography was performed on Merck silica gel 60F254 glass pre-coated 
plates (0.25 mm layer). Column chromatography was performed on Merck silica gel 60 (230-400 
mesh ASTM). HPLC water was purified using a Milli-Q system (Millipore, France). Tetrahydrofuran 
(THF) was distilled from sodium/benzophenone ketyl. Dimethylformamide (DMF), dichloromethane 
(DCM), and pyridine were dried on calcium hydride (CaH2) prior to distillation under an argon 
atmosphere. Methanol (MeOH) was dried over magnesium and distilled. All reactions involving air- 
or water-sensitive compounds were routinely conducted in glassware which was flame-dried under a 
positive pressure of nitrogen. HPLC grade acetonitrile (ACN), MeOH, ethanol (EtOH) and ethyl 
acetate (AcOEt) were provided by Carlo Erba (Rodano, Italy). 
Synthesis of the Leu-enkephalin-squalene bioconjugate with dioxycarbonyl linker (LENK-SQ-
Diox). 
1,1′,2-tris-norsqualenic acid chloromethyl ester. 1,1′,2-tris-norsqualenic acid was synthesized by 
oxidation of 1,1′,2-tris-norsqualenic aldehyde by Jone’s reagent as previously reported (35, 36). To a 
solution of 1,1′,2-tris-norsqualenic acid (400 mg, 1 mmol) and n-Bu4NHSO4 (34 mg, 0.1 mmol) in 
DCM (2 mL) was added a solution of KHCO3 (300 mg, 3.0 mmol) in water (2 mL). The reaction 
mixture was vigorously stirred, and chloromethyl chlorosulfate (185 mg, 1.15 mmol) was added 
dropwise. After stirring for 1 h, DCM (10 mL) was added to extract the product. The organic phase 
was separated, washed with brine, dried over magnesium sulfate, and concentrated under reduced 
pressure to afford a pale yellow oil which was used in the following step without further purification. 
Alloc-Leu-enkephalin-squalene(AllocLENK-SQ-Diox). The 1,1′, 2-tris-norsqualenic acid 
chloromethyl ester (200 mg, 0.445 mmol) was added into a mixture of Alloc-LENK (285 mg, 0.445 
mmol) and NaHCO3 (37 mg, 0.4 mmol) in 3 mL DMF. The reaction mixture was stirred at 40 ºC 
under argon for 4 days. The final reaction mixture was concentrated in vacuo, and the residue was 
purified by flash column chromatography on silica gel DCM /EtOH (100:0 to 97:3) to afford the title 
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compound as a yellow oil (168 mg, 40% yield). 
Leu-enkephalin-squalene (LENK-SQ-Diox). To a stirred solution of Alloc-LENK-SQ (110 mg, 
0.1 mmol) and 10% Pd-C (20% by weight of Alloc-LENK-SQ-Diox) in MeOH (11 mL) was added 
dropwise neat triethylsilane (TES) (1215 mg, 10 mmol) under argon. When the reaction was 
completed, the mixture was filtered through celite to remove the Pd-C, and the residual TES and 
solvent were removed by evaporation. The residue was first purified by flash column chromatography 
on silica gel with DCM/EtOH (90/10). The resulting product was dissolved in 200 μL of ethanol prior 
to undergo a second purification by semi-preparative reverse-phase HPLC (RP-HPLC) system 
(Waters, Ma 01757, USA) on a uptisphere C18 column (100 × 21.2 mm, pore size=5 μm) (Interchim, 
California, USA) to get the pure product (23 mg; 23% yield). HPLC was then performed using a 
gradient elution with the mobile phase composed of an ammonium acetate buffer (20 mM) and ACN. 
Elution was carried out at a flow rate of 21 mL/min for 10 min with the linear gradient from 10% to 
100% of ACN, then the system was held at 100% of ACN with isocratic flow during 10 min. 
Temperature was set at 30°C and UV detection was monitored at 280 nm and 257 nm. The retention 
time was 15 min, and the total yield of the pure product, after coupling and deprotection steps, 
corresponded to 9.5%.  
Synthesis of the Leu-enkephalin-Squalene Bioconjugate with diglycolic linker (LENK-SQ-Dig). 
1,1′,2-tris-norsqualenol was synthesized from squalene via 1,1′,2-tris-norsqualenic aldehyde 
according to previously reported methods (35, 36). To a solution of 1,1′,2-tris-norsqualenol (200 mg, 
0.52 mmol) in 3 mL of dry pyridine was added diglycolic anhydride (150 mg, 1.29 mmol). The 
reaction was stirred overnight at room temperature. The solvent was removed and the residue was 
extracted with DCM from dilute hydrochloric acid and brine. Conversion to the squalene-diglycolic 
acid, monitored by TLC, was approximately 100%. The resultant product was dried under vacuum, 
and used in the following step without further purification. To a solution of squalene-diglycolic acid 
(50 mg, 0.1 mmol) and triethylamine (TEA) (12 mg, 0.12 mmol) in 1 mL of anhydrous THF was 
added the ethyl chloroformate (10.8 mg, 0.1 mmol) under argon at 0°C. The reaction was stirred 
during 1 h at room temperature and a solution of LENK (55 mg, 0.1 mmol) in 1 mL anhydrous DMF 
was added. The mixture was maintained at 40°C during 2 days with stirring under argon. The solvents 
were removed in vacuo and the crude product was purified using silica gel chromatography (purified 
with gradient eluent DCM/EtOH: 100/0 to 90/10). Then ammonium salt was eliminated by simple 
filtration on silica using EtOH/AcOEt (40/60) as solvents. The pure bioconjugate was obtained with 
69% of yield.  
Synthesis of the Leu-enkephalin-Squalene Bioconjugate with amide linker (LENK-SQ-Am).  
1,1′,2-Tris-nor-squalenic acid (100 mg, 0.25 mmol) and TEA (34.79 mg, 0.3 mmol) were dissolved 
in 1.5 mL of anhydrous THF under argon and ethyl chloroformate (27 mg, 0.25 mmol) was added to 
the mixture at 0°C. The reaction was allowed to warm at room temperature and kept under stirring for 
1 h. A solution of LENK (138 mg, 0.25 mmol) in 1.5 mL of anhydrous DMF was then added to the 
reaction and the mixture was kept under stirring for 2 days. The solvents were removed in vacuo and 
the crude product was purified twice using silica gel chromatography (purification with gradient 
eluent DCM/EtOH: 100/0 to 90/10 and then simple filtration with EtOH/AcOEt: 40/60 to remove the 
ammonium salt). The pure bioconjugate was obtained with 73% of yield.  
Preparation and characterization of Leu-enkephalin-Squalene nanoparticles 
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Preparation of nanoparticles. LENK-SQ NPs were prepared using the nanoprecipitation 
methodology. Briefly, the LENK-SQ bioconjugate (ie. LENK-SQ-Diox, LENK-SQ-Dig or LENK-
SQ-Am) was dissolved in EtOH (8 mg/mL) and added dropwise under stirring (500 rpm) into a 5% 
aqueous dextrose solution (volume ratio EtOH: dextrose solution = 1:4). The solution became 
spontaneously turbid with a tyndall effect, indicating the formation of the nanoparticles. Ethanol was 
then completely evaporated using a Rotavapor® (80 rpm, 30°C, 30 mbar) to obtain an aqueous 
suspension of pure LENK-SQ NPs (final concentration 2 mg/mL). Blank SQ NPs (LENK-free NPs) 
were prepared by the same method as described above by adding dropwise an ethanolic solution of 
squalenic acid into 5% aqueous dextrose solution. Fluorescent LENK-SQ NPs were also obtained by 
the same procedure, except that the fluorescent probe DiD was solubilized in the ethanolic phase 
together with the LENK-SQ-Am bioconjugate (ratio DiD/LENK-SQ-Am was 4% wt), before addition 
to the dextrose solution. Fluorescent quenched LENK-SQ NPs were also prepared by the same way 
using DiR as a fluorescent quencher (ratio DiD/DiR/LENK-SQ-Am was 2/2/100 wt). The peptide 
drug loadings into the NPs were expressed as percentage (%), calculated from the ratio between 
LENK peptide Mw and LENK-SQ bioconjugate Mw. The LENK-SQ nanoparticles were regularly 
observed by cryo-TEM. All the NPs were freshly prepared and used within 2 h (conservation at 4 °C) 
before in vivo experiments. 
Dynamic Light Scattering (DLS) Measurements. The mean particle size, polydispersity index 
(PDI) and zeta potential were primarily evaluated by DLS (Nano ZS, Malvern; 173° scattering angle 
at 25 °C). The measurements were performed in triplicate following appropriate dilution of the 
nanoparticles in water (DLS) or in 0.1 mM KCl (zeta potential). The results represent the mean and 
standard deviation of three repeated sample preparations or more.  
Cryo-TEM. The morphology of the LENK-SQ NPs was investigated by Cryo-TEM. NPs were 
vitrified using a chamber designed and set up in the laboratory where both humidity and temperature 
could be controlled. 4 μL solution of LENK-SQ NPs (4 mg/mL in Milli-Q water) was deposited onto 
a perforated carbon film mounted on a 200 mesh electron microscopy grid. The homemade carbon 
film holes dimensions were about 2 mm in diameter. Most of the drop was removed with a blotting 
filter paper and the residual thin films remaining within the holes were quick-frozen by plunging them 
in liquid ethane cooled with liquid N2. The specimen was then transferred, using liquid N2, to a cryo-
specimen holder and observed using a JEOL FEG-2010 electron microscope. Micrographs were 
recorded at 200 kV under low-dose conditions at a magnification of 40 000 on SO-163 Kodak films. 
Micrographs were digitized using a film scanner (Super Coolscan 8000 ED, Nikon), and analyses 
were made using the ImageJ software.  
In vitro LENK release from NPs in serum 
Frozen serum of male SWISS mice (900 μL) was quickly thawed and then pre-incubated at 37 °C 
for 30 min before the addition of 300 μL LENK-SQ-Dig NPs or LENK-SQ-Am NPs (2 mg/mL). In 
the case of LENK-SQ-Diox NPs, diluted serum (30% in 5% dextrose solution) was used for the 
release study. At various time intervals, aliquots (80 μL) were collected and added into 320 μL ACN 
to denature and precipitate the enzymes and proteins of the serum, in order to remove them after 
centrifugation (3000 g for 15 min). To quantify the residual LENK-SQ bioconjugate and the released 
LENK, the resulting supernatants (150 μL) were evaporated to dryness at 40°C under nitrogen flow, 
and then solubilized in 150 μL of Milli-Q water. Free peptide quantification was performed using RP-
HPLC on a Uptisphere Strategy C18HQ column (4.6 x 100 mm, 5 μm, Interchim), a 1525 Binary LC 
Pump (Waters, a 2707 Auto-sampler (Waters) and a 2998 PDA detector (Waters). The HPLC was 
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carried out using a gradient elution with the mobile phase composed of 5 mM ammonium acetate in 
milli-Q water (phase A) and 5 mM ammonium acetate in ACN (phase B). Elution was carried out at a 
flow rate of 1 mL/min for 13 min with the linear gradient from 10% to 100% of B; then, the system 
was held at 100% of B with isocratic flow during 10 min. Temperature was set at 35°C and UV 
detection was monitored at 257 nm. The detection limit of the HPLC technique was 0.39 μg/mL for 
the peptide. This method exhibited linearity (R
2
=0.99998) over the assayed concentration range (0.39-
200 μg/ml) and demonstrated good precision with relative standard deviation (RSD) being all less 
than 2.01%. The accuracy corresponded to 96 ± 5%. 
General information on in vivo study 
Animals. Adult male Sprague-Dawley rats (200-220 g on arrival, 280-300 g at the time of 
experiments) and adult male Swiss mice (18-20 g on arrival, 22-25 g at the time of experiments) were 
purchased from Janvier Labs (France) for algesimetry tests and biodistribution respectively. They 
were housed in a standard controlled environment (22 ± 1 °C, 60% relative humidity, 12:12 h light-
dark cycle, lights on at 8:00 a.m.) with food and water available ad libitum, without any handling for 
at least 1 week before being used for experiments. In all cases, experiments were performed in 
conformity with the guidelines of the Committee for Research and Ethical Issues of the International 
Association for the Study of Pain (IASP) (37) and approved by the Animal Care Committee of the 
University Paris-Sud in accordance with the principles of laboratory animal care and the European 
legislation 2010/63/EU. All efforts were made to reduce animal numbers and minimize their suffering, 
as defined in the specific agreement (registered under #7493-2016102520355414).  
Carrageenan-induced paw edema model. Since the demonstration that indomethacin reduces 
inflammation caused by intraplantar injection of -carrageenan, this acute model is widely accepted 
for screening compounds with anti-inflammatory potentialities (38). λ-Carrageenan was dissolved in 
physiological saline (NaCl, 0.9%) just prior to injection. Rats or mice received a single intraplantar 
injection of λ-carrageenan solution in the plantar region of the right hind paw (23, 39) in order to 
induce inflammation. The injected λ-carrageenan dose corresponded to 100 μL (2% solution w/v) for 
rat, and 20 μL (3% solution w/v) for mice. Inflammation reached its maximum 3 h after λ-
carrageenan injection. Thermal nociceptive test was then performed on the ipsilateral inflamed hind 
paw. 
Nociceptive behavioral study in rats 
Thermal Nociceptive test. Hypersensitivity to thermal nociceptive stimuli was assessed using the 
Hargreaves test (23). Rats were placed individually in an open Plexiglas cylindrical chamber (20 cm 
in diameter, 35 cm high) on a 3 mm thick transparent glass floor, and allowed to habituate for at least 
20 min before testing. A moveable radiant heat source (Model 7370, Ugo Basile plantar test, Italy) 
was positioned under the glass floor directly beneath the plantar surface of the right hind paw and the 
time (in seconds) that elapsed from switching on the radiant heat until paw withdrawal was measured 
automatically. A cut-off time of 20 s was established to prevent tissue damage. Each trial was 
repeated 3 times with 5 min intervals for basal threshold and 2 times spaced of 2 min after NPs 
treatments at 3 h after λ-carrageenan injection. The average of paw withdrawal latencies (PWL) was 
calculated and expressed as mean values ± SEM. (standard error of mean). 
Experimental design for algesimetry test. Basal responses to thermal stimuli were obtained on 
the day before the λ-carrageenan injection. On the basis of previous studies, acute pharmacological 
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treatments were performed 3 h post-carrageenan injection, which corresponded to the peak 
inflammatory response.  
The efficacy of these treatments on thermal hyperalgesia was evaluated by measurement of paw 
withdrawal latencies (PWL) using Hargreaves test at regular time intervals after drug or vehicle 
administration, first at 10 min and then each 30 min during a period of 4 h (Fig. 4).  
Acute pharmacological treatments. Morphine and LENK were dissolved in dextrose 5%, 
whereas Nal and Nal-M were dissolved in physiological saline (NaCl, 0.9%). All these drugs and NPs 
suspensions were prepared just before administration. All acute treatments were performed at 3 h after 
λ-carrageenan intraplantar injection according to Fig. 4. Nal and Nal-M were injected subcutaneously 
(s.c.) whereas the intravenous (i.v.) route in the tail vein was used for LENK-SQ NPs, LENK and 
their controls. The antagonist (Nal or Nal-M) was administered 15 min before the agonist (morphine 
or tested NPs). A single dose of morphine (1 mg/kg), Nal (0.5 mg/kg) and Nal-M (0.5 mg/kg) was 
administered based on literature data (40). A single i.v. dose of LENK-SQ NPs (20 mg/kg, equivalent 
to 11.48 mg/kg of LENK) or control unconjugated SQ NPs (8.28 mg/kg) was used, based on maximal 
volume of LENK-SQ NPs that could be injected.  
Biodistribution study in mice 
In vivo imaging biodistribution studies were performed after i.v. injection of fluorescent LENK-
SQ-Am NPs (250 μL, 2 mg/mL containing 4% DiD) or control fluorescent DiD solution (250 μL, 80 
μg/mL in 5% dextrose solution) in shaved mice bearing λ-carrageenan-induced inflammation. In 
parallel, control non-inflamed shaved mice (injected with 20 μL saline into the right hind paw, instead 
of λ-carrageenan), received also injection of fluorescent LENK-SQ NPs. The biodistribution of the 
NPs was recorded at 0.5, 2, 4, 6 and 24 h after excitation at 640 nm and emission in the 695–775 nm 
filter respectively, using IVIS Lumina LT serie III system (Caliper, Life science). During imaging, the 
mice were kept on the imaging stage under anesthesia with 2% isoflurane gas in oxygen flow (1 
L/min) and were imaged in ventral position. Images and measures of fluorescence signals were 
acquired and analyzed with Living Imaging®. To measure photon radiance, regions of interest (ROI, 
threshold of 35%) were selected on the paw of the mice and average radiant efficiency values were 
used for quantification. Threshold of ROI for the inflamed paw was then pasted on the non-inflamed 
paw to compare the radiance with the same region.  
In a separate experiment, fluorescent LENK-SQ NPs injected mice were deeply anesthetized with a 
mixture of ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) before euthanisia by transcardiac 
perfusion of 40 ml saline (8 mL/min), until the fluid exiting the right atrium was entirely clear. Then, 
liver, spleen, kidneys, heart, lungs, brain, and inflamed right hind paw were excised and immediately 
imaged with the imager. The fluorescence emitted was quantified with Living Image software over 
the ROI (threshold of 20%). 
Toxicity study in rats 
Adult male Sprague-Dawley rats were injected with either LENK-SQ-Am NPs (20 mg/kg) or 
dextrose 5% (N = 3 animals per group). At 24, or 48 hours post-injection, the animals were 
anaesthetized under anesthesia with 2% isoflurane gas in oxygen flow (1 L/min) and blood was 
collected from tail blood vessels by anticoagulant (heparin, 500UI/mL) treated syringes. The blood 
samples were centrifuged at 1000g for 15 minutes and the plasma was collected and stored at -20°C 
before analysis. The AST and ALT levels in plasma were analyzed by Cerba Vet, France. 
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In a separate experiment, 24, or 48 hours post-injection, rats were deeply anesthetized by Doletal. 
Liver, kidneys, spleen, heart, and lungs were then excised, fixed by 4% formaldehyde, paraffin-
embedded, and cut into 5 μm thick sections. Haematoxylin and eosin staining was performed on all 
the organs for analysis of the morphology (Zeiss).  
Statistical analyses 
All values are expressed as means ± SEM. and statistical analyses were made with GraphPad prism 
6 software (San Diego, CA, USA). A two-way analysis of variance (Anova) was used with or without 
repeated measures as appropriate (see Materials and Methods and legends to figures). The comparison 
between groups was performed using the Bonferroni post hoc test. A one-way analysis of variance 
(Anova) followed by a tukey post test was used to compare 3 or more groups in bars of AUC. Areas 
under curves (AUC) were calculated using the trapezoidal rule. For all analyses, statistical 
significance was set at P ≤ 0.05.  
LIST OF ABBREVIATIONS 
ACN = acetonitrile 
AcOEt = ethyl acetate 
ALT = aspartate transaminase 
AST = alanine transaminase 
AUC = area under the curve 
Cryo-TEM = cryogenic transmission electron microscopy 
DCM = dichloromethane  
DMF = dimethylformamide  
DLS = dynamic light scattering 
EPR = enhanced permeation and retention 
EtOH = ethanol 
LDC = lipid-drug conjugates 
LENK = Leu-enkephalin 
LENK-SQ = Leu-enkephalin-squalene 
LENK-SQ-Diox = Leu-enkephalin-squalene with dioxycarbonyl linker 
LENK-SQ-Dig = Leu-enkephalin-squalene with diglycolic linker 
LENK-SQ-Am = Leu-enkephalin-squalene with amide linker 
MeOH = methanol 
Nal = naloxone 
Nal-M = naloxone methiodide 
NPs = nanoparticles 
PDI = polydispersity index 
PWL = paw withdrawal latency 
SQ = squalene 
TES = triethylsilane 
THF = tetrahydrofuran 
SUPPLEMENTARY MATERIALS 
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Supplementary Text: IR, NMR and MS characterization of bioconjugates 
Fig. S1. Synthesis of Leu-enkephalin-squalene with dioxycarbonyl linker (LENK-SQ-Diox) 
Fig. S2. Synthesis of Leu-enkephalin-squalene with diglycolic linker (LENK-SQ-Dig)  
Fig. S3. Synthesis of Leu-enkephalin-squalene with amide linker (LENK-SQ-Am)  
Fig. S4. 
1
H spectrum of LENK-SQ bioconjugates 
Fig. S5. 
13
C spectrum of LENK-SQ bioconjugates 
Fig. S6. Size and zeta potential of LENK-SQ NPs kept at +4°C 
Fig. S7. Hydrolysis of LENK or LENK-SQ-Am NPs in the presence of serum 
Fig. S8. In vitro colloidal stability of LENK-SQ-Am NPs in mouse serum 
Fig. S9. Biodistribution of fluorescent LENK-SQ-Am NPs or control fluorescent dye solution in mice 
with or without inflamed paw 
Fig. S10. Toxicity study of LENK-SQ-Am NPs upon systemic administration 
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Supplementary Text: IR, NMR and MS characterization of bioconjugates 
IR spectra were obtained from solids or neat liquids with a PerkinElmer UATR Two spectrometer. 
Only significant absorptions are listed. The 
1
H and 
13
C NMR spectra were recorded on a Bruker ARX 
400 spectrometer (400 and 100 MHz for 
1
H and 
13
C, respectively). Recognition of methyl, methylene, 
methine, and quaternary carbon nuclei in 
13
C NMR spectra rests on the J-modulated spin-echo 
sequence. Mass spectra were recorded on a Bruker Esquire-LC. High resolution Mass spectra (HR-
MS) were achieved with an LTQ-Orbitrap Velos Pro (Thermo Fisher Scientific) operating in positive 
and negative electrospray ionization. 
IR, NMR and MS characterization of LENK-SQ-Diox: IR (neat, cm
-1): ν 3289, 2958, 2916, 2849, 
1763, 1646, 1537, 1515, 1447, 1381, 1259, 1116, 1020, 982, 870, 802, 729, 700, 549, 493. 
1
H NMR 
(400 MHz, MeOD) δ: 7.31-7.23 (m, 4H, 2HAr-ortho Phe, 2HAr-meta Phe), 7.18 (m, 1H, HAr-para Phe), 7.04 
(d, 2H, HAr-ortho Tyr, J = 8.4 Hz), 6.71 (d, 2H, HAr-meta Tyr, J = 8.4 Hz), 5.77 (d, 1H, OCH2O, J = 5.6 
Hz), 5.71 (d, 1H, OCH2O, J = 5.6 Hz), 5.19–5.04 (m, 5H, HC=C(CH3)), 4.65 (dd, 1H, CH Phe, J = 
4.9 Hz, J = 9.6 Hz), 4.44 (m, 1H, CH Leu), 4.00-3.60 (m, 4H, 2 CH2 Gly), 3.54 (dd, 1H, CH Tyr, J = 
6.5 Hz, J = 7.6 Hz), 3.16 (dd, 1H, CHaHb Phe, J = 4.9 Hz, J = 14.0 Hz), 3.10-2.87 (m, 2H, CHaHb 
Phe, CHaHb Tyr), 2.80 (dd, 1H, CHaHb Tyr, J = 7.6 Hz, J = 13.9 Hz), 2.44 (m, 2H, CH2-CH2-CO 
SQ), 2.26 (m, 2H, CH2-CH2-CO SQ), 2.14-1.90 (m, 16H, 8 CH2 SQ), 1.75-1.48 (m, 21H, CH2 Leu, 
CH(CH3)2 Leu, 6 CH3 SQ), 0.94 (d, 3H, CH3 Leu, J = 6.2 Hz), 0.90 (d, 3H, CH3 Leu, J = 6.2 Hz). 
13
C 
NMR (75 MHz, MeOD) δ: 178.0 (CONH), 173.7 (CONH), 173.0 (CONH), 172.4 (CONH), 172.0 
(CONH), 171.3 (CONH), 157.6 (CAr-para Tyr), 138.3 (CAr Phe), 136.0 (HC=C(CH3)), 135.8 (2 
HC=C(CH3)), 134.1 (HC=C(CH3)), 132.0 (HC=C(CH3)), 131.5 (2 CHAr-ortho Tyr), 130.4 (2 CHAr-ortho 
Phe), 129.5 (2 CHAr-meta Phe, CAr Tyr), 127.8 (CHAr-para Phe), 126.5 (HC=C(CH3)), 125.7 
(HC=C(CH3)), 125.5 (2 HC=C(CH3)), 125.4 (HC=C(CH3)), 116.5 (2 CHAr-meta Tyr), 80.9 (O-CH2-O), 
62.6 (CH Tyr), 55.8 (CH Phe), 52.2 (CH Leu), 43.8 (CH2 Gly), 43.6 (CH2 Gly), 41.0 (CH2-CH(CH3)2 
Leu), 40.8 (CH2 SQ), 40.7 (2 CH2 SQ, CH2 Tyr), 38.7 (CH2 Phe), 35.3 (CH2-CH2-CO), 33.8 (CH2-
CH2-CO), 30.7 (CH2 SQ), 30.4 (CH2 SQ), 29.2 (CH2 SQ), 27.8 (CH2 SQ), 27.5 (CH2 SQ), 25.9 
(CH(CH3)2 Leu), 23.4 (CH3 Leu), 21.9 (CH3 Leu), 17.8 (CH3 SQ), 16.7 (CH3 SQ), 16.2 (CH3 SQ), 
16.1 (CH3 SQ), 16.0 (CH3 SQ), 14.5 (CH3 SQ). HRMS (+ESI): m/z 968.6064 ([M + H]
+
 calcd for 
C56H82N5O9: 968.6107).  
IR, NMR and MS characterization of LENK-SQ-Dig: IR (neat, cm
-1): ν 3297, 3068, 2958, 2924, 
2851, 1653, 1516, 1443, 1260, 1142, 1099, 1020, 799, 699, 583. 
1H NMR (400 MHz, MeOD) δ: 
7.30–7.22 (m, 4H, 2HAr-ortho Phe, 2HAr-meta Phe), 7.19 (m, 1H, HAr-para Phe), 7.06 (d, 2H, HAr-ortho Tyr, J 
= 8.5 Hz), 6.71 (d, 2H, HAr-meta Tyr, J = 8.5 Hz), 5.20–5.05 (m, 5H, HC=C(CH3)), 4.65 (dd, 1H, CH 
Phe, J = 4.7 Hz, J = 9.4 Hz), 4.57 (dd, 1H, CH Tyr, J = 6.1 Hz, J = 8.3 Hz), 4,40 (m, 1H, CH Leu), 
4.17-3.85 (m, 6H, 2 CH2 Diglycolyl, CH2-O SQ), 3.90-3.72 (m, 4H, 2 CH2 Gly), 3.20 (dd, 1H, 
CHaHb Phe , J = 4.7 Hz, J = 14.0 Hz), 3.11 (dd, 1H, CHaHb Tyr, J = 6.1 Hz, J = 13.9 Hz), 3.00-2.89 
(m, 2H, CHaHb Phe, CHaHb Tyr), 2.14-1.93 (m, 19H, 9 CH2 SQ, CHaHb-CH2-O SQ), 1.74 (m, 1H, 
CHaHb-CH2-O SQ), 1.71–1.54 (m, 21H, CH2 Leu, CH(CH3)2, 6 CH3 SQ), 0.94 (d, 3H, CH3 Leu, J = 
6.2 Hz), 0.91 (d, 3H, CH3 Leu, J = 6.2 Hz). 
13C NMR (75 MHz, MeOD) δ: 176.8 (CONH), 174.2 
(CONH), 173.4 (CONH), 172.2 (O-CO-CH2), 172.0 (CONH), 171.3 (CONH), 157.5 (CAr-para Tyr), 
138.5 (CAr Phe), 135.9 (3 HC= C(CH3)), 134.8 (HC=C(CH3)), 132.0 (HC=C(CH3)), 131.4 (2CHAr-ortho 
Tyr), 130.4 (2CHAr-ortho Phe ), 129.4 (2CHAr-meta Phe), 128.6 (CAr Tyr ), 127.7 (CHAr-para Phe), 126.3 
(HC=C(CH3)), 125.6 (2 HC=C(CH3)), 125.5 (HC=C(CH3)), 125.4 (HC=C(CH3)), 116.3 (2CHAr-meta 
Tyr), 71.5 (O-CH2-O), 69.4 (CO-CH2-O), 65.9 (CH2-CH2-CH2-O), 56.2 (CH Tyr), 56.0 (CH Phe), 
52.3 (CH Leu), 44.0 (CH2 Gly), 43.4 (CH2 Gly), 41.7 (CH2-CH(CH3)2 Leu), 38.6 (CH2Phe), 37.9 
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(CH2 Tyr), 36.8 (CH2-CH2-CH2-O), 29.2 (CH2 SQ), 27.8 (2 CH2 SQ), 27.6 (3 CH2 SQ), 25.9 
(CH(CH3)2 Leu, CH3 SQ), 23.4 (CH3 Leu), 22.0 (CH3 Leu), 17.8 (CH3 SQ), 16.2 (2 CH3 SQ), 16.0 (2 
CH3 SQ). HRMS (-ESI): m/z 1038.61572 ([M - H]
−
 calcd for C59H84N5O11 : 1038.61618).  
IR, NMR and MS characterization of LENK-SQ-Am: IR (neat, cm
-1): ν 3303, 2957, 2925, 2856, 
1711, 1697, 1543, 1516, 1440, 1282, 1241, 1213, 828, 671. 
1H NMR (400 MHz, MeOD) δ: 7.31–7.22 
(m, 4H, 2HAr-ortho Phe, 2HAr-meta Phe), 7.18 (m, 1H, HAr-para Phe), 7.05 (d, 2H, HAr-ortho Tyr, J = 8.5 Hz), 
6.71 (d, 2H, HAr-meta Tyr, J = 8.5 Hz), 5.19–5.05 (m, 5H, HC=C(CH3)), 4.68 (dd, 1H, CH Phe, J = 4.9 
Hz, J = 9.2 Hz), 4.50-4.39 (m, 2H, CH Tyr, CH Leu), 3.87-3.67 (m, 4H, 2 CH2 Gly), 3.20 (dd, 1H, 
CHaHb Phe , J = 4.9 Hz, J = 14.0 Hz), 3.07-2.93 (m, 2H, CHaHb Phe, CHaHb Tyr), 2.85 (dd, 1H, 
CHaHb Tyr, J = 8.2 Hz, J = 13.8 Hz), 2.31 (m, 2H, CH2-CH2-CO), 2.18 (m, 2H, CH2-CH2-CO), 2.13-
1.88 (m, 16H, 8 CH2 SQ), 1.73-1.53 (m, 21H, CH2 Leu, CH(CH3)2 Leu, 6 CH3 SQ), 0.94 (d, 3H, CH3 
Leu, J = 6.2 Hz), 0.91 (d, 3H, CH3 Leu, J = 6.2 Hz). 
13C NMR (75 MHz, MeOD) δ: 176.2 (CO2H), 
175.8 (CONH), 174.7 (CONH), 173.3 (CONH), 172.0 (CONH), 171.2 (CONH), 157.4 (CAr-para Tyr), 
138.4 (CAr Phe), 136.0 (2 HC=C(CH3)), 135.8 (HC=C(CH3)), 134.7 (HC=C(CH3)), 132.0 
(HC=C(CH3)), 131.3 (2CHAr-ortho Tyr), 130.4 (2CHAr-ortho Phe), 129.4 (2CHAr-meta Phe), 128.9 (CAr Tyr), 
127.7 (CHAr-para Phe ), 126.2 (HC=C(CH3)), 125.6 (HC=C(CH3)), 125.5 (HC=C(CH3)), 125.5 (2 
HC=C(CH3)), 116.3 (2CHAr-meta Tyr), 56.9 (CH Tyr), 55.9 (CH Phe), 52.3 (CH Leu), 43.9 (CH2 Gly), 
43.3 (CH2 Gly), 41.7 (CH2-CH(CH3)2 Leu), 38.7 (CH2Phe), 37.9 (CH2 Tyr), 36.5 (CH2-CH2-CO), 
35.8 (CH2-CH2-CO), 29.2 (3 CH2 SQ), 27.8 (4 CH2 SQ), 27.5 (2 CH2 SQ), 25.9 (CH(CH3)2 Leu, CH3 
SQ), 23.4 (CH3 Leu), 21.9 (CH3 Leu), 17.7 (CH3 SQ), 16.2 (2 CH3 SQ), 16.1 (CH3 SQ), 16.0 (CH3 
SQ). HRMS (-ESI): m/z 936.5826 ([M - H]
−
 calcd for C55H78N5O8 : 936.5845). 
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Fig. S1. Synthesis of Leu-enkephalin-squalene with dioxycarbonyl linker (LENK-SQ-Diox). 
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Fig. S2. Synthesis of Leu-enkephalin-squalene with diglycolic linker (LENK-SQ-Dig).  
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Fig. S3. Synthesis of Leu-enkephalin-squalene with amide linker (LENK-SQ-Am).  
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Fig. S4. 
1
H spectrum of LENK-SQ bioconjugates. (A) LENK-SQ-Diox, (B) LENK-SQ-Dig, and (C) LENK-
SQ-Am. 
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Fig. S5. 
13
H spectrum of LENK-SQ bioconjugates. (A) LENK-SQ-Diox, (B) LENK-SQ-Dig, and (C) LENK-
SQ-Am. 
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Fig. S6. Size and zeta potential of LENK-SQ NPs kept at +4°C. (A) LENK-SQ-Diox NPs, (B) LENK-SQ-
Dig NPs and (C) LENK-SQ-Am NPs. Results of three independent preparations are presented as mean ± SEM. 
 
Fig. S7. Hydrolysis of LENK or LENK-SQ-Am NPs in the presence of serum. 300 μL of LENK-SQ-Am 
NPs (2 mg/mL, 2 mmol) or LENK (1.15 mg/mL, 2 mmol) were incubated in 900 μL mouse serum, and samples 
were collected at different times for HPLC analysis. The LENK-SQ bioconjugate was unaltered during the 
course of the experiment, whereas free LENK was rapidly metabolized. 
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Fig. S8. In vitro colloidal stability of LENK-SQ-Am NPs in mouse serum. (A) Controls: When diluted in 5% 
dextrose LENK-SQ-Am NPs remained assembled (DiD: reporter dye; DiR: quencher). They disassembled in 
ethanol; (B) LENK-SQ-Am NPs (DiD: reporter dye; DiR: quencher) incubated in mouse serum (1:4). The 
fluorescence emission was measured to assess the progressive disassembly of the nanoparticles. 
 
 
 
 
Squalenoylated Leu-enkephalin nanomedicine 
 108
 
Fig. S9. Biodistribution of fluorescent LENK-SQ-Am NPs or control fluorescent dye solution in mice with 
or without inflamed paw. 4 h after λ-carrageenan or saline injection into the right paw, fluorescent LENK-SQ 
NPs or free dye were intravenously introduced into the mice. At different time points, mice were deeply 
anesthetized with a mixture of ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) before euthanasia by 
transcardiac perfusion of 40 ml saline (8 mL/min), until the fluid exiting the right atrium was entirely clear. 
Then, liver, spleen, kidneys, heart, lungs, brain, and inflamed right hind paw were excised and immediately 
imaged with the imager. The fluorescence emitted was quantified with Living Image software over the region of 
interest (ROI) with the threshold of 20%. (A) Ex vivo fluorescence imaging of the harvested brain, heart, 
kidneys, lungs, liver and paw from fluorescent NPs or free dye-injected SWISS mice. (B) Average radiant 
efficiency of these organs after 4 or 24 h injection of NPs or free dye. 
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Fig. S10. Toxicity study of LENK-SQ-Am NPs upon systemic administration. LENK-SQ-Am NPs 
(20mg/kg) were intravenously administered in rats. The AST (A) and ALT (B) levels in plasma showed no 
differences compared with dextrose solution (data presented as mean UI/L ± SED, N = 3 animals per group). 
Histological analysis of organs after intravenous administration of LENK-SQ-Am NPs (20mg/kg) did not show 
any signs of cell or tissue damage at 24 h and 48h, comparatively to a control 5% dextrose solution. Liver (C-F), 
spleen (G-J), kidneys (K-N), lungs (O-R) and heart (S-V). All tissue images were analyzed by microscopy at 
10× magnification except for kidneys which were at 5× magnification (Zeiss). 
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I. EXPERIMENTAL SECTION 
Materials: Fluorescent probes CholEsteryl BODIPY® FL C12 and CholEsteryl BODIPY® 
542/563 C11, were obtained from Life Technologies. Fmoc-Leucine enkephalin was purchased from 
Genecust, Luxembourg. Piperidine was obtained from Sigma-Aldrich, France. 
1. Failed attempts to link squalene and LENK thrugh an ester bond 
Several attempts were conducted to link LENK with squalene through direct ester bond, either by 
coupling SQ-COOH on the phenolic hydroxyl group of LENK (1
st
 strategy) or SQ-OH on C-terminal 
acid of LENK (2
nd
 strategy) (Supp. Fig. 1, Supp. Table. 1). But none of them could lead to an ester 
bond between SQ and LENK.  
 
Supp. Fig. 1. Strategies to link squalene with LENK through an ester bond. 
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Supp. Table 1. Strategies to link squalene with LENK through an ester bond. 
Strategy 1 
 
a). Activated by NHS 1
st
 step: activation of squalenic acid with NHS 2
nd
 step: bioconjugation 
Squalenic acid 1 equiv. SQ-NHS 2 equiv. 
NHS 2 equiv. Fmoc-LENK 1 equiv. 
EDCI 2 equiv. TEA 1 equiv. 
DMAP 0.025 equiv. Dry DMF  
DCM    
b). Activated by oxalyl 
chloride 
Squalenic acid 2 equiv.   
Oxalyl chloride 6 equiv.   
Fmoc-LENK 1 equiv.   
Toluene    
Dry DMF    
c). Activated by methyl 
chloroformate oxalyl 
Squalenic acid 2 equiv.   
Methyl chloroformate 1.6 equiv.   
Fmoc-LENK 1 equiv.   
Piridine    
Dry THF    
TEA 1.6 equiv.   
Strategy 2 
 
Activated by DCC Squalenol 2 equiv.   
Fmoc-LENK 1 equiv.   
DCC 1 equiv.   
PTSA 0.3 equiv.   
Piridine    
Notes: NHS: N-hydroxysuccinimide; EDCI: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; DMAP: 4-
Dimethylaminopyridine; DCM: dichloromethane; TEA: Triethylamine; DMF: N,N-Dimethylformamide; THF: 
Tetrahydrofuran; DCC: Dicyclohexylcarbodiimide; PTSA: p-Toluenesulfonic acid. 
2. Failed attempts to synthesize LENK-SQ-Diox through Fmoc protection. 
1,1′, 2-tris-norsqualenic acid chloromethyl ester (2) was added into a mixture of Fmoc-LENK and 
NaHCO3 (37 mg, 0.4 mmol) in anhydrous DMF. After reacting at 40 °C under argon for 4 days, 
Fmoc-LENK-SQ (4) was obtained. Piperidine is an efficient agent to deprotect the Fmoc group. But 
in the case of Fmoc-LENK-SQ-Diox, the dioxycarbonyl linker was cleaved during the deprotection 
(Supp. Fig. 2.). It was the same with triethylamine. 
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Supp. Fig. 2. Fmoc strategy failed to obtain Leu-enkepahlin-squalene wih dioxycarbonyl linker. (1) 1,1′, 
2-tris-norsqualenic acd; (2) 1,1′, 2-tris-norsqualenic acid chloromethyl ester; (3) Fmoc protected LENK; (4) 
Fmoc-LENK-SQ; (5-7) molecules after deprotection step. 
3. Failed attempts to remove the Alloc protection 
Supp. Table 2. Failed strategies to remove Alloc protection 
Strategy 1 (1) Strategy 2 (2) Strategy 3 (3) 
Alloc-LENK-SQ 1 equiv. Alloc-LENK-SQ 1 equiv. Alloc-LENK-SQ 1 equiv. 
Pd(PPh3)4 0.1 equiv. Pd(PPh3)4 0.1 equiv. Pd-C 0.1 equiv. 
Dimedone 7.5 equiv. PhSiH3 25 equiv. TES 10 equiv. 
Dry THF  Dry DCM  MeOH  
Problems: 
 Not totally deprotected. 
Problem: 
 Difficulty to remove Pd(PPh3)4. 
Problem: 
 Formation of allylamines as a side 
reaction. 
Notes: Pd(PPh3)4: Palladium-tetrakis(triphenylphosphine); PhSiH3: Phenylsilane; Pd-C: Palladium on carbon; TES: 
Triethylsilane. 
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4. In vitro transcytosis study through blood-brain-barrier model 
4.1. Preparation of fluorescent nanoparticles 
Briefly, for the NPs with BODIPY probes, a mixture of LENK-SQ (8 mg/mL in ethanol), 
BODIPY® FL C12 and BODIPY® 542/563 C11 (both at 0.5 mg/mL in a mixture of ethanol and 
acetone (1:1)) were added dropwise into a 5% aqueous dextrose solution under magnetic stirring. The 
solution became spontaneously turbid with a tyndall effect, indicating the formation of the 
nanoparticles. The solvent was then completely evaporated using a Rotavapor® (80 rpm, 30°C, 30 
mbar) to obtain an aqueous suspension of pure LENK-SQ NPs (final concentration 2 mg/mL). 
Keeping a constant total amount of incorporated probes at 2% with respect to the LENK-SQ, different 
formulations were prepared by varying the relative fraction of each probe. The size and surface charge 
were measured using Malvern Zetasizer Nano ZS 6.12 (173° scattering angle, 25°C). 
4.2. Transcytosis of the LENK-SQ through hCMEC/D3 cellular monolayer 
hCMEC/D3 cells were grown in EBM-2 medium supplemented with 5% FBS, 10 mM HEPES, 1 
ng/mL bFGF, 1.4 μM hydrocortisone, 5 μg/mL acid ascorbic, 1% Chemically Defined Lipid 
Concentrate and 1% penicillin-streptomycin at 37 °C and 5% CO2. Cells were passaged every 3 - 4 
days by 1:4. 
A total of 232500 hCMEC/D3 cells (50,000 cells/cm2) was seeded on 0.4 μm pores, 4.67 cm2, 
collagen precoated PTFE membrane transwells (Corning). 1.5 mL of medium was added in the apical 
compartment and 2.6 mL in the baso-lateral compartment. Cells were cultivated for 7 days at 37 °C 
and 5% CO2 to confluence and medium was changed after three days. In order to check the formation 
of tight junctions, transendothelial electrical resistance (TEER) was measured using an epithelial 
voltmeter (EVOM2), which should be more than 30 Ohm*cm
2
.  
Then, fluorescent LENK-SQ NPs (40 μg/ mL) diluted in culture medium were added to the apical 
compartments of the transwells, and after 4h and 6h of incubation, the media of the two compartments 
were withdrawn. The fluorescence intensity was measured using spectrofluorimeter. The 
transmembrane passage was expressed as the percentage of the fluorescence found in the baso-lateral 
compartment, as compared to the initial fluorescence placed in the apical compartment using a 
calibration curve. Transcytosis of Results were expressed as mean ± SD corresponding to three 
independent experiments run in duplicate.  
Apical media (0.25mL) was added to 0.75mL of acetonitrile. The baso-lateral media (0.5mL) was 
added to 1.5mL of acetonitrile. Each medium was then centrifuged under 5000g during 15 mins in 
order to precipitate the proteins from the medium, the surpernatant was then collected, dried under 
nitrogen flow and re-solubilized in 0.25mL of H2O for HPLC. 
II. SUPPLEMENTARY RESULTS 
1. Peptide quantification by HPLC 
The HPLC technique exhibited linearity for LENK over the assayed concentration range (0.39-200 
μg/ml) (Supp. Fig. 3). The linear regression analysis displayed a high correlation coefficient (R2= 
0.99998) between peak area and concentration and the detection limit of the HPLC technique was of 
0.39 μg/mL for LENK. The accuracy of the technique corresponded to 96 ± 5% which is within the 
acceptance limit (90%-110%), hence giving a suitable recovery of LENK. Percentage of RSD 
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(relative standard deviation) of the LENK was found to be less than 2.01%, showing a high degree of 
precision and reproducibility (Supp. Table 3).  
 
Supp. Fig. 3. Standard curve of LENK from 0.0004 to 0.2 mg/ml analysized by HPLC. The limitation of 
the HPLC technique for LENK is 0.0004mg/ml. 
 
Supp. Table. 3. Accuracy and precision of HPLC technique for LENK analysis 
 
True values (LENK) at 3 
levels 
 
Accuracy 
Precision/Repeatability 
Measured values (Mean±SD 
μg/mL) 
RSD 
125%, (71.875μg/mL) 96.41±1.39% 71.57±0.11 0.15% 
75%, (43.125μg/mL) 97.23±1.41% 43.85±0.88 2.01% 
25%, (14.375μg/mL) 96.87±4.95% 14.07±0.05 0.36% 
 
The release of peptide from LENK-SQ was confirmed by HPLC Alliance 2695 coupled to a MS-
TOF LCT Premier (WATERS) (Supp. Fig. 4). After incubation with serum, LENK-SQ-Diox NPs 
could release the free peptide, and the retention time for the released LENK (Mass plus H
+
 was 
556.27) corresponded to 7.58 mins. In the case of LENK-SQ-Dig NPs, LENK attached to its 
diglycolic linker was released, which corresponded to the peak at 6.90 mins, as shown in Supp. Fig. 
4B.  
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Supp. Fig. 4. Release study in mouse serum of LENK from LENK-SQ-Diox (A) or LENK-diglycolic 
fragment from LENK-SQ-Dig (B) by HPLC-MASS.  
2. In vitro study of the ability of NPs to cross the blood-brain-barrier 
For the transcytosis study, labeled LENK-SQ NPs with both BODIPY dyes were prepared by 
conanoprecipitation of the two BODIPY probes together with the LENK-SQ. The optimization of the 
FRET NPs was performed by varying the relative fractions of donor and acceptor dyes resulting a 
series of FRET NPs preparations which were characterized by fluorescence spectroscopy. Concerning 
intact FRET NPs, when the two dyes are close to each other, energy transfer could be observed by 
simultaneous donor PL intensity quenching and acceptor fluorescence intensity sensitization (Supp. 
Fig. 5A). The disassembled FRET NPs (in ethanol) and the mixtures of single-dye NPs showed only 
concentration-dependent donor fluorescence intensity changes (Supp. Fig. 5B, C), because of the 
variation in donor concentration fractions. This confirmed that only the intact FRET NPs showed 
FRET signal between BODIPY-FL and BODIPY-542/563, whereas disassembled NPs or donor-
NPs/acceptor-NPs physical mixture did not provide any FRET signal. Thus, the FRET signal could be 
used to determine the integrity (FRET on) or disassembly (FRET off) of the NPs. Concerning FRET 
LENK-SQ NPs, the strongest FRET signal was obtained for the NAs with fractions of 1.6% donor 
and 0.4% acceptor (1.6%D/0.4%A), as determined by the strongest acceptor PL intensity under 
equivalent donor excitation (Supp. Fig. 5A). Therefore, for all following experiment, were used the 
1.6%D/ 0.4%A preparation for all following experiments to investigate endocytosis and transcytosis 
of SQAd NAs across the BBB model. Moreover, incorporation of the BODIPY probes did not 
significantly alter the colloidal properties of the NPs (Supp. Fig. 5E). 
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Supp. Fig. 5: Characterization of FRET LENK-SQ-Am NPs. Upon donor excitation (478 nm), FRET NPs 
showed a strong acceptor emission intensity increase at 570 nm and a strong donor emission intensity decrease 
at 515 nm compared to the single dye NPs. The strongest FRET signal was obtained with the NPs preparation of 
1.6%D/0.4%A (A). Pictures of FRET LENK-SQ NPs preparations obtained by varying donor/acceptor 
concentration fractions as indicated below the images showed that the different preparations displayed various 
optical properties (D). Dillution of NPs in ethanol was used to mimic the disassembly of NPs (B). Measurement 
of the mixtures of single dye NPs at the same donor/acceptor concentration fractions did not show any FRET 
signals (C). 
The passage of LENK-SQ NPs across the in vitro blood-brain-barrier model has been analyzed 
using a transwell system (Supp. Fig. 6). hCMEC/D3 cells were grown on a collagen-coated 
membrane to form the barrier. Then, the FRET NPs or fluorescent NPs (dye C11 or C12 alone) were 
added in the apical compartment (modeling the blood compartment), whereas the translocation toward 
the baso-lateral compartment (modeling the brain compartment) was measured by spectrofluorimetry. 
It was found that the fluorescence intensity in the baso-lateral compartment increased with time, 
indicating a passage of the fluorophore across the BBB after 4 and 6 hours incubation (Supp. Fig. 7). 
But neither FRET signal (Supp. Fig. 7) nor LENK-SQ bioconjugates (Supp. Fig. 8) was detected in 
the baso-lateral compartment. 
 
Supp. Fig. 6: Transcytosis study of NPs using transwell system. hCMEC/D3 cells grown on collagen-coated 
membrane filter inserts were incubated apically with fluorescent or FRET NPs.  
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Supp. Fig. 7: Transcytosis study of fluorescent or FRET NPs using an in vitro model of blood-brain-
barrier. hCMEC/D3 cells grown on collagen-coated membrane filter inserts were incubated apically with 
fluorescent or FRET NPs. (A) FRET NPs were added in the apical chamber and the FRET intensity in apical 
and basolateral was measured 4h and 6h after incubation; (B) Fluorescent NPs with BODIPY® 542/563 C11 
(Acceptor) were added in the apical chamber and the fluorescent intensity in apical and basolateral was 
measured 4h and 6h after incubation; (C) Fluorescent NPs with BODIPY® FL C12 (Donor) were added in the 
apical chamber and the fluorescent intensity in apical and basolateral was measured 4h and 6h after incubation. 
 
Supp. Fig. 8: Transcytosis study of NPs using an in vitro model of blood-brain-barrier. hCMEC/D3 cells 
grown on collagen-coated membrane filter inserts were incubated apically with NPs. After 4h (A, C) and 6h (B, 
D), medium from apical (A, B) and basolateral (C, D) were taken and analyzed by HPLC.  
3. MASS spectra of the bioconjugates 
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Supp. Fig. 9. Isotopic profiles of (A) LENK-SQ-Diox, (B) LENK-SQ-Dig, (C) LENK-SQ-Am. 
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General discussion 
The main objective of this PhD project was to develop new nanomedicines allowing the specific 
delivery of Enkephalin neuropeptide into inflamed tissues for pain control, using “squalenoylation” 
concept. For this purpose, Leu-enkepahalin (LENK) neuropeptides were chemically linked to 
squalene through three different chemical linkers, i.e., dioxycarbonyl, diglycolate, and amide bond in 
order to obtain LENK prodrugs. These squalenoyl-LENK bioconjugates (LENK-SQ) showed the 
capability to form nanoparticles (NPs) using nano-precipitation technology. The potential of these 
NPs to releave pain has been studied using carrageenan-induced paw edema model in rats 
(Hargreaves test), and revealed a significant anti-hyperalgesic effect which lasted longer than after 
treatment with morphine. Pretreatment with opioid receptor antagonists such as naloxone (brain-
permeant) and naloxone methiodide (brain-impermeant), could reverse this anti-hyperalgesia , thus 
indicating that the LENK-SQ NPs acted through peripheral opioid receptors. A biodistribution study 
was conducted in order to confirm the peripheral action of these NPs using in vivo fluorescence 
imaging. This study showed a strong accumulation of fluorescently labeled LENK-SQ NPs in the 
inflamed paw, and also in the liver, spleen and lungs while no fluorescent signal could be detected in 
the brain, confirming the peripheral effect of LENK-SQ NPs. The safety of these NPs was also 
checked by toxicity studies which revealed normal AST/ALT levels. In addition, histological analysis 
didn’t show any anomaly in the organs.  
The present discussion aims to interpret and describe the global input of this PhD research to the 
pain treatment, and to discuss the remaining challenges for the translation of LENK-SQ NPs toward 
the clinics.  
Squalenolation of Leu-enkephalin 
Our group has explored the remarkable properties of squalene to form nanoparticles when 
conjugated to different kinds of small molecule drugs (i.e. gemcitabine, doxorubicine, cis-platin, 
Penicillin G, adenosine, and so on) (1). It has been shown that, in general, the resulting 
nanomedicines displayed safer and more efficient pharmacological activity than the parent drugs. The 
focus of the current study was to enlarge this groundbreaking concept to opioid peptide Leu-
enkephalin for efficient pain control. In this study, three different prodrugs of Leu-enkephalin were 
synthesized, using three different linkers between the peptide and the hydrophobic squalene, in order 
to modulate drug release in a specific environment such as inflammation. 
At the beginning, squalene conjugation on solid-supported peptides (LENK) was envisaged. 
However, since trifluoroacetic acid (TFA) treatment, commonly employed for the peptide–resin 
cleavage, pose the risk of possible SQ degradation, a postsynthetic strategy was designed by 
introducing squalene moiety on already preformed peptide sequences.  
Derivatives of squalene, 1,1’,2-trisnorsqualenoic acid (SQ-COOH), or 1,1’,2-tris-norsqualenol 
(SQ-OH), were recruited in order to bind enkephalin through its N-terminal amine, C-terminal acid or 
Phenol group of tyrosine (Fig. 1). A first part will be devoted to unsuccessful attempts that have not 
been described in the article and a second part will briefly go through the synthesis of the LENK-SQ-
Diox, LENK-SQ-Dig and LENK-SQ-Am bioconjugates.  
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Fig. 1. Linkage sites on Leu-enkephalin. 
A direct ester link has been first considered in order to couple directly SQ-COOH on the phenolic 
hydroxyl group of LENK (1
st
 strategy) or SQ-OH on C-terminal acid of LENK (2
nd
 strategy). Several 
attempts were conducted but none of them could lead to an ester bond between SQ and LENK. Thus, 
concerning the first strategy, in order to avoid additional protection/deprotection steps on C-terminal 
LENK, activation of SQ-COOH prior to the condensation was envisaged. Thus, SQ-COOH was 
activated using N-hydroxysuccinimide, oxallyl chloride or methyl chloroformate. Unfortunately, none 
of them could react with the phenol group of LENK. The second strategy was then adopted, using 
direct coupling of SQ-OH to C-terminal acid of the LENK using DCC coupling reagent, though, this 
strategy have proven to be unsuccessful too. Hence, direct ester link finally could not be achieved, 
probably due to the bulky moiety of squalene which hindered the access to the phenol group. As for 
the second approach, the nucleophilicity of squalenol was not enough sufficient to counteract the 
bulky moiety of squalene. 
Regarding to synthesis of LENK-SQ-Diox, LENK-SQ-Dig and LENK-SQ-Am bioconjugates, the 
synthesis could be successfully achieved. Indeed, 1,1′,2-trisnorsqualenoic acid (SQ-COOH), or 1,1′,2-
tris-norsqualenol (SQ-OH), were attached to LENK through its N-terminal amine or C-terminal acid. 
Therefore, the resulting LENK-SQ prodrugs were synthesized with either direct amide bond, 
diglycolic or dioxycarbonyl linker in order to investigate the possible influence of the linkage stability 
on the peptide release. It was expected that LENK-SQ-Diox released faster than LENK-SQ-Dig, and 
LENK -SQ-Am was supposed to trigger the slower release as reported in the literature (2-4). Both 
LENK-SQ-Am and LENK-SQ-Dig, were obtained in good yields (around 70%) (see article under 
review). However the synthesis of the bioconjugate with dioxycarbonyl linker at the C-terminal of 
LENK, was found particularly tricky. First of all, in order to avoid N-terminal conjugation, the 
primary amino group of LENK was protected before the conjugation process. In that respect, Fmoc 
(fluorenylmethyloxycarbonyl) strategy was first adopted for the protection of the primary amino 
group of LENK. Then, the Fmoc-LENK-SQ-Diox conjugate was easily synthesized by simple 
alkylation of the carboxylate function of the Fmoc-peptide with the chloromethyl ester of squalenic 
acid, which was prepared upon treatment of squalenic acid with chloromethyl chlorosulfate. However, 
the amine deprotection step involving the most common solution of 20% piperidine in DMF, resulted 
in the cleavage of the sensitive dioxycarbonyl linker. Among the byproducts, cyclized LENK, N-
squalenoylpiperidine and N-Leu-enkephanoylpiperidine were identified by HPLC-MS technique. 
Deprotection by tertiary amine such as triethylamine was also tried but with limited success. Hence, 
this approach was abandoned in favor of Alloc (Allyloxycarbonyl) strategy since the deprotection step 
is carried out under neutral conditions. Alloc-LENK was coupled to squalene derivative following the 
same reaction scheme as for Fmoc-LENK leading to Alloc-LENK-SQ-Diox. The first attempt to 
remove the Alloc involved tetrakis(triphenylphosphine)palladium(0) in presence of dimedone. This 
reaction led to partial deprotection of the bioconjugate after 24h. The deprotection step was 
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reproduced with the same palladium complex but replacing dimedone by phenylsilane. The Alloc 
protecting group could be removed, however during purification step the palladium complex could 
not be separated from the bioconjugate. Lastly, the palladium catalysed deprotection of allyl 
carbamate was reproduced using this time triethylsilane as scavenger and 10% Pd/C. Though, once 
deprotected, amine group of LENK-SQ bioconjugate competed the nucleophilic allyl group scavenger 
in the trapping of the π-allyl palladium complex, resulting in N-allylation of amine function of the 
bioconjugate (Fig. 2). This secondary reaction could finally be majorly prevented by the use of high 
amounts of triethylsilane (TES). This step yielded only 23% of deprotected bioconjugate, due to the 
cleavage of the sensitive bond during purification step. Finally, the total yield of LENK-SQ-Diox 
corresponded to 9%. 
 
Fig. 2. The problematic sidde reaction of allylamine formation during palladium catalysed deprotection. 
Given the fact that our approach was based on the covalent binding between squalene and the 
peptide, the peptide drug loadings into the NPs were calculated from the ratio between LENK peptide 
Mw and LENK-SQ bioconjugate Mw (57.38% for LENK-SQ-Diox NPs, 53.41% for LENK-SQ-Dig 
NPs and 59.22% for LENK-SQ-Am NPs). It is noteworthy that such drug payload was dramatically 
higher than into liposomes or PLGA enkephalin-loaded nanoparticles (respectively 0.4% and 4.75 % 
drug loading). As outlined before, high drug loading is an important feature for nanocarriers as a 
smaller quantity of carrier materials is administrated to reach the pharmacologically active 
concentration of the drugs, which in turn may decrease the associated potential toxicity (5). On that 
point, it is important to highlight that squalene is a natural and biocompatible raw material found 
among others in human sebum-like materials and in shark-liver oil (6). All LENK-SQ bioconjugates 
showed the ability to self-assemble in water as monodispersed spherical nanoassemblies with average 
diameter ranging from 75 nm to 122 nm using an easy formulation process (nanoprecipitation/solvent 
evaporation). The NPs exhibited positive or negative surface charge, denpending on the free terminal 
function of the peptide in the bioconjugates. Indeed, free N-terminal amine function led to a net 
positive surface charge while free C-terminal acid function resulted in a net negative surface charge. 
Moreover, the size and the surface charge of the LENK-SQ NPs were found to be quite stable at +4°C, 
even if a slight increase of the size was observed, likely due to the swelling of the particles resulting 
from NPs hydration, already observed previously with other squalene-based NPs (7). 
The main limitation for systemic peptide treatment arises from the enzymatic degradation in blood 
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circulation. Indeed, the plasma half-life of LENK in serum corresponds to 2 minutes approximatively 
(Fig. S7). Concerning LENK-SQ NPs, in vitro release study showed that LENK peptide was released 
from LENK-SQ-Diox and LENK-SQ-Dig but not from LENK-SQ-Am (Fig. 3). In the case of LENK-
SQ-Diox and LENK-SQ-Dig, the release of the respective LENK and LENK-linker fragment was 
followed by a progressive degradation of the peptide, due to serum enkephalinases. Regarding LENK-
SQ-Diox bioconjugate, both LENK and squalene moieties were each linked through an ester bond to 
the dioxycarbonyl linker. In the case of the LENK-SQ-Dig bioconjugate, the diglycolate linker was 
attached on one side to squalene by an ester bond and on the other side to the LENK through an amide 
bond while concerning LENK-SQ-Am bioconjugate, a direct amide bond connected the LENK to the 
SQ moiety. This suggests that the release of LENK from LENK-SQ NPs proceeded from enzymatic 
hydrolysis by serum esterases. It has been previously reported (2-4, 8) that an amide bond is generally 
more resistant to hydrolysis than an ester bond. This explains why in serum, LENK-SQ-Am didn’t 
release the peptide. Despite these in vitro data, all the 3 conjugates were recruited for anti-
hyperalgesia experiments. As a matter of fact, it was expected that the more aggressive in vivo 
enzymatic content, particularly rich in proteolytic enzymes at the inflammation site, would contribute 
to the release of LENK from all the bioconjugates (9, 10). 
Analgesic efficacy of LENK-SQ NPs 
λ-carrageenan is a commonly used inflammatory irritant that stimulates the release of inflammatory 
and proinflammatory mediators, including histamine, bradykinin, tachykinins, reactive oxygen, and 
nitrogen species (11). It is usually used to produce short-lasting acute inflammation and hyperalgesia 
in animal models. In the present study, λ-carrageenan was injected subcutaneously into the plantar 
surface of the right hind paw and produced local inflammation, designated by the 5 cardinal signs: 
hypersensitivity, swelling, redness, heat, and loss of function. The inflammation developed hyper-
sensitivity to thermal stimuli (thermal hyperalgesia) at the injected paw level. These changes became 
maximal 3-5 h post-λ-carrageenan injection and generally subsids within 24 hours (12, 13). This -
carrageenan-induced rodent edema model has been widely accepted for screening compounds with 
anti-inflammatory and anti-hyperalgesic potentialities (14). Thus, in our study, the hypersensitivity of 
the rats was measured 3 hours after carrageenan administration. The treatments were then injected and 
hypersensitivity to a noxious stimulus (hyperalgesia) was then assessed during 4 hours using 
Hargreaves test and was compared to morphine used as positive control. The Hargreaves test is 
specifically designed to assess thermal pain sensation in rodents such as rats and mice (15). It 
measures the response of the animals (i.e. paw withdrawal latency, PWL) to infrared heat stimulus, 
which was applied to the plantar surface. 
The results of this study showed that LENK-SQ NPs significantly increased the hindpaw 
withdrawal latency in rats bearing unilateral inflammation, which lasted longer than morphine, 
indicating marked anti-hyperalgesic efficacy. Surprisingly, LENK-SQ-Am NPs, which was expected 
to release the peptide slower in comparison with the other two NPs, exhibited a stronger effect with a 
shorter duration, probably due to enzymatic serum capability which is not predictive of the enzymatic 
ecosystem in the inflamed paw. LENK-SQ-Dig NPs and LENK-SQ-Diox NPs had nearly the same 
anti-hyperalgesic profile with prolonged effect, resulting in a significantly higher AUC (area under 
the curve) than morphine and LENK-SQ-Am NPs. In particular, the LENK-SQ-Dig NPs showed an 
anti-hyperalgesic effect, which lasted twice as long as morphine. In addition, as expected for an 
analgesic compound, PWL values after morphine treatment in λ-carrageenan-treated rats exceeded 
basal values in naïve healthy rats, whereas, in contrast, under the conditions used here, PWL values 
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after LENK-SQ NPs just reached these basal values. This would suggest that LENK nanoparticles are 
devoid of analgesic properties but are especially potent to counteract hyperalgesia in chronic pain 
suffering subjects. However, further studies are required to assess this hypothesis. In order to 
determine the involvement of central or peripheral opioid receptors during the anti-hyperalgesic effect 
of LENK-SQ NPs, opioid receptor antagonists naloxone or naloxone methiodide were subcutaneously 
injected 15 min prior to the injection of NPs or Morphine (positive control). Indeed, naloxone (NAL) 
is an opioid antagonist that acts upon μ, δ and κ opioid receptors while naloxone methiodide (NAL-
M), the quaternary derivative of naloxone, is thought to not cross the blood-brain-barrier. Naloxone 
methiodide is generally used as a research tool allowing to distinguish between central and peripheral 
mechanisms of the LENK-SQ NPs (16). Pretreatment with NAL could prevent the increase in PWL 
evoked by LENK-SQ NPs as well as morphine, indicating that the anti-hyperalgesic effect of all these 
compounds was effectively mediated by opioid receptors. Nal-M, that poorly penetrates the blood-
brain-barrier, antagonized the antihyperalgesic effect of the LENK-SQ NPs while it could almost not 
antagonize the antihyperalgesic effects of morphine. This result clearly suggested that LENK-SQ NPs 
acted exclusively on peripheral opioid receptors. As regards the morphine, the result was in 
accordance with the fact that morphine mainly acted on central opioid receptors (17).  
Biodistribution of LENK-SQ NPs 
Inflammatory responses in the peripheral play key roles in the development and persistence of 
many pathological pain states (18). Inflammation results in a dramatic change in blood vessel 
permeability as the capillary vasculature undergoes structural remodeling displaying fenestrations 
between the endothelial cells ranging from 300 nm to 4700 nm in size, thus allowing leukocyte 
diapedesis into the peripheral inflamed tissue (19, 20). Therefore, under inflammation process, when 
administered intravenously, nanoparticles that normally don’t cross the endothelial barrier of the 
capillaries, can then extravasate and accumulate in the interstitial space of inflamed tissues thus 
allowing an increase of drug concentration locally (21). This targeted delivery of macromolecules or 
drug nanocarriers to the site of inflammation is called enhanced permeability and retention (EPR) 
effect (Fig. 3) (22).  
 
Fig. 3: EPR effect at the inflammation site. Inflammation will cause the vessel to dilate resulting in a higher 
blood flow. Furthermore, the contraction of endothelial cells will allow the penetration of nanoparticles into the 
tissue. 
In order to check if LENK-SQ NPs acted peripherally within the site of inflammation, in vivo 
biodistribution study of these NPs was performed using fluorescent DiD-labeled LENK-SQ NPs. 
General discussion 
 125 
These fluorescently labeled NPs were intravenously injected into -carrageenan-induced mouse 
edema model. This study was conducted on mice since the IVIS® Lumina scan used in our faculty 
was adapted to mice but not to rats. Dramatic increase of fluorescence signal was already detected in 
the inflamed paw 0.5 h after injection, and was 3 times more intense than in the contralateral non-
inflamed paw. No difference in signal intensity was observed between this contralateral non-inflamed 
paw and the paw of mice injected with saline only (instead of with λ-carrageenan) and treated with 
fluorescently labeled NPs, which indicated that the process of subcutaneous injection per se didn’t 
cause any damage to the capillary vasculature. These results clearly indicated that the accumulation of 
the fluorescence in the inflamed paw was due to the inflammation process induced by λ-carrageenan. 
By the way, injection of free DiD fluorescent dye resulted in lower fluorescence intensity in the 
inflamed paw, suggesting that the enhanced accumulation of fluorescence in the inflamed paw was 
specifically due to the nanoparticle formulation. In that respect, the LENK-SQ was distributed within 
the inflamed area as nanoparticles rather than in a single LENK-SQ molecular form. This was in 
accordance with the in vitro colloidal stability in serum, which showed that a significant percentage of 
NPs remained intact. To support the idea that intact NPs reached the inflamed tissue, fluorescent 
nanoparticles containing the fluorescent dye DiD together with a fluorescent quencher DiR were 
prepared. When intact, the nanoparticles do not emit any fluorescence (since the dye and the quencher 
are very close to one another). On the contrary, when the LENK-SQ NPs were disassembled in 
ethanol, fluorescence emission was observed due to the seperation of the dye and the quencher. Thus, 
when incubated within the serum, the NPs disassembled progressively, as seen from the gradual 
increase of the fluorescence (20% after 5 min and 50% after 30 min, see Fig. S8). This means that a 
significant proportion of NPs remained intact long time enough to reach the inflamed tissue. This 
observation was relevant with in vivo fluorescence imaging by Fig. 6, showing a strong fluorescence 
in the inflamed paw 30 minutes after injection. This clearly suggested that a significant quantity of 
intact LENK-SQ NPs remained intact into the blood circulation and was able to reach the site of 
inflammation, probably through the EPR effect. Ex vivo imaging was also performed on collected 
tissues and organs from mice injected with fluorescently labeled NPs. A strong fluorescence signal 
was again observed in the inflamed paw, but also in the liver, the spleen and the lungs due to the RES 
uptake of fluorescent nanoparticles. However, no detectable accumulation of fluorescence was 
noticed in the brain, confirming the peripheral effect of the LENK-SQ NPS. Based on the present 
study, squalene based NPs showed to be a highly promising delivery system to target inflamed tissues. 
Thus, the novelty of the approach resulted from the unexpected ability of the peptide, when 
formulated under nanoparticular form, to reach safely and selectively the small area of the body where 
inflammation and nociception are occurring. 
Toxicity of LENK-SQ NPs 
Squalene is a natural lipid belonging to the terpenoid family which is largely widespread in nature. 
It is found in plants, animals and humans and is a precursor for biosynthesis of phytosterol and 
cholesterol. Squalene is synthesized by the liver and secreted in large quantities by the sebaceous 
glands in the skin (23, 24). It is transported in the blood by very low density lipoproteins (VLDL) and 
low density lipoproteins (LDL). Furthermore, squalene is a versatile biocompatible biopolymer 
excipient used in numerous pharmaceutical formulations for oral and parenteral administration. At 
reasonable supplemental levels (0.5g/day), it is safe for prolonged administration (25, 26).  
Concerning LENK-SQ NPs, since they also accumulated in the liver, as mentioned above in 
biodistribution studies, their safety was therefore assessed. For this purpose, AST and ALT levels 
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were first measured. Indeed, these two liver enzymes are good markers of damage to liver cells. ALT 
is found primarily in the liver while AST is found in the liver, cardiac muscle, skeletal muscle, kidney, 
brain, pancreas, lungs, leukocytes, and erythrocytes (27). These enzymes are normally present at low 
levels in the blood. If liver cells are damaged, these enzymes leak into the blood which results in an 
increase in ALT and AST levels. After intravenous administration of LENK-SQ-Am NPs (20 mg/Kg) 
to rats, the AST and ALT levels in plasma showed no differences compared to levels of rats before 
injection or to the placebo control (5% dextrose solution). Moreover, the absence of toxicity was also 
confirmed after histological analysis of tissue organs of rats comprising liver, kidneys, spleen and 
lungs. Indeed, no changes in the cellular integrity or tissue morphology were observed after injection 
of LENK-SQ-Am NPs.  
In conclusion, this research work resulted in the development of a novel 
nanomedicine approach allowing the specific delivery of intact Enkephalin 
neuropeptide into inflamed tissues and by-passing the blood-brain-barrier, for efficient 
pain control. 
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General conclusion & Perspectives 
This PhD research intended to address the treatment of pain disorder using squalenoylated Leu-
enkephalin NPs. The main achivements of this thesis are:  
1. The preparation and characterization of the LENK-SQ NPs. Synthesis of pure 
squalenoylated Leu-enkephalin bioconjugates with 1) dioxycarbonyl linker, 2) diglycolic 
linker and 3) amide bond was successfully achieved. All bioconjugates showed the capability 
to self assemble in nanoparticles with sizes around 100 nm, using simple nanoprecipitation 
process. These NPs were found to be quite stable under 4 °C for 8 days. 
2. The in vivo evaluation of anti-hyperalgesic effects of the LENK-SQ NPs in carrageenan-
induced paw edema model in rats. Hyperalgesia rat model was successfully established by 
intraplantar injection of λ-carrageenan. All LENK-SQ NPs showed significant anti-
hyperalgesic effects by activation of peripheral opioid receptors which lasted longer than 
morphine.  
3. The in vivo biodistribution study of the LENK-SQ NPs. Fluorescently labeled LENK-SQ 
NPs were prepared in order to study the biodistribution of LENK-SQ-Am NPs. The real-time 
in vivo imaging showed a strong accumulation of the fluorescence within the inflamed paw, 
thus highlighting the release of free peptides in the inflamed tissue. Flouorescence was also 
observed in RES organs especially in the liver, and in the lungs. The absence of detectable 
fluorescence in the brain supports the peripheral action of the LENK once released from NPs 
at the inflammation site.  
4. The toxicity study of NPs. Systemic administration of LENK-SQ NPs induced no damage to 
liver, as shown by the plasma AST or ALT levels. Histological examination of liver, heart, 
spleen, lungs, and kidneys didn’t show any anomaly.  
Further experiments should be explored for application improvement of LENK-SQ NPs in order to 
get as close as possible of clinical outcome: 
1. Scaling-up the LENK-SQ bioconjugates synthesis and nanoparticles preparation.  
2. Facilitating their manipulation by developing freeze-dryed LENK-SQ NPs easy to 
reconstitute into injectable form prior to administration 
3. Defining the lowest dose required to achieve the anti-hyperalgesic effect, the 
administration frequency and timing treatment. 
4. Studying the anti-hyperalgesic effect of LENK-SQ NPs on chronic pain model. 
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Abstract: Enkephalin is an endogenous pentapeptide producing potent analgesia by activating 
opioid receptors located on central and peripheral neuronal cell membranes. However, its clinical 
use has historically been limited due to pharmacokinetic issues, including restricted plasma stability 
and blood-brain-barrier impermeability. The aim of this project is to create a new enkephalin-based 
nanomedicine targeting pain, using biocompatible and biodegradable materials for drug delivery and 
targeting purposes, such as squalene (squalenoylation nanotechnology). This nanotechnology 
presents a new concept with numerous advantages in comparison with the conventional 
nanocarriers, such as high drug loading and absence of “burst release”. Here, we show for the first 
time, that the rapidly metabolized Leu-enkephalin (LENK) neuropeptide may become 
pharmacologically efficient owing to its simple conjugation with the squalene (SQ) using three 
different chemical linkers, i.e., dioxycarbonyl (Diox), diglycolate (Dig), or amide bond (Am). The 
resulting prodrugs were able to self-assemble in nanoparticles in aqueous media. This new squalene-
based nanoformulation prevented rapid plasma degradation of LENK and conferred to the released 
neuropeptide a significant anti-hyperalgesic effect in a carrageenan-induced paw edema model in 
rats (Hargreaves test). It should be stressed that this effect lasted 3 times longer than morphine. 
Pretreatment with brain impermeant opioid receptor antagonist naloxone methiodide (Nal-M) 
reversed the nanoparticles induced anti-hyperalgesia, indicating that LENK-SQ NPs acted through 
peripherally located opioid receptors. Moreover, the biodistribution of DiD-fluorescently labeled 
LENK-SQ NPs showed a strong accumulation of the fluorescence within the inflamed paw as well 
as in the liver, spleen, and lung, while no signal could be detected in the brain, confirming the 
peripheral effect of LENK-SQ NPs. Toxicological studies showed that despite nanoparticles 
accumulation in the liver, the levels of aspartate transaminase (AST) and alanine transaminase 
(ALT) were not increased after i.v. injection of LENK-SQ NPs, highlighting thus their safety. This 
study represents a novel drug targeting approach, allowing the specific delivery of LENK 
neuropeptide into inflamed tissues for pain alleviation. 
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Titre: Développement de nanomédicaments innovants pour vaincre la douleur: une alternative à la 
morphine 
Mots clés: Nanomédecine, Leu-Enképhaline, Squalène, Hyperalgésie, Douleur inflammatoire, 
Récepteurs périphériques opioïdes 
Résumé: Les neuropeptides endogènes chez l’homme, tels que les enképhalines et endomorphines, 
ont un potentiel thérapeutique considérable dans le traitement de la douleur. Ils agissent en activant 
les récepteurs opioïdes qui sont très largement distribués dans le système nerveux central ainsi que 
dans plusieurs tissus périphériques. Ces neuropeptides présentent, cependant, un certain nombre 
d’inconvénients qui limitent de manière importante leur efficacité thérapeutique. Tout d’abord, en 
raison de leur hydrophilie, ils ne passent pas la barrière sang/système nerveux, ce qui limite leur 
accès aux récepteurs opioïdes. De plus, ils présentent un temps de demi-vie plasmatique 
relativement court du fait d’une métabolisation rapide. Enfin, pour être efficaces, ces neuropeptides 
devraient résister à la protéolyse dans le système circulatoire et être suffisamment hydrophobes pour 
traverser ces barrières hémato-nerveuses. 
Le but de la thèse a consisté à créer de nouveaux nanomédicaments à base d’endorphines pour 
vectoriser et combattre la douleur de manière efficace. Dans ce but, a été établi une liaison chimique 
covalente, enzymatiquement clivable (ester ou amide), entre le squalène (SQ, un lipide naturel et 
biocompatible) et le neuropeptide. Ce couplage donne lieu à des prodrogues qui ont la capacité de 
s'auto-assembler en nanoparticules (NPs) dans l'eau sans l’aide d'un agent tensio-actif. D’une 
manière générale, cette technologie présente de nombreux avantages tels qu’un taux de charge élevé 
en principe actif, une protection efficace de celui-ci vis-à-vis de la métabolisation et l’absence de 
phénomène de «burst release». 
Durant ce travail de thèse, nous avons pu montrer pour la première fois que les Leu-enképhalines 
(LENK) pouvaient devenir efficaces pharmacologiquement une fois couplées au squalène, via une 
liaison amide (Am), ou via un bras espaceur, tel que le dioxycarbonyl (Diox), ou le diglycolate 
(Dig). Les prodrogues résultant de ce couplage ont toutes montré des propriétés d’auto-assemblage 
en milieu aqueux. Cette nanoformulation à base de squalène a permis, d’une part de protéger la 
LENK de la métabolisation rapide dans le plasma et d’autre part, de lui conférer un effet anti-
hyperalgésique significatif dans un modèle de douleur inflammatoire induite chez le rat par la 
carragénine (test de Hargreaves). Il est important de souligner que cet effet anti-hyperalgésique a 
duré 3 fois plus longtemps qu’avec la morphine. Un prétraitement avec un antagoniste des 
récepteurs opioїdes imperméable à la BHE, comme la méthylnaloxone a complètement antagonisé 
l’effet anti-hyperalgésique des nanoparticules de LENK-SQ, démontrant ainsi que celles-ci agissent 
via les récepteurs opioïdes périphériques. De plus, l’étude de biodistribution de NPs LENK-SQ 
fluorescentes a montré une forte accumulation des celles-ci au niveau de la patte œdémateuse, mais 
aussi dans le foie, la rate et les poumons alors qu’aucun signal n’a pu être détecté au niveau 
cérébral, ce qui confirme bien l’effet périphérique de ces nanoparticules. Enfin, des études 
toxicologiques ont montré que malgré l’accumulation des NPs dans le foie, les taux d’aspartate 
transaminase (AST) et alanine transaminase (ALT) n’ont pas augmenté garantissant ainsi l’innocuité 
des NPs LENK-SQ après leur injection i.v.  
Cette étude représente une approche innovante et prometteuse permettant une distribution ciblée du 
neuropeptide endogène LENK dans les tissus œdémateux pour soulager efficacement la douleur 
inflammatoire. 
